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Obstructive sleep apnea (OSA), a disorder in which the airway intermittently collapses 
and obstructs during sleep, is associated with increased cardiovascular and 
cerebrovascular morbidity and mortality, increased risk of motor vehicle accidents, 
metabolic syndrome, hypertension, and depression. Treatment of OSA attenuates or 
reverses many of these associated risks.  However, most cases of OSA are unrecognized 
and untreated.  The two most recent studies using 1990s data found that only 6.5 – 15.4% 
of OSA cases, depending on severity, are clinically recognized in mixed gender 
populations. Based on a conceptual framework of improved physician awareness of OSA, 
and reduced diagnostic access bias with the increased availability of sleep laboratory 
services, increased OSA recognition since the 1990s was predicted. Study participants 
with clinically recognized OSA were identified using the resources of the Rochester 
Epidemiology Project, while the Berlin Questionnaire OSA high risk classification was 
used as a surrogate for prevalent OSA in this population.  Analysis in a mixed gender 
population determined that OSA clinical recognition among those with prevalent OSA 
was 22.7 % (95% CI 19.6 – 25.8%) for mild or greater OSA severity leaving more than 
75% of prevalent OSA clinically unrecognized and untreated in this population.  Obesity 
and male gender were associated with increased likelihood of clinical recognition in 
bivariate and multivariate analyses, though even among obese men only 36.5% of OSA 
was clinically recognized. In order to support positive social change and address these 
inequities of OSA clinical recognition, strategies that enhance OSA recognition overall, 
and more specifically target recognition of OSA among women and the nonobese, should 
be developed and implemented. Further research regarding such strategies should 
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CHAPTER 1:  INTRODUCTION TO THE STUDY 
Background 
Obstructive sleep apnea is a disorder in which the airway collapses causing an 
airway obstruction during sleep and recurrent arousals from sleep (Parish & Somers, 
2004).  The airway collapse and the resulting sleep interruptions produce the common 
symptoms of OSA that include excessive snoring, daytime sleepiness, and pauses in 
breathing reported by sleeping partners (Caples, Gami, & Somers, 2005; Parish & 
Somers, 2004).   
Across the population, OSA of at least mild severity is not rare. In one early, 
classically cited, population-based epidemiologic study the prevalence of OSA with 
daytime symptoms was found to be 2% and 4% in women and men, respectively. 
However, the prevalence of at least mild OSA with or without symptoms was found to be 
9% and 24% in women and men, respectively (Young et al., 1993). A later larger 
multicenter study demonstrated a similar prevalence with at least moderate OSA present 
in 11% and 25% of women and men, respectively (Young, Shahar et al., 2002).  Overall 
those with sleep apnea are usually older, more obese, and more likely male with the 
prevalence higher among African-Americans and Asians (Young, Peppard, & Gottlieb, 
2002).  
OSA is associated with a variety of significant health problems including 
increased cardiovascular (Caples, Garcia-Touchard, & Somers, 2007) and 
cerebrovascular (Yaggi et al., 2005) morbidity and mortality, metabolic syndrome 




Esnaola, Rubio, & Iztueta, 2001), and depression (Peppard, Szklo-Coxe, Hla, & Young, 
2006). In addition, OSA is associated with increased risk of motor vehicle accidents 
(Young, Blustein, Finn, & Palta, 1997). 
OSA Diagnosis and Treatment 
The “gold standard” diagnostic technique for OSA is polysomnography (PSG) 
(Schlosshan & Elliott, 2004) which involves sleeping overnight in a laboratory with 
multichannel monitoring of brain, eye, and muscle activity, respiratory effort, heart rate, 
and blood oxygen saturation (Chesson et al., 1997). The diagnosis of OSA is then based 
on an evaluation of this array of physiologic parameters that determines the stage of 
sleep, number of apneas, hypopneas, and oxygen desaturations that occur and are then 
correlated with respiratory effort movements. The number of apneas plus the number of 
hypopneas occurring per hour of sleep represents the apnea-hypopnea index (AHI) which 
is a measure of OSA severity. OSA is generally considered present if the AHI is greater 
than five with daytime symptoms such as sleepiness, or greater than 15 with or without 
symptoms (Berry & Foster, 2005; Silber, Krahn, & Morgenthaler, 2004). 
Continuous positive airway pressure (CPAP) is considered to be first-line therapy 
for those with moderate to severe OSA, especially those that have symptomatic daytime 
sleepiness (Giles et al., 2006; Kushida et al., 2006). CPAP devices use airflow generated 
by a fan and applied to the patient’s airway by way of tubing and a nasal or oronasal 
mask to maintain the patency of the airway during sleep. Thus, CPAP functionally 
represents a pneumatic splint that prevents OSA-related airway obstruction (Hirshkowitz 




against a placebo of sham CPAP therapy demonstrated effectiveness in reducing OSA 
severity (Gay, Weaver, Loube, & Iber, 2006).  
There is evidence that the negative long-term effects of OSA are attenuated by 
treatment with CPAP.  Several studies of cardiovascular morbidity and mortality have 
demonstrated reductions with CPAP therapy (Doherty, Kiely, Swan, & McNicholas, 
2005; Milleron et al., 2004; Peker, Carlson, & Hedner, 2006). Unfortunately the ability to 
adhere to CPAP therapy among those for whom it has been prescribed has been limited 
and variable. A classic study (Kribbs et al., 1993) demonstrated that only 46% were able 
maintain use of CPAP at four or more hours per night. More recent studies have shown 
similar adherence rates ranging from 31% (Richards, Bartlett, Wong, Malouff, & 
Grunstein, 2007) to about 48% (Joo & Herdegen, 2007) with a usual pattern of care. 
Historic Clinical Under Recognition of OSA 
There is evidence that a significant portion of those with OSA historically have 
been clinically undiagnosed. However, the extent of this under diagnosis has not been 
assessed since the 1990s.  In the 1980s it was thought that less than 1% of prevalent OSA 
had been diagnosed clinically (Dement, 1993; Strohl & Redline, 1996).  There are only 
two population-based studies that evaluated the portion of prevalent OSA that was 
clinically diagnosed, both based on data collected in the 1990s (Kapur et al., 2002; 
Young, Evans, Finn, & Palta, 1997).  These studies demonstrated that 2 – 18% of OSA 
had been clinically diagnosed varying based on gender and OSA severity.  Thus, from the 




was clinically diagnosed.  However, most OSA, 82 – 98%, remained undiagnosed in the 
1990s. 
The under recognition of clinical OSA has been identified by the Institute of 
Medicine as an unmet public health problem (Colten & Altevogt, 2006). Among the 
potential explanations for limited clinical OSA recognition are the following:  (a) limited 
OSA awareness by physicians (Papp, Penrod, & Strohl, 2002; Reuveni et al., 2004; R. 
Rosen & Zozula, 2000), (b) limited access to sleep laboratories and specialists (Flemons, 
Douglas, Kuna, Rodenstein, & Wheatley, 2004; Morgenthaler et al., 2006), and (c) the 
expensive and intrusive nature of laboratory-based PSG (Colten & Altevogt, 2006; van 
de Mortel, Laird, & Jarrett, 2000).  
Changes in health professional education, access to PSG, and the development of 
new OSA diagnostic techniques not requiring PSG are described in chapter 2. These 
changes could all provide a basis for an increase in OSA clinical recognition in the past 
decade.  However, there has been no research measuring the rate of OSA clinical 
recognition subsequent to the 1990s. 
In the first of the two studies evaluating clinical diagnosis of OSA, the following 
characteristics were associated in bivariate analysis with a greater likelihood having been 
diagnosed:  male gender, previous cardiovascular disease, age, Caucasian race, and 
higher socioeconomic status based on income and education (Young, Evans et al., 1997).  
In the second of these studies (Kapur et al., 2002) bivariate analysis identified male 
gender, history of hypertension, higher body mass index (BMI), college graduation, and a 




diagnosed.  However, in multivariate regression analyses, only gender and BMI remained 
predictive of a clinical diagnosis in this study. 
Problem Statement 
OSA is associated with increased cardiovascular and cerebrovascular morbidity 
and mortality (Caples et al., 2007; Yaggi et al., 2005). The diagnosis and subsequent 
treatment of OSA attenuates this long-term morbidity and mortality (Doherty et al., 2005; 
Milleron et al., 2004; Peker et al., 2006).  However, most OSA is clinically unrecognized 
and untreated (Dement, 1993; Kapur et al., 2002; Strohl & Redline, 1996; Young, Evans 
et al., 1997).  There is some evidence that clinical OSA recognition in the 1990s had 
improved from the 1980s, but still only 2 – 18% of OSA was diagnosed (Kapur et al., 
2002; Young, Evans et al., 1997). Since the 1990s there have been improvements in 
several of the factors associated with under diagnosis (Marshall et al., 2007; Namen et al., 
2002; Zozula, Rosen, Jahn, & Engel, 2005). The proportion of prevalent OSA that has 
been clinically diagnosed has not been assessed since a previous analysis of data obtained 
in 1995 – 1998 (Kapur et al., 2002). With this most recent analysis of the clinical 
recognition of OSA having been done more than ten years ago, factors predictive of 
clinical recognition have not been evaluated following the changes of the past decade. 
Nature of the Study 
An expansion of an existing population-based study was used to determine the 
proportion of prevalent OSA that had been diagnosed clinically, and identify predictors 
of clinical diagnosis.  The longitudinal Prevalence of Asymptomatic Ventricular 




study identified a population-based sample randomly selected from the residents of 
Olmstead County, Minnesota who were at least 45 years old on January 1, 1997.  In the 
PAVD study OSA risk was characterized using a modified Berlin Questionnaire (Netzer, 
Stoohs, Netzer, Clark, & Strohl, 1999). Data collection that would allow the OSA risk 
characterization, either high or low, for all PAVD round two participants, was completed 
in 2004 as part of the ongoing study.  
This study used the resources of the Rochester Epidemiology Project (Melton, 
1996) to link PAVD participants and their OSA risk with their clinical records. This 
matching allowed the determination of (a) the frequency of clinical evaluation for OSA, 
(b) the prevalence of a clinical diagnosis of OSA among those at high risk for OSA, and 
(c) the differential characterization of those diagnosed and undiagnosed with OSA among 
those at high risk for the disorder. 
 Thus, the research questions addressed by this study are as follows: 
1. What proportion of those at high risk for OSA based on the Berlin 
Questionnaire have been clinically evaluated for OSA? 
2. What is the prevalence of clinically diagnosed OSA among those at high risk 
for OSA based on responses to the Berlin Questionnaire? 
3. Has the prevalence of clinically diagnosed OSA increased in the past decade? 
4. What factors were predictive of the clinical diagnosis of OSA among those at 
high risk of OSA? 




1. There is a portion of those at high risk for OSA that has not been clinically 
evaluated. 
2. There is a portion of those at high risk for OSA that has not been clinically 
diagnosed. 
3. There has been an increase in the proportion of prevalent OSA that is 
diagnosed clinically compared to the mid-1990s. 
4. Among those at high risk for OSA the following characteristics will be more 
common among those with a clinical diagnosis of OSA than among those 
undiagnosed:  age, male gender, higher BMI and higher socioeconomic status. 
 Thus the null hypotheses (H0) for this study were the following: 
1. There is no difference between the population at high risk for OSA and those 
that have been clinically evaluated. 
2. There is no difference between the population at high risk for OSA and those 
that have been clinically diagnosed. 
3. There has been no change in the proportion of prevalent OSA that is 
diagnosed clinically compared to the mid-1990s. 
4. Among those at high risk for OSA there is no difference regarding the 
following characteristics among those with a clinical diagnosis of OSA than 
among those undiagnosed:  age, gender, BMI, and socioeconomic status. 
Purpose of the Study 
The purpose of this study was to determine if the proportion of OSA that is 




OSA based on the modified Berlin Questionnaire (Netzer et al., 1999) were identified by 
the use of the instrument in the PAVD study (Redfield et al., 2003). Through matching of 
this sample with clinical records those with clinically diagnosed OSA will be identified. 
Factors predictive of clinical diagnosis were identified. 
In this study the independent variables include OSA risk based on the modified 
Berlin Questionnaire and demographic variables including age, gender, BMI, 
socioeconomic status, and other clinical parameters assessed in the PAVD study.  The 
dependent variable was the clinical diagnosis of OSA based on a review of clinical 
records. 
Theoretical Basis 
The under recognition of OSA has been partly attributed to limited physician 
awareness of the disorder. The clinical diagnostic process has been studied for many 
years and has been described as an iterative process of hypothesis generation followed by 
deductive hypothesis testing.  Together, these processes are referred to as the 
hypothetico-deductive strategy (Round, 2001). Theory of hypothesis generation requires 
that the diagnostician have some prior knowledge of a disorder in order for that disorder 
to be among the diagnostic hypotheses generated (Bockenholt & Weber, 1993; Round, 
2001). Simply put, clinicians are unable to diagnose disorders about which they have no 
awareness. Thus, if there is increased awareness of OSA among physicians, one would 
predict an increased prevalence of clinical recognition. 
The theory of diagnostic access bias has been defined as the nonidentification of 




In applying this theory to the clinical recognition of OSA, the lack of access to PSG 
(which is the primary clinical diagnostic technology for OSA) would be expected to limit 
OSA clinical recognition.  Therefore the clinical recognition of OSA would be expected 
to increase as access to PSG technology increases. 
One qualitative study of patients undergoing PSG (van de Mortel, Laird, & 
Jarrett, 2000) generated a satisfaction-compliance theory which states “The degree of 
satisfaction with the sleep studies experience is to some degree a predictor of 
compliance” (p. 167). If sleep centers have been at all successful in pursuing improved 
patient satisfaction with PSG since the completion of the original OSA clinical 
recognition studies (Kapur et al., 2002; Young, Evans et al., 1997), this theory would 
predict increased compliance with completing PSG, and thus a higher prevalence of 
clinically recognized PSG. 
In summary, a theoretical basis exists relative to (a) physician OSA awareness, (b) 
PSG diagnostic access, and (c) satisfaction-compliance theory for increased prevalence of 
OSA clinical recognition since its previous assessments based on data collected about 10 
years ago. 
Operational Definitions 
For the purposes of this study operational definitions and acronyms as described 
below are used. 
Apnea:  the termination of airflow at the mouth or nose for 10 seconds or more 




AHI:  Apnea-hypopnea Index, the total number of apneas and hypopneas 
occurring per hour of sleep as quantified by polysomnography (Berry & Foster, 2005). 
BMI:  Body mass index, an index of obesity calculated as the weight in kilograms 
divided by the height in meters squared (Thomas, 1997) 
Clinically diagnosed obstructive sleep apnea: a patient whose clinical records 
indicate that their healthcare provider had made the diagnosis of sleep apnea typically 
based on polysomnography.  
Hypopnea:  a reduction in thorocoabdominal abdominal respiratory movement or 
airflow that is 30% or more less than baseline associated with an oxygen desaturation that 
is four per cent or more less than baseline during polysomnography (Meoli et al., 2001) 
CPAP:  Continuous Positive Airway Pressure, a breathing support device used 
primarily at night involving transmission of air pressure produced by a fan through tubing 
and a nasal or oro-nasal mask producing a pneumatic airway splint designed to prevent 
airway obstruction (Hirshkowitz & Sharafkhaneh, 2005). 
OSA:  Obstructive Sleep Apnea, a sleep-related breathing disorder in which the 
upper airway collapses during sleep producing an obstructed airway. Respiratory efforts 
continue despite the obstruction often leading to arousal due to falling oxygen saturation 
levels (Berry & Foster, 2005). 
OSA Risk:  Obstructive Sleep Apnea Risk, in the context of this study OSA risk is 
determined based on the Berlin Questionnaire, a previously validated instrument that 




PAVD Study:  Prevalence of Asymptomatic Ventricular Dysfunction Study, a 
longitudinal population-based study in Olmstead County, Minnesota primarily to assess 
the cardiac dysfunction over time that now also includes an assessment of obstructive 
sleep apnea risk (Redfield et al., 2003). 
PSG:  Polysomnography, sleeping overnight in an observational clinical 
laboratory with a multichannel monitoring system for brain, eye, and muscle activity, 
respiratory efforts, heart rate, and blood oxygen saturation (Chesson et al., 1997). 
RDI:  Respiratory Disturbance Index, generally equivalent to the AHI, though 
some centers use a respiratory effort-related arousal rather than hypopneas to calculate 
this index (Berry & Foster, 2005). 
Assumptions and Limitations 
Several assumptions are inherent in the design of this study.  This study used a 
modified Berlin Questionnaire (BQ) as the method of identifying those with OSA.  High 
risk for OSA was used as a proxy for prevalent OSA making the assumption that all of 
those identified as at high risk for OSA actually have the disease. The basis for this 
assumption is the high positive and negative predictive values for the BQ from the 
originally published validation study (Netzer et al., 1999).  Further analysis of the BQ, 
along with its modification and diagnostic performance in multiple subsequent studies is 
provided in the literature review. Thus, it is important to recognize the weakness of this 
assumption, namely, that those classified as high risk by the BQ represent all of those 
with prevalent OSA.  Though the definitive measure of prevalence would be performance 




would be cost prohibitive. There will be opportunity to assess the diagnostic performance 
of the BQ in this sample based on the results of the polysomnography studies done 
clinically; however diagnostic performance based on these results will itself be subject to 
test verification bias (Roger et al., 1997). 
The random selection and longitudinal nature of the PAVD study (Redfield et al., 
2003) that provided the population-based sample for this study requires consideration of 
assumptions regarding participation bias and attrition. Participation bias in the original 
sample in round one was considered previously with little evidence of impact on overall 
results (Jacobsen et al., 2004). A further analysis of round two participation bias is 
presented in chapter 4. 
The outcome measure for this study was the clinical diagnosis of OSA and thus 
will assume consistency of diagnostic criteria and methodology in making that diagnosis.  
However, in making the diagnosis of OSA it has been recognized that there is variability 
in the gold standard PSG sensors (Redline & Sanders, 1999), the definition of hypopnea 
(Tsai, Flemons, Whitelaw, & Remmers, 1999), patient night-to-night variability 
(Bittencourt et al., 2001), and inter-rater variation (Loredo, Clausen, Ancoli-Israel, & 
Dimsdale, 1999).  Some of this variation has been addressed by recently published PSG 
scoring criteria (Redline et al., 2007). With the clinical diagnoses for the study coming 
from primarily two sleep laboratories involving multiple clinicians over a period of years 
there will be variation in the basis for the diagnoses. Chapter 4 presents an analysis of the 




outcome measure is by its definition a measure of the clinical process of care over time, 
this variation is expected and acceptable. 
This population-based sample was drawn from the Olmstead County, Minnesota 
population in 1997. Olmsted County had been 95.6% Caucasian in 1990, 90.3% in 2000, 
and more recently, 88.9% in 2006.  In 2000 the Olmsted County adult population (age 18 
and over) was 99.1% Caucasian (US Census Bureau, 2007).  The sample for this study 
having been drawn from those ages 45 and older in 1997 was by self-report 97.9% 
Caucasian.  This appears representative of the county at the time of sampling.  However, 
because less than 3% of the sample was non-Caucasian, the results of the study are 
interpreted in light of this limited racial diversity. 
Significance of the Study 
In a recent monograph (Colten & Altevogt, 2006) OSA was identified as a public 
health problem by the Institute of Medicine which recommended that there be support for 
“additional surveillance and monitoring of sleep patterns and sleep disorders.” (p. 11). 
This study measured changes in the clinical recognition of OSA in the past decade during 
which time enhanced physician awareness of OSA and improved access to PSG may 
have increased the likelihood of clinical recognition. This information is of value to 
public health officials and the health care system for allocation and organization of the 
systems that evaluate and treat OSA in order to improve health outcomes. 
The Pickwickian syndrome, an early term for what is now recognized as OSA, 
was epitomized by Fat Joe from Charles Dickens and represents the classic description 




snoring, obesity, male gender, and age are all considered to be among the risk factors for 
the disorder (Young, Peppard et al., 2002). Previous studies evaluating the clinical 
recognition of OSA (Kapur et al., 2002; Young, Shahar et al., 2002) have suggested that 
these factors, along with socioeconomic status as measured by income and education, 
increase the likelihood of clinical recognition.  Because this study identified the 
characteristics of those both likely to and unlikely to be clinically diagnosed with OSA, 
those factors are useful in guiding future strategies for clinical recognition.  This study 
represents a timely assessment of progress related to OSA clinical diagnosis in the past 
decade and provides information useful in (a) guiding future diagnostic strategies, 
particularly for those more likely to be previously undiagnosed; and (b) resource 
allocation to address OSA as public health problem. 
Summary 
OSA is a sleep-related breathing disorder that is associated with significant 
cardiovascular and cerebral vascular morbidity and mortality.  Treatment with CPAP 
does attenuate this increased morbidity and mortality, but adherence to CPAP is 
challenging and limited.  More importantly, most OSA is undiagnosed. Previous research 
has shown that no more than 18% of prevalent OSA was clinically diagnosed in the 
1990s.  OSA along with other sleep-related problems has been identified as public health 
problem by the Institute of Medicine. 
In the past decade there have been efforts to increase health professional 
awareness and PSG diagnostic capacity for OSA. Thus, this study represents a timely 




differentially identifies characteristics of those likely and unlikely to be among those with 
clinically diagnosed OSA. 
The study identified those at high risk for OSA using the previously validated BQ 
in a population based sample from Olmsted County, Minnesota.  The sample was 
matched with clinical records including PSG to determine the clinical diagnostic rate and 
factors that predict having clinically diagnosed OSA. 
In chapter 2 a literature review is presented which addresses in greater detail OSA 
risk factors, diagnostic considerations, and treatment characteristics.  The literature 
regarding validation, modification, and performance of the BQ as a screening instrument 
for OSA is also be reviewed.  Previous research estimating OSA clinical recognition is 
evaluated along with factors thought to contribute to under recognition.  
The methods used in this study are described in chapter 3.  This includes the 
population sampling and OSA screening methods used as part of the ongoing PAVD 
research.  The method of identifying those with clinical PSGs and OSA using the 
resources of the Rochester Epidemiology Project (REP) (Melton, 1996) are also 
described. 
Analyses of the study’s data related to participation bias, validation of the REP 
methods for identifying those participants that had undergone PSG and were clinically 
recognized with OSA, and analysis of the application of the BQ are presented in chapter 




Finally in chapter 5 these results are interpreted along in light of the study’s 
strengths and weaknesses. Based on these results recommendation for action and further 
research regarding OSA clinical recognition are made.
 
 
CHAPTER 2:  LITERATURE REVIEW 
Introduction 
A review of the literature related to the epidemiology, diagnosis, and treatment of 
obstructive sleep apnea (OSA), previous assessments of the prevalence of the clinical 
diagnosis OSA, the use of the BQ for assessing OSA risk, and the use of patient clinical 
records for epidemiologic research is provided in this chapter.   
Organization of the Literature Review  
This chapter is organized in a series of five sections designed to systematically 
provide readers background necessary for the study’s context, a review of previous 
studies of the under diagnosis of OSA, and the nature of the study’s instrument and 
methods.  A background review of the epidemiology, diagnosis, and treatment of OSA is 
provided in the first section of this chapter and is the scientific context for this study’s 
analysis of OSA clinical recognition.  A critical review of the previous assessments of the 
OSA under diagnosis, a description of factors potentially explaining that under diagnosis, 
and the changes that have occurred regarding these factors are presented in the second 
section. A review of the development, use, and performance characteristics of the BQ as 
a tool for identifying those at high risk for OSA is presented in the third section.  The a 
review of the use of patient clinical records for epidemiologic research, in particular the 
structure and resources of the Rochester Epidemiology Project is presented in section 
four. Finally a review of the Prevalence of Asymptomatic Ventricular Dysfunction study 
(Redfield et al., 2003) which had created the population-based sample in which the 
prevalence of clinically recognized OSA was evaluated is presented in the fifth section. 
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Literature Search Strategies 
The identification of publications for this review has been carried out through 
multiple iterative searches using primarily the MEDLINE database of the National 
Library of Medicine (NLM) searched with the proprietary search interface known as the 
Ovid Web Gateway™ (Ovid Technologies, Inc., Norwood, MA). In addition, the 
EMBASE, CINAHL, and PsycINFO databases were also used for some selected topics.  
Most literature regarding OSA was identified from among over 5600 publications 
indexed under the NLM’s medical subject heading (MeSH) “Sleep Apnea, Obstructive” 
although some searches were expanded to include citations indexed under the MeSH 
terms “Sleep Apnea Syndromes” which together include nearly 17,000 citations. 
Additional searches using the terms “Continuous Positive Airway Pressure” with over 
2200 citations, or “Polysomnography” also with over 10,000 citations were carried out.  
In addition, the reference lists from retrieved papers, review articles, and relevant texts 
were searched to identify citations not otherwise identified. Papers identified were most 
commonly retrieved through the digital resources of the Mayo Clinic Libraries ("Mayo 
Clinic Libraries," 2007) including interlibrary loan, with supplementation from the 
Walden University Library, and personal subscriptions providing access to the journal 
Sleep, and the Journal of Clinical Sleep Medicine.  Generally only English language 
papers were reviewed, although for selected topics uniquely addressed by German or 
Italian papers these were also reviewed.  Except for topics related to the historical 
development of OSA science, review was largely limited to papers published since 1990. 
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Epidemiology, Diagnosis, and Treatment of OSA 
Prevalence of Obstructive Sleep Apnea 
In the past 27 years there have been at least 27 papers (see Table 1) that have 
estimated the prevalence of obstructive sleep apnea in various populations.  These studies 
have been done in several countries including Italy, Spain, Sweden, Hong Kong, Korea, 
India, the United Kingdom, Australia, New Zealand, and Brazil in addition to the United 
States. In comparing the reported prevalence from these studies there is substantial 
variability with a range from less than 1% (Lavie, 1983) to over 50% in adult, nonelderly, 
male populations (Redline, Schluchter, Larkin, & Tishler, 2003).  Previous commentators 
have suggested that this variability could be attributed to variation in the definition used 
for the disorder, study design, sample selection, physiologic parameter measurement 
methods, and the day-to-day variability of these sleep parameters (Lindberg & Gislason, 
2000; Young, Peppard et al., 2002).  
OSA is a chronic condition along a continuum of severity in the symptoms and 
physiologic measures used to define the disorder including snoring, hypersomnolence, 
sleep fragmentation, apneas, hypopneas, blood oxygen saturation, and sleep arousal. 
There are several syndromes described along this continuum including sleep apnea (SA), 
obstructive sleep apnea syndrome (OSAS), sleep apnea hypopnea syndrome (SAHS), and 
upper airway resistance syndrome (UARS), all of which can be considered to be part of 
the global continuum of sleep-related breathing disorders (SBD).  For any one of these 
syndromes there is considerable variation in the study definition used leading to divergent 
reports of prevalence (Lindberg & Gislason, 2000; Young, Peppard et al., 2002).   
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Table 1  
 
Studies Reporting Population Prevalence of Obstructive Sleep Apnea in Chronological Order 
OSA Prevalence (%) 




Criteria All ♂ ♀ 
Lavie 1983 Israel Men ≥18 NP 2-stage L-PSG AI≥10  0.9b  
Berry 1986 Florida Men >30 NP 1-stage L-PSG AHI≥5  13  
Gislason 1988 Sweden Men 30-70 PB 2-stage L-PSG RD>30  1.3 b  
Cirignotta 1989 Italy Men 30-70 PB 2-stage L-PSG AHI≥5 AHI≥10  
4.0 b 
2.7 b  







Stradling 1991 United Kingdom Men 35-65 NP 2-stage L-PSG ODI>5 sev. OSA 
5 
0.3 b   





Redline 1994 Cleveland Both ≥16 NP H-PSG RDI≥15  26 13 
Olson 1995 Australia Both 35-70 PB 1-stage PulOx+ RDI≥15 3.6 b 25.9 7.7 
Kripke 1997 San Diego Both 40-65 PB 1-stage PulOx ODI≥20  9.3 5.2 
Ohayon 1997 United Kingdom Both ≥15 PB 1-stage Qust-SE ICSD 1.9 3.5 1.5 
Bixler 1998 Pennsylvania Men ≥20 PB 2-stage L-PSG AHI≥10 AHI≥10a  
10.5 
3.3  
Netzer 1999 Cleveland Both ≥15 NP 2-stage H-PSG RDI≥5 RDI≥15 
66 
38   
















Young 2002 Multicenter USA Both 39-99 PB 2-stage H-PSG AHI≥15  25 11 
21 
  
    
Netzer 2003 Cleveland Both ≥15 NP Qust-B HR 32.3 37.9 27.8 
(table continues) 
OSA Prevalence (%) 




Criteria All ♂ ♀ 











Udwadlia 2004 India Men 35-65 PB 2-stage H-PSG AHI>5 AHI>5 a  
19.5 
7.5  












Hiestand 2006 continental USA Both ≥18 PB 1-stage Qust-B HR 26 31 21 
Reddy 2009 Delhi, India Both 30-65 PB 2-stage L-PSG AHI≥5 9.3 13.5 5.5 
Mihaere 2009 New Zealand Both 30-59 PB 1-stage H-PSG RDI≥5  12.5 3.4 




    
 
Notes.  
AHI: Apnea Hypopnea Index calculated as the number of apneas plus the number of hypopneas divided by the number of hours of sleep; AI: Apnea Index calculated 
as the number of apneas divided by the number of hours of sleep;  H-PSG:  Home polysomnography, a portable device recording system that measures a subset of the 
typical laboratory polysomnography parameters in the participant’s home without an attendant present with later data scoring;  HR: High risk: defined by the BQ 
(Netzer et al., 1999);  ICSD: International Classification of Sleep Disorders as defined by symptoms in groups A, B, and C (Thorpy, 1990), p. 57);  L-PSG: 
Laboratory polysomnography, an in laboratory monitoring of a complete montage of sleep and breathing parameters carried out with an attendant and both real-time 
and post data collection analysis and scoring;  NP:  nonpopulation-based sampling design;  ODI: oxygen desaturation index, calculated as the number of oxygen 
desaturations greater than 4% below baseline divided by the number of hours of sleep;  OSA: Obstructive Sleep Apnea;  PB:  population based sampling design;  
PulOx: pulse oximetry monitoring including recording continuous oxygen saturation and audio recording of breathing sounds;  PulOx+: pulse oximetry monitoring 
recording including continuous oxygen saturation, and audio recording of breath sounds with the addition of chest and abdominal movement sensor recordings 
Qust-B: questionnaire evaluation using the BQ (Netzer et al., 1999; "Reprinting of the Berlin Questionnaire," 2000);  Qust-SE: questionnaire evaluation using the 
computerized Sleep-Eval knowledge based system (Ohayon, Guilleminault, Priest, & Caulet, 1997);  RD: the number respiratory disturbances per night without 
regard to the number of hours of sleep;  RDI: Respiratory Disturbance Index calculated as the number of respiratory disturbances divided by the number of hours of 
sleep;  sev. OSA: severe OSA as defined by long-term symptoms, and AHI≥20; 
a these criteria require a constellation of daytime symptoms in addition to the minimum required AHI; 




As examples of this variability, Lavie’s (1983) early report of the prevalence of 
sleep apnea uses the apnea index (AI) which was defined by apneas alone with a criterion 
of at least 10 per hour of sleep.  In contrast,  a later paper by Redline and colleagues 
(2003) which reports the highest prevalence, used the respiratory disturbance index (RDI) 
which included both apneas and hypopneas with the later defined as a “discrete 
reductions in airflow or chest impedance, lasting at least 10 seconds and associated with 
at least a 2.5% fall in oxygen saturation” (p. 704). Here the criterion for OSA was at least 
five apneas and hypopneas per estimated hour of sleep with no requirement for daytime 
symptoms. Thus, the particular syndrome evaluated and the specific criterion used to 
define that syndrome impact the reported prevalence of the disorder. 
  A variety of methods for sample selection and identification of OSA have been 
used, often including a two-stage design in which a questionnaire or interview screening 
process was used to identify a segment of the population with a high likelihood of sleep 
disordered breathing.  Then participants in this high risk group are selected (or in some 
studies, over-sampled for study along with a sample from the remaining lower risk 
portion of the population) to undergo a more definitive evaluation for the actual presence 
of a SBD syndrome based on the definition used in the study.  Some papers using a multi-
stage method have reported a population prevalence based on a weighting of the 
prevalence obtained from high and low risk groups (E.O. Bixler et al., 2001; E.O. Bixler, 
Vgontzas, Ten, Tyson, & Kales, 1998; Tufik, Santos-Silva, Taddei, & Bittencourt, 2010). 
By contrast, other papers have made the assumption that all those with SBD in the 
population are detected by the screening questionnaire and did not definitively study any 




used are neither 100% sensitive nor 100% specific, several of these papers have reported 
the resulting prevalence as the lower limit of the population prevalence (Duran et al., 
2001; Gislason, Almqvist, Eriksson, Taube, & Boman, 1988; Lavie, 1983; Olson, King, 
Hensley, & Saunders, 1995; Stradling & Crosby, 1991). 
Though many of these papers have used a population based sampling method with 
either a single or two-stage case detection method, other papers have not used population-
based sampling.  For example, Redline and colleagues (1994) used a population 
consisting of relatives and neighbors of participants with known sleep apnea.  Two other 
studies (Netzer et al., 2003; Netzer et al., 1999) used a convenience sample of patients 
presenting to selected primary care physicians offices. Though the samples resulting from 
these methods may have a resemblance to the general population in the areas from which 
they are drawn, that resemblance might be considered accidental rather than by design. 
Studies have used a variety of testing methods to identify OSA in their sampled 
populations.  As described in the “Sleep Monitor” column of Table 1, about half of the 
studies reviewed here used the clinical gold-standard of polysomnography conducted in 
the sleep laboratory monitored by a trained sleep laboratory technician (L-PSG: 
laboratory PSG). About one-third of the studies used a type of the less expensive portable 
polysomnography carried out in the participants’ homes without the benefit of an 
attending sleep laboratory technician (H-PSG: Home PSG).  A few studies have also used 
detection methods based primarily on oxygen saturation monitoring (Kripke et al., 1997; 
Olson et al., 1995) or a purely questionnaire based detection method (Hiestand, Britz, 




techniques may generally detect those with a syndrome along the SDB continuum, the 
exact syndrome, and associated severity reported is variable for these methods. 
A number of these studies (E.O. Bixler et al., 2001; Ip et al., 2001; Kim et al., 
2004; Sharma, Kumpawat, Banga, & Goel, 2006; Udwadia, Doshi, Lonkar, & Singh, 
2004; Young et al., 1993) have reported population prevalence using a particular AHI or 
RDI criterion both with and without regard to daytime symptoms for the particular AHI 
criterion. In all of these studies the symptomatic prevalence is much lower, ranging from 
about one sixth to one half of the prevalence when daytime symptoms are not included in 
the criteria.  
The inclusion of a daytime symptom requirement in the research diagnostic 
criteria for OSA by the American Academy of Sleep Medicine Task Force (Flemons et 
al., 1999) was suggested as an “operational definition” (p. 670) but it was recognized that 
there were no studies validating this criterion. There is evidence that adverse long-term 
outcomes result from SDB regardless of the presence of daytime symptoms. The two 
largest OSA prevalence cohorts (Young et al., 1993; Young, Shahar et al., 2002) have 
demonstrated increased risk of hypertension for those with mild OSA without regard to 
daytime symptoms (Nieto et al., 2000; Young, Peppard et al., 1997). Another large study 
(E. O. Bixler et al., 2000) demonstrated associations of SDB with hypertension even for 
those with AHI<5, again without regard for daytime symptoms. There is also evidence 
that those with mild SDB and no pathologic sleepiness demonstrate reduced AHI (a 
measure of OSA severity) and improved mood, functional status, general health, and 




Daytime sleepiness is associated with increased OSA severity as demonstrated in 
the large Sleep Heart Health Study where the Epworth Sleepiness Scale (ESS) showed a 
statistically significant correlation with RDI severity (Gottlieb et al., 1999). In addition, 
sleepiness has been found to be predictive of diminished cardiac output even when OSA 
severity, as measured by RDI, was held constant (J. B. Choi et al., 2006). Thus, daytime 
sleepiness appears to be a marker of OSA disease severity, though as a binary marker, 
sleepiness seems to be a poor criterion for the presence or absence of OSA. 
Analysis of the varying prevalence demonstrated in Table 1 shows that if one 
considers studies with population based samples that used an AHI or RDI criterion of 
greater than or equal to five without a daytime sleepiness requirement eight of the ten 
such studies (Ancoli-Israel et al., 1991; Cirignotta et al., 1989; Duran et al., 2001; Ip et 
al., 2001; Kim et al., 2004; Mihaere et al., 2009; Reddy et al., 2009; Sharma, Kumpawat 
et al., 2006; Udwadia et al., 2004; Young et al., 1993) report a rather consistent male 
OSA prevalence of 12.5% – 28%.  The two papers among these eight that substantially 
deviate from this population prevalence include one which selected for PSG study only 
40 every-night snorers with the assumption that all those with OSA snore (Cirignotta et 
al., 1989). The remaining study (Ip et al., 2001) made a similar conservative assumption 
that there was no OSA among those who did not undergo PSG. Thus, these two studies 
(Cirignotta et al., 1989; Ip et al., 2001) used analytic methods that would under-report 
OSA.   
The six other population based studies in Table 1 include those that used criteria 
involving either AHI cut-off values of 10 or more (E.O. Bixler et al., 2001; E.O. Bixler et 




desaturation index (ODI) (Kripke et al., 1997) and total respiratory disturbances during 
the night (RD) (Gislason et al., 1988). Thus, these studies might be expected to under-
represent the OSA prevalence that would be expected based on an AHI cut-off of 5.  
Despite these differences one of these studies reports a male OSA prevalence of 25.9% 
(Olson et al., 1995), similar to the range noted previously. Thus, it seems that a 
population prevalence estimate of 19 – 25% for OSA in males using an AHI greater than 
or equal to 5 without a daytime sleepiness requirement represents a rather consistent 
estimate across these studies. 
Reviews of the gender prevalence of OSA and SDB have suggested that the male 
to female ratio is in the range of 1.5 – 3:1 (Jordan & McEvoy, 2003; Kapsimalis & 
Kryger, 2002). Similar to the male analysis described above, there are six population 
based studies that report a female prevalence using an AHI or RDI greater than or equal 
to five without a daytime sleepiness requirement (Ancoli-Israel et al., 1991; Duran et al., 
2001; Kim et al., 2004; Sharma, Kumpawat et al., 2006; Young et al., 1993; Young, 
Shahar et al., 2002).   These studies show male to female ratios that range from 0.9 – 
2.7:1 with the one study showing a greater prevalence for females compared to males 
having been conducted in Spain (Duran et al., 2001).  For the other population based 
studies that report prevalence for both genders using other OSA criteria, the male to 
female ratios range from 1.8 – 3.4:1 (E.O. Bixler et al., 2001; Kripke et al., 1997; Olson 
et al., 1995). Though the origins of these differences are not well established, there is the 
suggestion that women may less commonly present with classical symptoms leading to 
relatively greater under-recognition (Jordan & McEvoy, 2003; Kapsimalis & Kryger, 




OSA Symptoms and Risk Factors 
The most common symptom associated with OSA is snoring which has been 
found in as many as 97% of those with OSA (Whyte, Allen, Jeffrey, Gould, & Douglas, 
1989). Among men with OSA about 85% report habitual snoring defined as snoring at 
least three nights per week (Flemons, Whitelaw, Brant, & Remmers, 1994; Rowley, 
Aboussouan, & Badr, 2000), and about 90% of those with OSA having at least some 
snoring regardless of gender (Rowley et al., 2000). However, some reports acknowledge 
that snoring is not present in significant portions of some populations with OSA such as a 
Danish study which found that 48% women and 19% of men with OSA did not report 
snoring (Jennum & Sjol, 1992). 
In the general adult population 59% report snoring (Hiestand et al., 2006) and in 
other studies 25 - 28% and 44 - 46% of women and men, respectively, report habitual 
snoring (Duran et al., 2001; Young et al., 1993).  These two population-based studies 
demonstrated an independent association between snoring and OSA with the odds ratios 
for sleep apnea that range from 2.87 to 4.72 with habitual snoring after adjusting for age, 
gender, race, BMI, neck girth, and waist to hip ratio in a multicenter American population 
(Young, Shahar et al., 2002), and age and gender in a Spanish population (Duran et al., 
2001), respectively. Often those with OSA report such severe, disruptive snoring that it 
can be considered socially isolating even within a marital relationship (Cartwright & 
Knight, 1987). Thus, snoring is a common and sometimes isolating symptom of OSA.  
However, it is neither a necessary or sufficient condition for the presence of OSA and is 




Excessive sleepiness is the most common daytime symptom among those with 
OSA (Engleman & Douglas, 2004). It too is a relatively common symptom in the general 
population with 26% reporting that they wake up feeling tired or fatigued (Hiestand et al., 
2006).  As a subjective symptom, sleepiness is better characterized and often measured 
with a descriptive tool such as the Epworth Sleepiness Scale (ESS) (Johns, 1991; Kirsch 
& Chervin, 2007).  When sleepiness was originally measured among those with OSA 
using the ESS the score correlated with the severity of OSA based on RDI (Johns, 1991). 
This relationship between OSA severity and sleepiness as defined by the ESS was also 
demonstrated in a large population-based study, the Sleep Heart Health Study (Gottlieb et 
al., 1999). However, it is important to note that nearly two-thirds of those with severe 
OSA (AHI>30) do not meet the ESS criteria for excessive daytime sleepiness (ESS 
score>10) (Gottlieb et al., 1999). 
Obesity has long been associated with OSA as illustrated by the prototypical case 
of sleep apnea, Joe, the Fat Boy, from Charles Dickens (Conti et al., 2006).  Of the 
studies reviewed in Table 1 above, all 20 of the studies that considered obesity as a 
covariate for either presence or severity of OSA found an association.  The remaining 
studies (Gislason et al., 1988; Lavie, 1983; Roehrs, Kapke, Roth, & Breslau, 2006) did 
not present an analysis of obesity as an OSA covariate.  Some reviewers (Young, Peppard 
et al., 2002) have suggested that there is “little controversy that the associations seen in 
observational studies represent a causal role of excess weight in OSA” (p. 1228).  
In the multicenter Sleep Heart Health Study a one standard deviation difference 
(5.3 kg/m2) in Body Mass Index (BMI) increased the odds of OSA by about 55% when 




addition, a longitudinal weight increase of 10% is associated with a 32% increase in OSA 
severity as measured by the apnea-hypopnea index, whereas a 10% reduction in weight 
reduces OSA severity by 26% (Peppard, Young, Palta, Dempsey, & Skatrud, 2000). 
Thus, though difficult to achieve, weight loss can be effective in treating OSA (Veasey et 
al., 2006). 
Male gender has been considered an OSA risk factor.  OSA is generally two to 
three times more common among men than women (Strohl & Redline, 1996). In the two 
large population based studies of OSA prevalence male to female gender ratios ranged 
from 1.67:1 (Baldwin et al., 2001) to 3.7:1 (Young et al., 1993) depending on the severity 
criteria used to define OSA.   Among sleep clinic populations the male predominance 
was much greater with reviewers citing ratios of 5-8:1 (Jordan & McEvoy, 2003) to as 
high as 90:1 (Strohl & Redline, 1996). This suggests that men are more likely to be 
referred for sleep clinic evaluation possibly because they have more severe disease and 
more classic symptoms (Jordan & McEvoy, 2003; Shepertycky, Banno, & Kryger, 2005; 
Strohl & Redline, 1996). 
OSA Clinical Diagnosis 
Historically polysomnography (PSG) has been the recommended technique for 
the clinical diagnosis of OSA (Chesson et al., 1997; Schlosshan & Elliott, 2004; P. L. 
Smith et al., 1994).  This technique involves the placement of multiple electrodes, probes, 
and belts to monitor neurological, respiratory, cardiovascular, and other physiologic 
parameters during sleep.  It is typically carried out in a hospital-like setting with a sleep 
technician present to supervise and monitor the recording of these multiple parameters 




2004).  Thereafter the PSG recording is interpreted by a physician to formulate an 
interpretation and clinical diagnosis. 
Accepted OSA diagnostic criteria (Flemons et al., 1999) include both subjective 
symptoms and objectively measured obstructive events during sleep.  Obstructive sleep 
events occurring at a rate of least 15 per hour of sleep (AHI ≥ 15), regardless of 
subjective symptoms, meets these criteria for OSA, as does an AHI of five or more, but 
less that 15, with subjective symptoms such as excessive daytime sleepiness, choking or 
recurrent sleep awakenings, unrefreshing sleep, daytime fatigue or impaired 
concentration. OSA severity is graded based on AHI with 5 – 15 classified as mild 
whereas 15 – 30, and >30 being considered moderate and severe, respectively. 
Though full, attended polysomnography is the primary OSA diagnostic method, 
other unattended testing methods with fewer recorded physiologic parameters (Collop et 
al., 2007; Ghegan, Angelos, Stonebraker, & Gillespie, 2006; Littner, 2005) and 
alternative clinical diagnostic strategies have been considered (Brietzke, Katz, & 
Roberson, 2004; Mulgrew, Fox, Ayas, & Ryan, 2007; Senn, Brack, Russi, & Bloch, 
2006). The unattended diagnostic devices and methods have been classified as Levels II 
to IV based on the number and type of physiologic sleep parameters monitored during the 
study; full, attended PSG is then designated a Level I study (Littner, 2005). Clinical 
guidelines developed by the American Academy of Sleep Medicine recommend that 
these unattended techniques only be used in the context of a comprehensive patient 
evaluation system in populations where the sensitivity and specificity of the method is 




Among the other diagnostic strategies has been a clinical medical history and 
physical exam. This strategy has proven to be ineffective with a low sensitivity and 
specificity even when performed by expert clinicians (Brietzke et al., 2004; Viner, Szalai, 
& Hoffstein, 1991). More recently a diagnostic algorithm combined with a therapeutic 
trial of CPAP and follow up overnight oximetry (a Level IV unattended monitoring) was 
shown to be as effective as full PSG in making the diagnosis in a population with high 
OSA prevalence.  The study suggested that with this strategy treatment adherence was 
improved compared to standard methods (Mulgrew et al., 2007). 
Recently a coverage determination by the Centers for Medicare and Medicaid 
may allow reimbursement OSA treatment with CPAP when the OSA has been diagnosed 
using Level II to IV unattended diagnostic methods. (Phurrough, Jacques, Spencer, 
Stiller, & Brechner, 2008) Historically CPAP was reimbursed only when OSA was 
diagnosed using full PSG.  Thus, it is possible that the clinical diagnosis of OSA will in 
the future be more commonly made in some settings using unattended diagnostic 
methods.  Thus, the assessment of the prevalence of clinically recognized OSA in the first 
decade of the 21st century would be a timely and useful benchmark for comparison to the 
previous assessments in the 1990s (Kapur et al., 2002; Young, Evans et al., 1997) prior to 
potential change in diagnostic methods used for the future. 
OSA Treatment 
There have been multiple treatment modalities employed for OSA.  Weight loss 
by dietary restriction has been demonstrated to reduce the severity of OSA and associated 
hypertension (Kansanen et al., 1998; Suratt, McTier, Findely, Pohl, & Wilhoit, 1992). 




recur even in those that are able to maintain a reduced weight (Sampol et al., 1998). 
Though more than 20 different drugs have been tested for the treatment of OSA, in 
clinical trials none have been proven effective (I. Smith, Lasserson, & Wright, 2006). 
Several surgical and mechanical treatments have, however, been demonstrated to 
be effective. A surgical tracheostomy which places a permanent opening in the airway 
below the area of airway obstruction in OSA was among the first treatments shown to be 
effective in the long-term (Guilleminault et al., 1981). Other surgical procedures used for 
OSA involve modifications to both soft tissue and boney structures (Colin & Duval, 
2005). A 1996 systematic review of the success of surgical OSA treatment found success 
rates no higher than 50% (Sher, Schechtman, & Piccirillo, 1996).  Subsequently the 
surgical approaches have used staging systems (Friedman, Ibrahim, & Joseph, 2004; Li, 
Powell, Riley, Troell, & Guilleminault, 1999) that attempt to more directly tailor the 
surgical procedure(s) to the OSA patient’s specific anatomy.  With such staging there has 
been improved success rates in the 70 – 80% range for some OSA anatomical types 
(Friedman & Schalch, 2007). 
Oral and dental appliances are devices that move the mandible anteriorly or retain 
protrusion of the tongue during sleep (Chan, Lee, & Cistulli, 2007).  There is some 
variability in the definition of treatment success in the oral appliance literature. However, 
for mild to moderate OSA there is overall a 52% success rate (Ferguson, Cartwright, 
Rogers, & Schmidt-Nowara, 2006). Controlled trials have demonstrated that these 
appliances are generally inferior to continuous positive airway pressure treatment (Lim, 




Continuous positive airway pressure (CPAP) is considered to be first-line therapy 
for those with moderate to severe OSA, especially those that have symptomatic daytime 
sleepiness (Giles et al., 2006; Kushida et al., 2006). CPAP devices use airflow generated 
by a fan and applied to the patient’s airway by way of tubing and a nasal or oronasal 
mask to maintain the patency of the airway during sleep. Thus, CPAP functionally 
represents a pneumatic splint that prevents OSA-related airway obstruction (Hirshkowitz 
& Sharafkhaneh, 2005). 
There have been two recent comprehensive literature reviews (Gay et al., 2006; 
Weaver & Chasens, 2007) of studies of CPAP therapy efficacy for OSA in adults.  
Combined these two reviews considered a total of 34 published studies that met the 
quality criteria regarding relevance and study design for the respective review. Of these 
studies a wide variety of study end points were used including AHI reduction, improved 
sleep architecture, reduction in daytime sleepiness and other OSA-related symptoms, 
improved neurobehavioral symptoms, functional status, quality of life, blood pressure, 
cardiac function, coagulation factors, cholesterol, and nocturia (Gay et al., 2006; Weaver 
& Chasens, 2007).   
Collectively in these two reviews (Gay et al., 2006; Weaver & Chasens, 2007) a 
total of 28 of the 34 papers demonstrated some beneficial effect for CPAP with OSA with 
respect to at least one of the endpoints studied. These studies included variable study 
designs, disease severities, ages, treatment, and endpoint definitions. Endpoints involving 
daytime sleepiness, snoring, gasping, cognitive processing, memory, executive function, 
motor speed, and nonverbal learning variably demonstrated improvement in one or more 




greater than 15 with daytime sleepiness) the following endpoints demonstrated more 
consistent improvement with CPAP:  AHI, sleep architecture, blood pressure, cardiac 
contractility, stroke volume, vascular resistance, and platelet coagulability (Gay et al., 
2006; Weaver & Chasens, 2007). 
Gay and colleagues (2006) found that eight studies that had reported no 
improvement for the endpoints considered did not report a power analysis estimating the 
probability of Type II error for these negative results.  Of the additional six negative 
studies (Barbe et al., 2001; Henke, Grady, & Kuna, 2001; Kajaste, Brander, Telakivi, 
Partinen, & Mustajoki, 2004; Robinson, Pepperell, Segal, Davies, & Stradling, 2004; 
Robinson, Smith, Langford, Davies, & Stradling, 2006) included in the later review 
(Weaver & Chasens, 2007) only one reported a power analysis (Robinson et al., 2006).   
That study (Robinson et al., 2006) used a power analysis based on detection of a 5 
mm of Hg blood pressure reduction with CPAP.  However, from the cardiovascular 
literature, a meta-analysis of 29 studies involving more than 150,000 patients a 
population mean blood pressure reduction as small as two mm of Hg produced 
statistically significant reduction in risk for stroke and cardiovascular disease (Turnbull, 
2003). So the study by Robinson and colleagues (2006) may not have been sufficiently 
powered to detect the smaller blood pressure changes that other studies have shown to be 
associated with cardiovascular risk reduction. Therefore, these 14 negative studies 
generally may not have been of sufficient size to avoid Type II errors in evaluating 
physiologic endpoints. 
Indeed two subsequent meta-analyses specific to the effect of CPAP on blood 




about 1.7 mm Hg based on 572 participants (Haentjens et al., 2007) whereas systolic BP 
is reduced about 2.5 mm Hg based on 818 participants (Bazzano, Khan, Reynolds, & He, 
2007).  An additional small study (Hui et al., 2006) not included in these meta-analyses 
demonstrated a reduction in 24 hour mean BP of 3.8 mm Hg. Thus, the identification and 
treatment of those with OSA is associated with a population BP reduction of a magnitude 
that has produced a reduction of stroke and cardiovascular risk in pharmacologic 
treatment studies. 
The benefits of CPAP treatment in those with moderate to severe OSA including 
daytime symptoms has been well established and accepted (Gay et al., 2006; Weaver & 
Chasens, 2007) even by those taking a conservative position regarding CPAP treatment 
in OSA (Montserrat, Barbe, & Rodenstein, 2002; Wright & Sheldon, 2000). Whether to 
treat mild to moderate OSA, and those without daytime symptoms has been much more 
controversial having been the topic of two point-counterpoint pairs of editorials in the 
sleep literature (Davies & Stradling, 2000; Levy, Pepin, & McNicholas, 2002; Montserrat 
et al., 2002; Wright & Sheldon, 2000).  
A recent meta-regression of randomized controlled trials of CPAP demonstrated 
that, across the spectrum of OSA severity, the reduction in blood pressure with CPAP 
though larger with a higher AHI, approaches zero with a pre-treatment AHI between 10 
and 20 (Haentjens et al., 2007, Figure 3A, p. 762). In reviewing randomized studies of 
CPAP treatment restricted to those with mild to moderate disease Gay and colleagues 
(2006) report that CPAP did reduce AHI, did not improve objective sleepiness or blood 
pressure, and had mixed results for subjective sleepiness, and quality of life. However, a 




Neill, Campbell, & Sheppard, 2005) not available to Gay and colleagues (2006) that was 
able to demonstrate collectively a statistically significant improvement in both subjective 
sleepiness by the Epworth Sleepiness Scale, and objectively with the Maintenance of 
Wakefulness Test.  In this analysis (Marshall et al., 2006) a significant improvement with 
the Multiple Sleep Latency Test was not found.  Thus, though the treatment effect is 
smaller, and thus more difficult to detect without larger samples or pooled data, there 
does appear to some benefit to CPAP treatment of mild to moderate OSA. 
Research regarding efficacy of CPAP has been challenging in the selection of an 
adequate control for the CPAP treatment (Babar & Quan, 2003; Hein, 2002; Wright, 
Johns, Watt, Melville, & Sheldon, 1997). In the review by Weaver and Chasens (2006) 
eight of the 26 controlled trials reviewed used a placebo tablet, and four used 
conservative measures such as a low calorie diet and behavioral therapy, whereas 12 
studies used subtherapeutic or sham CPAP as the control. Subtherapeutic or sham CPAP 
involves the participants’ use of a CPAP machine that is either set to provide a pressure 
so low that it should be ineffective, or with a CPAP system modified to prevent it from 
delivering a therapeutic pressure (Farre et al., 1999). Not surprisingly there is evidence 
from research with acupuncture that there is a differential placebo effect between sham 
devices and tablet placebos (Kaptchuk et al., 2006).  There has also been controversy 
regarding the ethics  of the deception associated with the use of sham CPAP and other 
placebos in CPAP research (Karlawish & Pack, 2001). Thus, it seems there is no ideal 
placebo control for the evaluation of CPAP efficacy, and this research must be interpreted 




Overall, CPAP treatment effects have been most consistently beneficial in those 
with moderate to severe disease with symptoms of daytime sleepiness (Gay et al., 2006; 
Weaver & Chasens, 2007). However, as described in the analysis of Table 1 above there 
is evidence that those with mild sleep disordered breathing even without daytime 
sleepiness are also at increased risk of hypertension, a known cardiovascular risk factor 
(E. O. Bixler et al., 2000; Nieto et al., 2000; Young et al., 1993; Young, Peppard et al., 
1997; Young, Peppard et al., 2002). Because the evidence from controlled trials, albeit 
some underpowered studies, has not demonstrated a clear benefit from CPAP treatment 
in mild OSA without daytime symptoms, treatment with CPAP in this population remains 
controversial (Gay et al., 2006; Hedner & Grote, 2001; Levy et al., 2002; Weaver et al., 
2007). 
The ability to adhere to prescribed CPAP therapy among those with OSA has 
been limited and variable. A classic study (Kribbs et al., 1993) had demonstrated that 
only 46% were able maintain use of CPAP at ≥4 hours per night. A recent review of the 
CPAP adherence literature (Weaver & Grunstein, 2008) using a standard of at least 4 
hours of CPAP application per night, found a wide range of adherence from 17 – 71%.  
This review suggested that OSA disease severity, as measured by AHI and level of night 
time hypoxia, were only weak predictors of adherence.  Technological CPAP innovations 
such various mask interfaces, heated humidification, and automatic pressure titration or 
bilevel positive airway pressure devices have been shown to only minimally enhance 
adherence (Haniffa, Lasserson, & Smith, 2004; Weaver & Grunstein, 2008) despite the 
fact that many of these innovations have often been marketed for improved adherence 




cognitive behavioral therapy have demonstrated an increase in the average number of 
hours used nightly by 1.5 (Hoy, Vennelle, Kingshott, Engleman, & Douglas, 1999) to 2.9 
hours (Richards et al., 2007).  Thus, it is likely that clinical optimization of adherence 
will require a multidimensional program involving device technical support and, more 
importantly, cognitive behavioral support (Engleman & Wild, 2003).  
Limited Clinical Recognition of OSA 
Historically most people with OSA have been clinically undiagnosed.  Among the 
earliest reports was a published letter from British physicians (Apps, Gillon, & Stradling, 
1983) suggesting that the disorder was under diagnosed in the United Kingdom relative 
to America.  Then, based on hospital discharge diagnostic code data from 1985 to 1987, it 
was reported that only 36 from the database of about ten million discharges were found to 
reference OSA (Dement, 1993; Strohl & Redline, 1996). If the OSA population 
prevalence in this mixed gender population is postulated to be about 3% based on a 
population based study initiated in 1988 (Young et al., 1993) and making the assumption 
of an approximately equal gender mix among these hospital discharges, there would have 
been about 300,000 participants with OSA in this cohort. Thus, the 36 diagnostic 
references to OSA among these discharge diagnoses might suggest a very low prevalence 
of clinical diagnosis at about 0.012%.  
Given that OSA is generally managed in the outpatient setting there is some 
weakness in assessing clinical OSA recognition from such an inpatient database. 
However, in a diagnostic review of outpatient charts for ten northern California primary 
care clinics in 1991 there was no mention of an OSA diagnosis for any of the participants 




the weaknesses of these early assessments of OSA clinical recognition, it appears that as 
recently as 1991 OSA was very infrequently identified by the clinical care system. 
Population-based studies of OSA clinical recognition 
There have been two systematic population-based studies conducted using data 
collected in the 1990s that have assessed the clinical recognition of OSA (Kapur et al., 
2002; Young, Evans et al., 1997). The earlier of these two studies (Young, Evans et al., 
1997) was based on data from the Wisconsin Sleep Cohort (Young et al., 1993) and 
identified participants clinically diagnosed with OSA based on their indication on a 
mailed survey that they had been told by a physician that they had sleep apnea. From the 
4925 who responded to the survey, positive responses were received from 49 participants.  
Telephone follow up of those respondents showed that only 16 had actually been 
clinically diagnosed whereas nearly all of the others had only personally suspected OSA 
but had never been clinically evaluated. These 16 participants represented 15.4% of those 
ultimately identified with moderate to severe OSA, and 6.5% of those identified with the 
broader spectrum of mild to severe OSA based on the study’s screening and 
polysomnography methods. When stratified by gender it was estimated that only 7% and 
18% of women and men, respectively, with moderate to severe OSA, and 2% and 10%, 
respectively, with mild to severe OSA had been diagnosed. A demographic comparison 
of those diagnosed clinically and those identified by study screening showed that only 
male gender and age statistically predicted clinical diagnosis.  In addition, there was a 
trend toward a history of hypertension or cardiovascular disease and higher income 




This study (Young, Evans et al., 1997) has a number of strengths including its 
population-based sample, two stage screening with both high risk and low risk 
participants undergoing PSG, diagnosis of OSA based on in laboratory rather than in 
home PSG, and confirmation of survey reports of physician OSA diagnosis. Among the 
weaknesses are the truncated age range that involved no patients over age 60, the fact that 
only positive responses to the physician diagnosis survey question were confirmed, and 
the lack of medical record verification of physician diagnoses. Overall, within these 
limitations the study appears well done. 
The later study (Kapur et al., 2002) was based on data from the multicenter Sleep 
Heart Health Study (Quan et al., 1997) which included a total of nearly 16,000 
participants. Those clinically diagnosed with OSA were identified based on their positive 
response to question “Have you ever been told by a physician that you have sleep 
apnea?” (Kapur et al.,2002, p. 50).  The study’s screening for prevalent OSA was based 
on participants’ response to survey questions regarding frequency of snoring and 
excessive daytime sleepiness.  Participants that reported snoring three or more nights per 
week and feeling excessively sleepy more than five days per month were identified as 
being “consistent with a higher probability” (Kapur et al.,2002, p. 50) of OSA, 
particularly those with moderate to severe OSA.  
By survey responses 253 participants reported having a physician diagnosis of 
OSA with 90 of these under treatment whereas 650 participants met the proxy criteria for 
OSA. Of the 650 participants meeting the OSA proxy criteria, 54 or 8.3% reported 
physician diagnosis.  Demographic analysis of these participant groups demonstrated that 




severe OSA who reported being diagnosed and treated for OSA:  male gender, body mass 
index, hypertension, lower HDl cholesterol, and being a college graduate. In a logistic 
regression model using these factors only male gender and body mass index remained 
statistically significant. 
In their analysis of these results Kapur and colleagues (2002) noted that OSA 
prevalence using this proxy criteria was 4.1% which was comparable to that in a previous 
population based sample (Young et al., 1993).  However, among the 10 sites involved in 
the study the prevalence varied from 1.55% to 7.23% with prevalence of physician 
diagnosed, and physician diagnosed and treated OSA showing comparable inter-site 
variation albeit at much lower prevalence rates.  The authors also noted that some in the 
physician diagnosed, and physician diagnosed and treated groups did not meet the study’s 
OSA proxy criteria. These OSA proxy criteria were not validated as a part of the study 
nor were they specifically validated as OSA proxy criteria in any of the references cited 
in support of these criteria (Bradley et al., 1998; Newman et al., 2001; Strohl & Redline, 
1996).  Rather, these references identified these criteria as important risk factors, among 
others, for OSA. Therefore the sensitivity, specificity, and other performance 
characteristics of the proxy criteria used for OSA in the study are unknown. 
From the nearly 16,000 participants in the study (Kapur et al., 2002) some 6400 
were elsewhere reported to have undergone in home polysomnography (Shahar et al., 
2001).  Thus, an opportunity existed for validating the proxy criteria in the same sample, 
or alternatively, the study could have been performed using home polysomnography as 
the basis for OSA diagnosis. The study’s  methods (Kapur et al., 2002) also did not 




though it did acknowledge the resulting possibility of misclassification. Based on the 
earlier study (Young, Evans et al., 1997) where only 33% of those reporting a physician 
diagnosis of OSA were confirmed, it is unfortunate that this study did not attempt to 
validate, even a portion of these positive responses. 
In comparing these two studies (Kapur et al., 2002; Young, Evans et al., 1997), 
the point prevalences reported for clinically recognized moderate to severe OSA are 
generally compatible with Kapur and colleagues (2002) having reported 8.3% whereas 
Young and colleagues (1997) had reported 7% and 18% in women and men, respectively, 
and 15.4% overall.  Though the larger sample size represents a strength of the Kapur 
(2002) study, with the lack of validation for the study’s method of identifying OSA, and 
lack of confirmation for any of the participant reported physician OSA diagnoses, it 
seems that this study has less credibility relative to the early study (Young, Evans et al., 
1997).  
There have been two more recent nonpopulation-based studies that analyzed OSA 
clinical recognition (Brown et al., 2009; Warmouth et al., 2008). The first, presented in 
abstract form (Warmouth et al., 2008), involved a sample of patients undergoing 
preoperative assessment for surgery that found 159 participants from a sample of 2614 
had been previously diagnosed with OSA.  Of the remaining participants that completed 
OSA screening using the BQ (n = 2316) there were 671 (29%) who were identified as 
high risk for OSA. A total of 830 participants were identified with OSA or at high risk for 
OSA by either clinical report or the BQ, respectively.  Thus, the prevalence of clinical 





The second study (Brown et al., 2009) conducted as an online survey of 
professional orchestra players identified 348 (31%) participants as being high-risk for 
OSA based on the BQ in a mixed gender sample.  Of these, 66, representing 19.1% of 
those with BQ identified OSA, had been clinically recognized based on participant self-
report. 
The prevalence of clinically recognized OSA reported by these two studies is 
similar to that reported in the population-based sample by Young and colleagues (1997) 
for men, but higher than that reported for women by Young and colleagues (1997) and in 
a gender mixed population by Kapur (2002).  
In summary, in population based studies there is very limited clinical recognition 
of moderate to severe OSA with a range from 7-18% for women and men, respectively, 
with the most recent credible study having been conducted in the mid-1990s. 
Analysis of the OSA under-recognition problem 
A report from the National Commission on Sleep Disorders Research (Dement, 
1993) suggested that some 70 million Americans suffered from a spectrum of sleep 
disorders including OSA that had consequences including “reduced productivity, lowered 
cognitive performance, increased likelihood of accidents, higher morbidity and mortality 
risk, and decreased quality of life” (p. vi). The Commission estimated that in 1990 the 
associated direct sleep-related costs totaled more than $15.9 billion with billions of 
additional indirect costs related to accidents and diminished productivity. The report’s 
analysis (Dement, 1993) suggested that general public ignorance and a lack of health 




responsible for the failure of American society “to recognize and attend effectively to 
sleep-related issues” (p. vi). 
Limited physician awareness of OSA has long been identified as one of the 
explanations for the limited clinical recognition of OSA.  Among the earliest published 
reports of limited physician awareness of OSA came from a national sample of the 
American Geriatrics Society (Haponik, 1992). This telephone survey of 45 physicians 
conducted in 1990 demonstrated that, though 73% of the physicians surveyed believed 
sleep problems were an important part of their practice, none identified sleep apnea an 
important cause of their patients’ sleep disturbances. A decade earlier a study of medical 
school curricula had demonstrated that 93% of American medical schools provided no 
instruction in sleep disorders (Orr, Stahl, Dement, & Reddington, 1980), probably at least 
in part, accounting for this lack of awareness.  
By 1988 informal surveys suggested increased medical school instruction and a 
curricular outline was provided to guide further developments (Dement et al., 1988). The 
increase in sleep curricula was documented with the 1993 publication of a survey of 126 
medical schools (R. C. Rosen, Rosekind, Rosevear, Cole, & Dement, 1993).  This survey 
demonstrated an average of about two hours of total instructional time in the preclinical 
and clinical curricula, but 29.4% of medical schools continued to have no structured sleep 
and sleep disorders curriculum. 
A systematic study of outpatient clinical diagnoses from a nationally 
representative practice sample demonstrated a 12-fold increase in the number of OSA 
diagnoses made over the nine year time period from 1990 to 1998 (Namen et al., 2002).  




and upper respiratory tract infection, and less common sleep disorders such as narcolepsy 
and parasomnias, all remained essentially constant.  The sampling frame of this study did 
not allow assessment of the prevalence of clinically recognized OSA.  The study found 
over this time period a statistically significant correlation of increasing OSA diagnoses 
with increases in the number of OSA publications in the medical literature and the 
number of accredited diagnostic sleep laboratories.  Namen and colleagues (2002) 
concluded that their observations suggested “a positive response on the part of health-
care providers to the prevalence and morbidity” (p. 1747) of OSA. 
Two reports have assessed physician awareness of sleep disorders.  The first 
conducted in late 1999 and early 2000 reported on a survey and knowledge assessment of 
primary care physicians in northeastern Ohio (Papp et al., 2002).  Ninety per cent of 
respondents agreed that OSA was potentially life-threatening, and 84% indicated it was a 
common problem.  However, in the 33 item multiple choice sleep knowledge assessment, 
the mean number of correct items was 12.  This may suggest an increased awareness of 
OSA compared to that demonstrated by Haponik in 1992, though Papp and colleagues 
(2002) concluded that there was “a low rate of expertise” (p. 105). 
The second study (Reuveni et al., 2004) was conducted in Israel and included no 
graduates of medical schools in the United States. This study used a very different 
method incorporating a standardized patient into the practices of randomly selected 
primary care physicians consenting to the study.  The standardized patients reported 
suffering from “fatigue, reduction in work efficiency and a general reduction in mental 
function” (p. 1524) and reported having recently been involved in an automobile crash 




questions as they felt appropriate.  Of the five questions identified by sleep experts as 
important questions for this patient presentation only 10% of the primary care physician 
sample asked three or more, 30% only asked one while 50% of the physicians failed to 
ask any of the identified questions.  In knowledge assessment questions following the 
standardized patient interview, 87% recognized that polysomnography was needed in the 
diagnosis of OSA, and 90% recognized that CPAP was useful in its treatment (Reuveni et 
al., 2004).  Thus, though these physicians clinical acumen for recognizing probable OSA 
in their practice was quite limited, a large majority did have a basic knowledge of 
strategies for OSA diagnosis and treatment. 
Other studies have also demonstrated that instructional interventions for physician 
can enhance their clinical recognition of OSA.  In a study of primary care physicians and 
medical interns, among those that had received training in sleep disorders 82% obtained a 
sleep history in standardized patient encounters whereas only 13% of untrained interns 
and none of the primary care physicians obtained this history (Haponik et al., 1996).   
A more comprehensive intervention in Walla Walla, Washington involved the 
education of physicians, along with education of the general public and the development 
of a local sleep testing laboratory (Ball et al., 1997). This intervention let to an increase in 
evaluation by PSG from 0.27% to 2.1% of adult patients. Of the 360 patients that 
underwent PSG in the project, 276 (77%) were found to have OSA. Of the 214 patients 
for whom CPAP was prescribed and whose CPAP usage status could be assessed, only 
22% had returned their CPAP machine one to three years after testing. The authors (Ball 
et al., 1997) concluded that community physicians can identify and care for a much larger 




Finally, an educational intervention for medical residents and attending physicians 
regarding sleep disorders that extended over a four year period demonstrated an increase 
in the annual referral rate for PSG from 0.06% to 0.21% of active patients (Zozula et al., 
2005).  However, the prevalence of clinical recognition only increased from 0.11% to 
0.26% of active patients.  Among the factors that were identified as barriers to clinical 
recognition in the study were the fact that 48% of those referred for PSG failed to 
complete the study, and that 16% of the PSGs completed did not have a report available 
to the patients’ physicians thus limiting the opportunity for implementation of treatment. 
It seems clear that physician awareness of sleep disorders such as OSA has 
contributed to the lack of clinical recognition of OSA, and that instruction regarding sleep 
disorders does increase the rate of clinical recognition by physicians. 
Patient access to sleep laboratories and sleep specialists has also been identified as 
a factor contributing to the low rate of clinical recognition of OSA (Flemons et al., 2004; 
Morgenthaler et al., 2006). The first of these reports (Flemons et al., 2004) presents an 
international analysis of the availability of sleep laboratories and PSG in the United 
States, United Kingdom, Belgium, Canada, and Australia.  That analysis found waiting 
times for polysomnography ranged from two to sixty months, and that the number of 
PSGs performed relative to the population varied five-fold across these countries. The 
authors (Flemons et al., 2004) predict that in order to diagnose and manage currently 
undiagnosed OSA (based on Young, Evans et al., 1997) over a 10-year period based on 
the prevalence of only moderate to severe OSA (based on Young et al., 1993) an 
additional 555 PSGs per 100,000 population would be required each year. In addition, 




of diagnostic PSGs are positive, the authors project the need for a total of 2310 PSGs per 
100,000.  In 2003 this demand exceeded the capacity in the United States by a factor of 
5.4 and in the United Kingdom by a factor of 54, and fails to account for PSGs needed for 
any other type of sleep disorder. Thus, despite a 12-fold increase in the number of OSA 
diagnoses made in the 1990s, and a doubling of the number of accredited sleep 
laboratories (Namen et al., 2002) Flemons and colleagues (2004) projected a need to 
further increase the number of PSGs performed by more than 5-fold. 
An analysis at one large institution’s sleep center demonstrated that sleep referrals 
from within the institution exceeded capacity by nearly 100% (Morgenthaler et al., 2006).  
In response, that institution developed an alternative evaluation method reducing the 
physician time spend by 50% in order to increase capacity and found that patient 
outcomes and satisfaction were maintained relative to standard evaluation methods.  
Subsequently this alternative process was adopted as the standard at the sleep center 
(Morgenthaler et al., 2006). 
In studies of PSG utilization a wide variability has been found across both the 
United States and Australia in the number of PSGs performed for the population 
(Marshall et al., 2007; Tachibana, Ayas, & White, 2005).  The American study 
(Tachibana et al., 2005), based on a survey of accredited sleep laboratories found that 
there were on average about 427 PSGs performed per 100,000 population on an annual 
basis.  However, by state this rate varied by nearly 10-fold from 121 in Colorado, to 1161 
in Maryland. Thus, it would appear that availability of PSG varies substantially across the 




noted in Australia where the overall number of PSGs per 100,000 population has 
increased by about 150% from 1995 to 2004 (Marshall et al., 2007).  
In addition to increasing access to sleep laboratories and specialists, 
commentators (Banno & Kryger, 2004; Pack, 2004; Tarasiuk & Reuveni, 2004) have 
proposed a number of other strategies to increase access to OSA diagnosis including the 
use of home PSG, overnight oximetry recordings, and symptom scoring algorithms. Two 
recent trials have initiated CPAP treatment without prior diagnostic PSG (Mulgrew et al., 
2007; Senn et al., 2006). The first study used clinical improvement with CPAP as a proxy 
diagnosis of OSA among participants referred for evaluation of possible OSA (Senn et 
al., 2006).  In this study response to CPAP at 2 weeks had positive and negative 
predictive values for PSG confirmed OSA of 97% and 78%, respectively.  Of those with 
OSA identified by CPAP response, 94% then had a successful and sustained response to 
CPAP treatment at four months (Senn et al., 2006).  
In the second study, a randomized clinical trial, CPAP treatment was initiated for 
presumed OSA among those with a pre-treatment probability of OSA of at least 95% and 
compared to traditional diagnostic PSG followed by CPAP treatment (Mulgrew et al., 
2007). The study demonstrated similar CPAP effectiveness with and without diagnostic 
PSG, and improved CPAP adherence among those treated without initial PSG (Mulgrew 
et al., 2007).  
Access to PSG has been a factor limiting the clinical recognition of OSA and 
probably continues to remain a limitation. However, in the past 15 years there has been 




diagnostic and treatment strategies for OSA that are less reliant on PSG for diagnosis of 
OSA. 
Because laboratory PSGs are expensive and somewhat intrusive, the very nature 
of the diagnostic evaluation has been a factor identified as contributing to the limited 
prevalence of clinical recognition of OSA (Colten & Altevogt, 2006). The fact that one 
must spend one or more nights away from home in order to be evaluated in the sleep 
laboratory is particularly problematic for those with responsibility for the care of family 
members (Colten & Altevogt, 2006). In addition, there is the suggestion from one 
qualitative study that the challenges associated with the process of diagnosis ultimately 
had a negative impact on patients’ interest and ability to adhere to therapy following 
diagnosis (van de Mortel et al., 2000). 
In summary the following factors have been identified as contributing to the 
limited prevalence of clinical recognition of OSA:  (a) limited OSA awareness by 
physicians, (b) limited access to sleep laboratories and specialists, and (c) the expensive 
and intrusive nature of laboratory-based PSG. There is evidence that to some extent there 
have been improvements with regard to several of these factors with enhanced physician 
education related to OSA, increased access to sleep studies laboratories, and the 
development of diagnostic technologies less dependent on PSG.  Thus, it is reasonable to 
hypothesize that the prevalence of clinically recognized OSA has increased since the 
1990s. 
The Berlin Questionnaire 
The Berlin Questionnaire is an eleven item instrument that was developed in 1996 




al., 1999).  The questions were chosen to identify characteristics that placed participants 
at high risk for OSA in the areas of snoring, daytime sleepiness, hypertension, and 
obesity. The instrument’s scoring algorithm places participants in one of two categories, 
high or low risk, for OSA. The instrument was initially validated in consecutive patients 
seen for any reason in the practices of five internal medicine physicians in the Cleveland, 
Ohio area (Netzer et al., 1999).     
Of the 1008 BQs distributed for this initial report 744 were completed and 
included in that analysis.  The validation study invited the 75 participants placed by the 
instrument at high risk, and the 65 participants placed at low risk, to under go in-home, 
unattended PSG. Participants for PSG were selected from alphabetically ordered lists and 
were visited in their homes for instruction regarding use of the PSG device.  Ultimately 
100 participants completed PSG with scorable studies including 69 of the 75 from the 
high risk group and 31 of 65 in the low risk group. The PSGs were scored by a single 
researcher who was blinded to the results of the questionnaire (Netzer et al., 1999). 
The initial publication of the validation study reported sensitivities for OSA based 
on RDI criteria of >5, >15, and >30 as being 0.86, 0.54, and 0.17, respectively.  
Specificities at these same RDI levels were reported as 0.77, 0.97, and 0.97, respectively. 
The positive predictive value (PPV) for OSA at an RDI >5 was reported as 0.89.  
However, a subsequent letter to the editor raised questions about these calculations 
(Strauss & Browner, 2000). Based on the published validation data from Netzer and 
colleagues’ original paper (1999) sensitivities, specificities, positive and negative 
predictive values (PPV and NPV) are recalculated using standard methods (Weiss, 2008) 






BQ Performance Measures Calculated From Data Published in Netzer, et al (1999) 













ficity PPV NPV 
High Risk 59 10 69 
Low Risk 7 24 31 RDI > 5 









High Risk 37 32 69 
Low Risk 1 30 31 
RDI > 
15 









High Risk 12 57 69 
Low Risk 1 30 31 
RDI > 
30 










Thus, based on this re-calculation of these performance measures for OSA with 
an RDI severity of greater than five and including no daytime sleepiness requirement the 
BQ demonstrated a sensitivity of 89.4%, specificity of 70.6%, positive predictive value of 
85.5%, and a negative predictive value of 77.4%. Note that this level of severity is similar 
to that which rather consistently demonstrated a population prevalence of 19 – 25% for 
adult men in the analysis of Table 1 above. 
The questionnaire consists of 11 questions grouped in three categories 
("Reprinting of the Berlin Questionnaire," 2000). Most of the questions are answered 
using a series of responses on an ordinal frequency or severity scale. Based on 
participants’ responses to the questions in each category that category is scored as either 




considered to be at “high risk” for OSA, whereas the participant is considered to be at 
“low risk” if less than two categories are positive. Table 2 below enumerates the 
categories and items. 
The initial publication (Netzer et al., 1999) of the BQ provided a general 
description of the scoring algorithm to be used for the questionnaire but without 
sufficient detail to establish a specific scoring algorithm.  Subsequently the questionnaire 
with more detailed scoring algorithms was published (Dement & Netzer, 2000). 
Unfortunately there were a number of errors in this more detailed publication of the 
algorithm that were later corrected ("Reprinting of the Berlin Questionnaire," 2000). 
Probably in part because the publication of this later correction was not indexed in the 
journal’s table of contents, or in the medical indexes, multiple scoring methods have been 
described by those that subsequently used the instrument. 
These scoring methods have included some deviation from that original questions 
used by Netzer and colleagues (1999) and scoring method as subsequently published 
("Reprinting of the Berlin Questionnaire," 2000).  Among the deviations are the 
following: 
1. When the instrument was reviewed by legal counsel prior to its application in 
atrial fibrillation and cardiology patients (Gami et al., 2004) concern was 
expressed regarding the vicarious liability associated with documenting that 
participants nodded off while driving (A.S. Gami, personal communication, 
July 17, 2007).  Thus, items 8 and 9 (Table 3) regarding drowsy driving were 
not included in the questionnaire used in this study. Similarly in another study 




appeared to be answered inaccurately in pilot studies, and was a deterrent to 
participation. 
2. The original questionnaire ("Reprinting of the Berlin Questionnaire," 2000), 
in addition to a the binary question regarding drowsy driving (Table 3, item 
8), included a follow up question regarding frequency (Table 3, item 9). At 
least four investigators (Chung et al., 2008; Gibbs, 2006; Leveque, Yu, 
Musch, Chervin, & Zacks, 2007; Singh, Drake, Roehrs, Hudgel, & Roth, 
2005) have omitted this follow up question and/or its associated scoring. 
3. Two investigators (Tasali, Van Cauter, & Ehrmann, 2006; Ybarra, Planas, & 
Pou, 2008) studying populations with near universal obesity, and a very high 
prevalence of hypertension excluded responses for Category 3 in their scoring. 
4. One investigator, recognizing that driving a vehicle was rare in the population 
and culture being studied, introduced three alternative daytime sleepiness 
items regarding sleepiness while waiting for a doctor appointment, in line to 
pay a bill, and while watching television (Sharma, Vasudev et al., 2006). In 
addition, this investigator used a BMI cutoff of 25 rather than 30 as was 
described originally. 
5. An additional question in Category 3 regarding a “very small jaw or a large 
overbite” (p. 2339) was added by one investigator (H. Singh et al., 2005). 
6. One investigator (Leveque et al., 2007) scored positive responses to item 5 




Thus, though the basic structure of the BQ and its scoring has been consistent 
across its application in over 50 publications in the past decade, there have been multiple, 
generally subtle, variations in the questions and scoring algorithm used. 
Table 3 highlights some of these BQ scoring algorithm variations relevant to the 
present study. Included are the original instrument and algorithm used by Netzer and 
colleagues (1999), the algorithm used by Gami (2004) which represented a pilot 
application of the instrument for the present investigation in our institution, the most 
recent detailed publication of a complete scoring algorithm (Gibbs, 2006), along with the 







Berlin Questionnaire Items and Scoring Algorithm 
 Points scored for the response based on 
identified scoring algorithm 
Question Responses Netzer Gami Gibbs PAVD 
Category 1:  Snoring Positive if ≥2 points scored for the 
following items: 










2.  If you snore, your snoring 
is: 
Slightly louder than breathing 
As loud as talking 
Louder than talking 


















3.  How often do you snore? Nearly every day 
3 to 4 nights per week 
1 to 2 nights per week 
1 to 2 nights per month 






















4. Has you snoring ever 











5. Has anyone noticed that 
you quit breathing during 
sleep? 
Nearly every day 
3 to 4 times a week 
1 to 2 times a week 
1 to 2 times a month 


























Category 2: Daytime fatigue and sleepiness Positive if ≥2 points scored for the 
following items: 
6. How often do you feel 
tired or fatigued after your 
sleep? 
Nearly every day 
3 to 4 times a week 
1 to 2 times a week 
1 to 2 times a month 


























7. During your waketime, do 
you feel tired, fatigued or 
not up to par? 
Nearly every day 
3 to 4 times a week 
1 to 2 times a week 
1 to 2 times a month 


























8. Have you ever nodded off 
or fallen asleep while 













9. If so, how often does it 
occur? 
Nearly every day 
3 to 4 times a week 
1 to 2 times a week 
1 to 2 times a month 


















 Points scored for the response based on 
identified scoring algorithm 
Question Responses Netzer Gami Gibbs PAVD 
Category 3: Hypertension and Obesity Positive if ≥1 point scored for the 
following items: 












11. Body Mass Index (BMI): 

















As mentioned above, since its original publication the BQ has been used as an 
OSA ascertainment instrument in 53 additional research publications. As depicted in 
Figure 1, most of these publications have occurred in the five years from 2006 through 
2010. The instrument has been used in a wide variety of settings (see Table 4), with the 
instrument’s high risk classification having been used as a proxy for OSA in many of 
these publications.  There has also been one published abstract that did not lead to a 
complete published paper that included PSG validation data (Steinel, Shaman, & 
Auckley, 2007) that is also included in Table 4.  Though most papers have not validated 
the instrument as part of its application to that study population, thirteen publications 
subsequent to the instrument’s initial publication that do report a study population 
validation analysis (Ahmadi, Chung, Gibbs, & Shapiro, 2008; Chung et al., 2008; Drager 
et al., 2010; Friedman et al., 2010; Gami et al., 2004; Gus et al., 2008; Olivarez et al., 
2010; Rasmin, 2006; Sharma, Vasudev et al., 2006; Tang et al., 2009; Weinreich, Plein, 
Teschler, Resler, & Teschler, 2006; West et al., 2006). In addition, among the 32 
published abstracts that reported using the BQ as a research instrument ("Sleep Abstract 
Supplements," 2008) there was one published abstract (Steinel et al., 2007) that did not 
lead to publication of a full, peer reviewed paper that used a PSG-based method to 









































Research Publications Using the BQ  for OSA Risk Assessment Listed Chronologically 
 
1st Author Year Location Description 
Netzer 1999 Cleveland Initial validation study of BQ. 
Netzer 2003 USA, Germany & Spain 
Descriptive analysis of OSA symptoms & risk factors in primary care 
population 
Calhoun 2004 Alabama Evaluated association of OSA & aldosterone in resistant hypertension. 
Gami 2004 Minnesota Evaluated association of afiba with OSA, included PSG BQ validation. 
Moreno 2004 Brazil Evaluated risk of OSA among Brazilian truck drivers. 
Gassino 2005 Italy Evaluated association of oral anatomy with OSA and depression. 
Mustafa 2005 Cleveland Assessed prevalence of OSA and other sleep disorders by survey. 
Principe-
Rodriguez 2005 Cleveland 
Assessed prevalence of OSA & other sleep disorders by survey instruments 
including the BQ. 
Singh 2005 Winnipeg Prevalence & association of OSA with nonalcoholic fatty liver disease. 
Chen 2006 Taiwan Analysis of OSA prevalence among those on chronic hemodialysis. 
Hiestand 2006 US Evaluated OSA by BQ in national population by telephone survey. 
Moreno 2006 Brazil Analysis regarding OSA in truck drivers, data from Moreno et al., 2004. 
Padeletti 2006 Italy Evaluated afib
a association with OSA in those with pacemakers for 
bradycardia. 
Rasmin 2006 Indonesia BQ validation with portable PSG monitoring in pilot study of 15. 
Sharma 2006 India Validation study of BQ modified for Indian culture. 
Tasali 2006 Chicago OSA association with glucose tolerance in polycystic ovarian syndrome. 
Vignatelli 2006 Italy Prevalence of sleepiness, sleep quality and OSA in frontal lobe epilepsy. 
Weinreich 2006 Germany Validation of BQ in a population undergoing pulmonary rehabilitation. 
West 2006 United Kingdom Prevalence of OSA by BQ for type 2 diabetic men, PSG validation. 
Chung 2007 Canada Prevalence of OSA in a population undergoing elective surgery. 
Koch 2007 Miami Association of OSA by BQ with ischemic stroke. 
Leveque 2007 Michigan Association of OSA with central serous chorioretinopathy. 
Molnar 2007 Budapest Compares OSA by BQ in hemodialysis and kidney transplant populations. 
Steinel 2007 Cleveland Evaluated use of BQ among bariatric surgery candidates. 
Ahmadi 2008 Toronto Validation of BQ in a sleep clinic population. 
Auckley 2008 Cleveland Comparison of OSA by BQ in asthmatic& general medicine populations. 
BaHammam 2008 Saudi Arabia Determined prevalence of high risk by BQ for primary care males. 
Banabilh 2008 Malaysia Evaluated BQ association with cephalometrics in children age 7-15. 
Chung 2008 Toronto Validation of BQ, Anesthesia questionnaires in pre-surgical population 
Daccarett 2008 Salt Lake City OSA by BQ in daytime bradyarrhthmias and a control population 
Gus 2008 Brazil Analysis of OSA in resistant hypertension,  PSG based validation study. 
Oliven 2008 Israel Evaluated association of airway closing pressures with OSA by BQ. 
Palma 2008 Alabama BQ used to exclude OSA in study of hepatopulmonary syndrome. 
Soleo 2008 Italy Assessed OSA prevalence by BQ & risk factor for cement workers. 
Ybarra 2008 Spain Association of OSA with ventricular dysfunction in obese females. 
Adewole 2009 Nigeria Assessed OSA prevalence by BQ among two hospitals’ employees. 
Alexandrov 2009 Alabama Assessed association of OSA with blood flow steal in acute stroke. 
BaHammam 2009 Saudi Arabia Determined prevalence of high risk by BQ for primary care females. 
Blondet 2009 Puerto Rico Assessed OSA prevalence by BQ with risk factor analysis. 
Brown 2009 USA, Puerto Rico Assessed OSA prevalence & recognition in professional musicians. 
Chilukuri 2009 Baltimore BQ-based OSA used as predictor for failure after afiba ablation. 





1st Author Year Location Description 
Kapsimalis 2009 USA Modified BQ used to assess prevalence of OSA in national sleep poll. 
Khassawneh 2009 Jordan Assess OSA prevalence by BQ among primary care patients. 
Khiani 2009 USA Assessed risk of hypoxia with endoscopy for BQ-defined OSA patients. 
Lemos 2009 Brazil BQ used for ascertainment of OSA in truck drivers. 
Taj 2009 Pakistan Assessed BQ defined OSA prevalence for public health professionals. 
Tang 2009 Beijing, China Association of OSA by BQ with afiba recurrence after catheter ablation. 
Ybarra 2009 Spain Evaluated correlations with BQ defined OSA in obese females. 
Drager 2010 Brazil Analysis of BQ, Epworth & metabolic syndrome in hypertensive patients. 
Enciso 2010 California Using BQ & airway dimensions to predict OSA in case-control study. 
Fraser 2010 Chicago, Atlanta OSA risk assessment in men with idiopathic intracranial hypertension. 
Friedman 2010 Chicago BQ & other OSA screening instruments combined & validated in sleep clinic population. 
Olivarez 2010 Houston Validation of BQ by PSG in 100 hospitalized pregnant females. 
Sabry 2010 Egypt Assessed sleep disorders in hemodialysis & chronic kidney disease. 




Among these thirteen publications and the one abstract that included a validation 
analysis there has been a range of reported sensitivities from 35 – 100% and specificities 
ranging from 20 – 95%.  Table 5 collates these studies and the associated sensitivities, 
specificities, positive and negative predictive values from the validation analyses. 
Together these studies have used a variety of diagnostic criteria to define OSA. Five 
studies (Ahmadi et al., 2008; Chung et al., 2008; Netzer et al., 1999; Steinel et al., 2007; 
Weinreich et al., 2006) have done the validation analysis using multiple severity criteria 
with indexes (AHI or RDI) ranging from greater than five to greater than 30. The size of 
these studies varies ranging from 15 participants (Rasmin, 2006) to more than 200 
(Friedman et al., 2010; West et al., 2006). 
Data published in these studies and one abstract allow the pooling of the results 
from the studies that used a similar index (AHI or RDI) and criteria to define OSA.  This 
pooled analysis of sensitivity, specificity, PPV, and NPV is an estimates of these test 
performance characteristics based on a larger number of patients than any of the 
individual studies.  For example, for an index >5 a total of 1038 participants are included 
in the pooled analysis.  Table 6 details this pooled analysis along with the 95% 
confidence intervals for the resulting sensitivities, specificities, PPVs, and NPVs, and the 
median value for these measures from the studies that contributed to each pooled 
analysis. This analysis demonstrates that the BQ varies in its ability to predict different 
levels of OSA severity across the spectrum of sleep disordered breathing.
 






Published Population Studied 
OSA 
Criteria Sensitivity Specificity PPV NPV n 

















Gami 2004 Cardiology patients 
AHI>5 & 
symptoms 0.86 0.89 0.97 0.60 44 
Rasmin 2006 Pulmonary patients with suspected OSA 
AHI>5 & 
symptoms 0.78 0.33 0.78 0.33 15 
Sharma 2006 Medical patients with an OSA symptom AHI>5 0.86 0.95 0.96 0.82 104 











West 2006 Male type 2 diabetes mellitus 
ODI>10 & 
+ PSGa 0.75 0.54 0.27 0.91 238 











































Gus 2008 Patients with resistant and controlled hypertension AHI>10 0.86 0.65 0.75 0.79 126 
Tang 2009 Recurrence of atrial fibrillation after catheter ablation AHI>5 1.00 0.30 0.74 1.00 30 
Friedman 2010 Sleep clinic patients AHI>5 0.62 0.23 0.67 0.18 223 
Drager 2010 Hypertensive adults AHI>5 0.93 0.80 0.75 0.56 99 
Oliverez 2010 Hospitalized pregnant women AHI>5 0.35 0.64 0.19 0.64 100 
a  This study validated the BQ with a two-stage process requiring an ODI>10 by overnight oximetry before undergoing full PSG.  The 
criteria for OSA on PSG were not published.  
Table 5 
 
Studies and Abstracts Reporting BQ Validation Analyses with Sensitivity, Specificity, PPV, NPV, and Study Size 
 






BQ Summary Performance Measures for Validation Studies Pooled by Severity Criteria 
  Sensitivity Specificity PPV NPV Total n Studies included 
AHI or RDI>5 without 




















Sharma, Steinel, Tang 

















56 Gami, Rasmin 
AHI or RDI>10 without 
















566 Ahmadi, Chung, Gus, Weinreich 
AHI or RDI>15 without 
















357 Ahmadi, Netzer, Steinel, Weinreich 
AHI or RDI>30 without 
















277 Netzer, Chung 
   66 
 
  
To assess which level of severity is best predicted by the BQ several 
characteristics can be considered, (a) likelihood ratios (LR), both positive and negative (R 
Jaeschke, G. Guyatt, & J. Lijmer, 2002); (b) the Youden J statistic (Youden, 1950); and 
(c) the diagnostic odds ratio (Deeks, 2001). The diagnostic odds ratio (DOR) is a single 
summary measure of diagnostic performance that combines measures of sensitivity, 
specificity, positive and negative likelihood ratios (Deeks, 2001). Higher diagnostic odds 
ratios, positive likelihood ratios, lower negative likelihood ratios and a larger Youden’s J 
statistic are indicative of stronger diagnostic performance (Deeks, 2001; R. Jaeschke, G. 
Guyatt, & J. Lijmer, 2002; Youden, 1950).  Thus, as depicted in Table 7 below, the BQ 
best predicts OSA with an AHI > 5 with daytime symptoms.  However, given the 
relatively small number of participants (n = 56) contributing to this measure, and the 
resulting wide confidence interval, the questionnaire also performs favorably in 
predicting OSA with an AHI>5 without regard to symptoms. This later level of severity 
without a daytime sleepiness requirement again was the one considered in the OSA 
population prevalence analysis of Table 1 above. 
Table 7 
 
BQ Diagnostic Performance at Different Levels of OSA Severity 
OSA Severity LR + LR - DOR Youden’s J (95% CI) 
AHI or RDI>5 without regard to symptoms 1.72 0.46 3.75 0.31 (0.25 – 0.37) 
AHI or RDI>5 with daytime symptoms 3.31 0.21 15.73 0.59 (0.46 – 0.73) 
AHI or RDI>10 without regard to symptoms 1.62 0.47 3.46 0.29 (0.25 – 0.33) 
AHI or RDI>15 without regard to symptoms 1.41 0.47 2.99 0.23 (0.19 – 0.27) 
AHI or RDI>30 without regard to symptoms 1.52 0.28 5.53 0.30 (0.26 – 0.43) 
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In summary, the BQ, first published in 1999, is an instrument designed to identify 
OSA risk based on tabulation and scoring of symptoms related to snoring and daytime 
sleepiness along with the presence of hypertension and obesity. The instrument has been 
used in 53 original studies including fourteen that included validation of the instrument 
against a PSG based gold standard.  There has been subtle variability in the questions and 
scoring algorithm for the instrument, though the structure of the instrument has been 
generally consistent. The instrument’s diagnostic performance has also been variable.  As 
one might expect for an instrument based on OSA symptoms, it performs best in 
predicting OSA with day-time symptoms, and not as well for OSA without a daytime 
sleepiness criteria. For the range of severity without daytime symptoms, the BQ performs 
best for mild OSA with an AHI (or RDI) greater than five. 
A Population-based Laboratory: The Rochester Epidemiology Project 
Kessler and Levin (1970) suggest that the epidemiologic study of a community as 
a population-based laboratory began with the very founding of epidemiology as a science 
in the sanitary surveys of the 19th century by Chadwick and Shattuck, respectively. They 
(Kessler & Levin, 1970) argue that the most persuasive reasons for choosing a 
community for epidemiologic study are “pragmatic and administrative” (p. 8).  The 
Rochester Epidemiology Project (REP) is one such population-based laboratory that has 
developed because of several local circumstances, some going back to the late 19th and 
early 20th centuries.  In this study, the REP provided a unique opportunity to use clinical 
record systems in a population-based study.   
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When Dr. William W. Mayo, established his practice in Rochester in the 1860s 
Rochester was a frontier center of commerce in southern Minnesota but was rather 
isolated from the growing Minneapolis and St. Paul area about 90 miles away and other 
developing health care centers (Clapesattle, 1990). As that practice grew from a 
partnership of a few physicians to a multi-specialty group practice a single medical 
record for each patient that would be shared by all of the group’s physicians was 
developed by Dr. Henry Plummer in 1907 (Kurland & Molgaard, 1981).  In order to 
facilitate research and teaching Plummer and his secretary, Mabel Root, developed record 
index systems based on (a) diagnoses by organ system, and (b) surgical procedures which 
were known as the Plummer-Root indexes. As diagnostic techniques and pathogenic 
understanding improved, in the 1930s Dr. Joseph Berkson developed a revised diagnostic 
coding system combined with an early Hollerith punch card automated indexing and 
sorting technology that became known as the Berkson file (Berkson, 1936). This coding 
system was used until 1974 when a modified Hospital Adaptation of the International 
Classification of Diseases, second edition (H-ICDA-2) coding system, originally 
published by the World Health Organization, was adopted (Kurland & Molgaard, 1981). 
As a unified multispecialty medical practice with a single record for each patient 
documenting all care provided, the systematic indexing of these records by diagnosis and 
surgical procedures created a substantial opportunity for clinical and epidemiologic 
research. 
The relative isolation of Rochester from other larger medical centers, and with the 
presence of virtually every specialty and subspecialty within the Mayo Clinic, the people 
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of Olmstead County where Rochester is located have little need to seek care from a 
spectrum of providers across a broad, potentially multi-state region; rather they are able 
to obtain nearly all of their care locally (Melton, 1996).  There are several providers of 
care in Olmstead County outside of Mayo Clinic, most notably the Olmstead Medical 
Center which developed in the 1950s ("Learn about OMC: Our history," 2008) and now 
includes over 150 providers (Yawn, 2008). In addition there are a handful of other private 
practitioners, several nursing homes, governmentally provided public health services, and 
Veteran’s Administration system in the region.  Thus, in 1966 what would become the 
Mayo Department of Health Science Research, in partnership with these other Olmstead 
County and regional healthcare providers, received National Institutes of Health funding 
to support the collection, archiving, and medical record linkage for records from all of 
these health care institutions, and the vital records for the county (Erickson, Pankratz, 
Schrage, & Stotz, 2007; Melton, 1996).  Through 2004 this record linkage system has 
supported the publication of more than 1500 clinical and epidemiologic research papers 
(Rocca & Yawn, 2008).  With this comprehensive record linkage system and a nearly 
century long record system archive, the REP is a unique laboratory in which to do 
longitudinal population-based epidemiology research (Melton, 1996). 
The REP uses a probabilistic method to assign records from multiple sources to a 
single master REP identification number along with all records later received for that 
participant.  This probabilistic method utilizes the following demographic information: 
last name, first name, middle name, suffix, gender, birth date, social security number, and 
geographic residency.  Hand matching of individual records is used when missing 
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demographic information makes probabilistic matching impossible. As of 2008 about 
1.53 million records from 50 different sources have been matched to 788,130 unique 
patients (J. St. Sauver, personal communication, October 8, 2008).   
To assess the reliability of the system a random sample stratified by age of 400 
REP participants was manually examined to identify records incorrectly linked to these 
individuals and to identify any additional records that should have been linked to these 
participants.  The REP system had matched a total of 1333 records to these 400 
participants with 2.5% (95% Confidence interval: 1.2 – 4.6%) of these individuals having 
incorrectly matched records.  In addition, 1.3% (95% Confidence interval: 0.4 – 2.9%) of 
these participants appeared to have additional records that should have been matched (J. 
St. Sauver, personal communication, October 8, 2008).  
Together, these data suggest that the REP computer matching algorithms perform 
extremely well in correctly identifying and linking medical records from multiple 
institutions to single individuals, even when individual medical records have 
multiple names, multiple spellings of names, name changes, and spelling errors (J. 
St. Sauver, personal communication, October 8, 2008). 
The REP has been identified by at least two groups as one of only six population-
based medical record linkage systems in the world that are comprehensive in both the 
spectrum of diagnoses and the settings in which care is provided (Brameld, Holman, 
Lawrence, & Hobbs, 2003; Holman, Bass, Rouse, & Hobbs, 1999). The other similar 
systems include the Oxford Record Linkage Study (Goldacre, Kurina, Yeates, Seagroatt, 
& Gill, 2000), the Scottish Record Linkage System (Kendrick & Clarke, 1993; Walsh, 
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Smalls, & Boyd, 2001), the Population Health Information System in Manitoba (Roos et 
al., 1995), the British Columbia health database (Chamberlayne et al., 1998), and the 
Western Australian Health Services Research Linked Database (Holman et al., 1999).  
Thus, the REP may be the only comprehensive record linkage system in the United 
States. 
In the course of developing the Western Australia database Holman and 
colleagues (1999) studied and visited all of the identified databases except that found in 
British Columbia. In the course of this evaluation they developed a “set of benchmarks 
for international best practice” (p. 457) for such databases (Holman et al., 1999).  A list 
of the benchmarks and a description of the REP relative to each benchmark is provided in 
Table 8. 
Subsequently a similar set of general guidelines for comprehensive linkage 
systems has developed recognizing that such systems each develop in very different 
contexts (D.A. Holman, personal communication, October 5, 2008).  Those guidelines 
are as follows: 
Population:  The population covered by the system is ideally geographically 
defined and relatively stable, of adequate size for most analyses (ideally >1 
million) and with adequate longitudinal coverage (>10yr).  The advantage of a 
geographically defined population, as distinct from register-based populations 
such as members of a health insurance plan, is that research based on the former 
will enjoy the greater external validity gained from a study population more 
representative of the general community. 
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Data resources:  Health events and other data should be ascertainable for the 
whole population (not merely a sample or population subgroup) on a continuous 
basis (not an ad hoc or intermittent basis).  The range of data resources should be 
sufficient to address the research agendas of primary interest.  Linked hospital 
morbidity data and deaths are arguably the minimal system, but ideally the system 
should include ambulatory health service encounters, key disease registers, birth 
and perinatal data and a population register such as an electoral roll. 
Technical facilities:  Linkage should be achieved by either high performance 
probabilistic matching or a reliable unique person identification number or a 
hybrid of these methods.  A program of data validation and assessment of linkage 
performance is highly desirable.  A tracing system is desirable to censor patients 
who emigrate from the geographic area and are therefore lost to longitudinal 
follow-up.  Geocoding of addresses will enhance the capacity for spatial analysis 
and assignment of socio-economic status and remoteness indices. 
Organisational [sic] supports:  These include a governance structure for leadership 
and management of the data linkage enterprise; instruments for co-operation 
between agencies providing data (eg, MOUs); consumer participation; a 
facilitative or at least nonobstructive legal framework; and multidisciplinary 
research teams including collaboration with health service providers (D.A. 
Holman, personal communication, October 5, 2008).





International Benchmarks for Record Linkage and Health Services Research Databases  
Benchmark (Holman et al., 1999, p. 458) REP description relative to benchmarks 
1. Population 
 1.1 Geographically defined and 
relatively stable 
 1.2 Adequate size for most analyses 
(ideally >1 million) 
 1.3 Adequate longitudinal population 
coverage (>10 yr) 
The REP is geographically defined as the residents of Olmsted 
County, Minnesota. For Olmstead County in the six years 
from 2000-2006 there was a net in-migration of 3.35% of the 
2000 population, the second highest rate by county in the state 
(US Census Bureau, 2008c). The population is estimated to be 
137,521 in 2006, smaller than referenced in this benchmark 
(US Census Bureau, 2008b). However, during the course of its 
existence the REP has matched more than 750,000 unique 
individuals (J. St. Sauver, personal communication, October 8, 
2008).  REP allows record review for 50 or more years 
(Melton, 1996) 
2. Data Resources 
 2.1 Named population register 
 2.2 Socio-demographic data from the 
Census 
 2.3 Birth and death registrations 
 2.4 Perinatal events 
 2.5 Hospital in-patient data 
 2.6 Physician contacts 
 2.7 Pharmaceutical benefits data 
 2.8 Laboratory services data 
 2.9 Cancer notifications 
 2.10 Domiciliary care data 
 2.11 Residential care data 
 2.12 Residential care data 
 2.13 Health survey data 
The REP has grown to include data from essentially all 
medical care providers within the county and many providers 
elsewhere in the region that might have occasion to provide 
care to Olmsted County residents.  It includes hospital, 
nursing home, state mental hospital, veterans administration, 
and prison health facilities. Public health records including 
birth and death registrations are part of the database.  The 
REP, however, does not have direct participant linkage to 
socio-demographic census data, and does not include 
pharmaceutical benefit data.  To the extend laboratory services 
were provided through a medical care provider indexed in 
REP this laboratory data is included.  Currently home health 
care agency data is not included.  The REP is not linked to 
NHANES (US Centers for Disease Control and Prevention, 
2008b) participants that might live in Olmsted County, and the 
county is not currently in the BRFSS (US Centers for Disease 
Control and Prevention, 2008a). 
3. Technical systems 
 3.1 Unique person identification number 
 3.2 High performance probabilistic 
matching 
 3.3 A program of validation studies 
 3.4 Facility for follow-up (tracer 
systems) 
 3.5 Facility for geocoding and spatial 
analysis 
The REP does use a REP master identification number to 
match records once received from various sources.  The social 
security number is one demographic identifier used in the 
probabilistic matching. Validation of REP probabilistic 
matching is done as reported above (J. St. Sauver, personal 
communication, October 8, 2008). There is no formal follow 
up tracer system to eliminate those that have emigrated.  
However, study designs can be used to censor participants at 
the latest recorded care provided. Participants’ residential 
addresses are geocoded to facilitate spatial analysis (Erickson 
et al., 2007). 
4. Organizational Supports 
 4.1 Multidisciplinary research team 
 4.2 Supportive legal framework 
 4.3 Federal health agency cooperation 
 4.4 State health agency cooperation 
 4.5 Health care practitioner collaboration 
The REP involves a long term multi-disciplinary research 
team including epidemiologists, information technologists, 
programmers, physicians, nurses, and other clinicians 
(Erickson et al., 2007).  Veterans Administration facilities and 
state health department are federal and state agencies that 
historically had cooperated with the REP, though currently 
new relationships to provide current records to the REP are 
being negotiated (J.J. Pankratz, personal communication, 
October 14, 2008). State mental health institutions have also 
been partners in the project (Erickson et al., 2007).  The REP 
has been able to engage essentially all health care practitioners 
in the county, as well as many in neighboring counties 
(Melton, 1996). 
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Thus, it appears that the REP is a record linkage system that has validated linkage 
performance, is internationally recognized and substantially meets available benchmarks 
and guidelines for such systems. The REP provided a unique opportunity to use clinical 
record systems for population-based study, such as the analysis of the prevalence of 
clinically recognized obstructive sleep apnea in this study. 
A Population-based Sample:  The Prevalence of Asymptomatic Ventricular Dysfunction 
In 1997 a population-based sample was drawn in Olmstead County, Minnesota for 
the purpose of longitudinally studying asymptomatic cardiac ventricular dysfunction. 
That study, known as the prevalence of asymptomatic ventricular dysfunction (PAVD) 
study, included an assessment of OSA risk as part of the longitudinal follow up of 
participants for the study’s second round.  With the availability of this population-based 
assessment of OSA risk in this study, the participants in the study provided the sample in 
which the prevalence of clinically recognized OSA was assessed. Thus, the literature 
regarding the establishment and nature of this study sample are reviewed. 
The initial sample for the PAVD study was drawn, using the resources of the 
Rochester Epidemiology Project (REP) (Melton, 1996), from the residents of Olmsted 
County, Minnesota who were 45 years of age or older on January 1, 1997 (Redfield et al., 
2003).  At that time the total population of the county by linear interpolation from the 
decennial censuses of 1990 and 2000 was 118,931 (US Census Bureau, 2008a).  A 7% 
random sample of each 5 year age and gender strata were selected for participation 
(Ammar et al., 2006) including a total of 4203 potential participants (Redfield et al., 
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2003). Of those invited, a total of 2,042 (47%) participated in round one of the study 
(Redfield et al., 2003). 
In round one of the study participants completed a 17-page questionnaire 
regarding health behaviors, evidence of cardiovascular disease, and functional status.  In 
addition, participants completed a physical examination, pulmonary function testing, 
electrocardiogram, and an echocardiogram (Jacobsen et al., 2004).  Using the REP, 
participants’ medical records were reviewed by trained nurse abstractors for evidence of 
hypertension, myocardial infarction, coronary artery disease, diabetes mellitus, and 
congestive heart failure based on specific criteria (Redfield et al., 2003). This record 
abstraction did not record clinical data related to sleep-disordered breathing.  
A study (Jacobsen et al., 2004) was done of the first 963 persons receiving 
invitations to participate in the study that included 488 (51%) who completed all aspects 
of PAVD round one.  Participation rates by gender were not appreciably different with 
52.7% of men, and 49.0% of women, participating.  Participation by the youngest (age 
45-54 years) and oldest (age ≥75 years) groups, ranging from 34.9 to 45.4%, were lower 
than the remainder (age 55-74 years) which ranged from 58.0 to 61.3%. Using the 
resources of the REP analysis of potential associations between disease diagnoses and 
participation was carried out.  Participation was not different among those with and 
without a prior history of coronary artery disease, congestive heart failure, other 
cardiovascular diseases, diabetes or other co-morbidities. However, those with chronic 
obstructive pulmonary disease (COPD), even after adjusting for age differences, were 
less likely to participate than those without COPD (19% vs 51%). This study (Jacobsen et 
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al., 2004) concluded that there was “some reassurance that participation bias in this study 
may have little influence on its overall findings, although this cannot be conclusive” (p. 
579). 
For round two of the study, beginning in 2001 all participants that had completed 
round one were invited to participate approximately four years after their initial round 
one assessment (Rodeheffer et al., 2000).  A total of 1,402 participants participated in 
Round Two of the study involving a follow up questionnaire, physical examination, 
electrocardiogram, blood sample, and echocardiogram.  The round two PAVD 
questionnaire included the BQ items as described for PAVD in Table 3 above.  
Trained nurse abstractors again reviewed round two participants’ medical records 
using the resources of the REP to obtain the following information:  sociodemographic 
information; cardiovascular diagnostic evaluations, diagnoses, and treatment; and 
laboratory samples for potential testing of lipid profiles, thyroid studies, and hematocrit 
were obtained (Rodeheffer et al., 2000). In this record review and abstraction clinical data 
related to sleep-disordered breathing again was not part of the protocol. 
With the PAVD study, round two now including a uniform assessment of OSA 
risk using the BQ, the study provided an assessment of the prevalence of the clinical 
recognition of OSA in a population-based sample. 
Summary 
This literature review has considered a variety of aspects of the epidemiology, 
diagnosis, and treatment of OSA, previous reports of the prevalence of the clinical 
recognition of OSA, the performance of the BQ, and nature of the Rochester 
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Epidemiology Project as community-based laboratory. This final section attempts to 
summarize this data as it relates to the planned study of the prevalence of clinically 
recognized OSA in a population based sample. 
OSA is a disorder in the continuum of sleep-related breathing disorders.  A 
quarter century of prevalence studies suggest that it is relatively common with 19 – 25% 
of adult men having OSA defined as an AHI ≥ 5 without regard to daytime sleepiness.  
The disorder has a somewhat lower prevalence in women with a gender ratio of about 
2:1, and increases in prevalence with age up to about 65 years.  Obesity, snoring, daytime 
sleepiness, hypertension, and male gender are all considered risk factors for OSA.  Full 
laboratory PSG is the gold standard diagnostic technique for OSA, though the less 
cumbersome techniques of in home monitoring are gaining favor. CPAP is the first-line 
therapy for OSA whereas dental appliances and surgical treatment can play a role in 
selected patients.  OSA is associated with increased risk of hypertension, cardiovascular, 
and cerebrovascular disease.  Unfortunately CPAP is a therapy that is difficult to adhere 
to limiting the risk reduction associated with treatment for these associated diseases. 
Studies prior to 1990 suggested that the prevalence of clinically recognized OSA 
among those with OSA was no more than 1%.  Two subsequent population-based studies 
using data from the 1990s showed that clinical recognition of OSA could be as high as 
7% and 18% in women and men, respectively.  Among the limitations of these studies 
was the use of a self-reported OSA diagnosis.  Among the explanations for the limited 
clinical recognition has been (a) limited OSA awareness by physicians, (b) limited access 
to diagnostic sleep laboratories and sleep specialists, and (c) the intrusive nature and 
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expense of PSG. There is evidence that there has been improvement in all of these factors 
over that past decade. 
The BQ is a simple survey instrument developed in the late 1990s to assess 
individuals’ risk of OSA. In recent years there has been a growing research use of the 
instrument with a total of 53 publications now reporting its use.  In a pooled analysis of 
the fourteen studies that have validated the instrument against a PSG standard, the 
instrument’s performance varies with the level of OSA severity inclusion criteria used.  It 
performs best in detecting OSA defined by an AHI ≥ 5 both with and without a daytime 
symptom criteria. 
This study used REP resources to assess the prevalence of clinically recognized 
OSA among those with OSA based on the BQ.  The REP is a longitudinal clinical record 
linkage system for the population of Olmsted County, Minnesota.  Historically this 
system developed as a result of the unified, shared medical record developed at the Mayo 
Clinic in 1907 that has since evolved and been linked with the records of essentially all 
health care providers in the region along with birth and death records through the support 
of the National Institutes of Health beginning in 1966. The REP is identified as one of 
only six comprehensive record linkage systems internationally, and the only such system 
in the United States. 
The PAVD study is a population-based longitudinal study primarily considering 
myocardial ventricular function in which participants had a rather comprehensive 
evaluation and medical record abstraction focused on cardiac risk factors, initially and 
approximately four years later.  Though no assessment or record review of sleep-related 
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breathing problems was included in either the first or second round of the study, the 
survey instrument for round two included a modified BQ that identified those at high risk 
for OSA in a consistent manner. 
Thus, the literature suggests that OSA is rather prevalent disorder that historically 
has been substantially under recognized clinically. The BQ is a reasonable instrument by 
which to classify participants’ risk of OSA as has been done in Round two of the PAVD 
study.  With use of REP resources, participants in the PAVD study with clinically 
diagnosed OSA were identified, and the prevalence of OSA clinical recognition among 




CHAPTER 3:  RESEARCH METHOD 
Introduction 
OSA is a sleep-related breathing disorder that is associated with significant 
cardiovascular and cerebral vascular morbidity and mortality.  Treatment with CPAP, 
considered to be the first-line OSA treatment, does attenuate this increased morbidity and 
mortality.  However, patient adherence to CPAP therapy is challenging and is limited.  
More importantly most OSA is undiagnosed and thus untreated. Previous research has 
shown that no more than 18% of prevalent OSA was clinically diagnosed in the 1990s. 
Lack of physician awareness of OSA, access to sleep lab services and sleep medicine 
specialty treatment had provided explanation for this under recognition. There is evidence 
that there is now improved physician awareness and access to sleep medicine services.  
Thus, this study assessed the prevalence of clinically recognized OSA among those at 
high risk for OSA in a community-based sample.   
The methods used to identify those considered to be at high risk for OSA, and the 
method for identifying those participants in the sample that have been clinically 
recognized with OSA are described in this chapter. The methods used for data collection 
and analysis, and measures taken to protect participants’ rights are also described. 
Research Design and Approach 
This study utilized the community based sample established in 1997 for the 
ongoing study titled the Prevalence of Asymptomatic Ventricular Dysfunction (PAVD) 
Study (Redfield et al., 2003) to evaluate the prevalence of clinically recognized OSA 
among those with BQ defined OSA.  As described in chapter 2 round two of the PAVD 
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study included a modified BQ.  Thus, participants in this sample were classified as either 
high or low risk for OSA. This study then used the resources of the Rochester 
Epidemiology Project including the patient database, clinical record access system, and 
technical support staff, to identify all PAVD participants that had the clinical diagnosis of 
OSA. The analysis of this data identified factors predictive of clinical recognition, and 
assessed whether there was evidence of increased OSA clinical recognition among those 
at high risk for OSA compared to the previous studies of OSA clinical recognition. 
In the two previous assessments (Kapur et al., 2002; Young, Evans et al., 1997) of 
the prevalence of clinically recognized OSA, the participant’s self-reported physician 
diagnosis was used as the marker of OSA clinical recognition.  Although one of these 
studies used a laboratory-based PSG to determine the presence of OSA in the population 
(Young, Evans et al., 1997), the other study (Kapur et al., 2002) used as an OSA proxy of 
self-reported symptoms of frequent snoring and excessive daytime sleepiness. Though 
these factors are recognized as OSA risk factors, this two-symptom proxy had never been 
validated as an OSA predictor, even in the sources cited by Kapur and colleagues (2002) 
in support of its use (Bradley et al., 1998; Newman et al., 2001; Strohl & Redline, 1996).  
Thus, the use of medical record verification of the clinical diagnosis of OSA, along with 
a previously validated instrument, the BQ, as the OSA proxy, represented an improved 
method over previous studies in this area.  In addition, performing this study based on 
data collected from 2001 to 2010 will represent a timely reevaluation following improved 
physician recognition and sleep medicine access in the 1990s (Namen et al., 2002). 
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Setting and Sample 
This study was carried out using the population-based community sample 
established for the PAVD study as previously described in chapter 2 (Ammar et al., 2006; 
Redfield et al., 2003). That sample was drawn from the residents of Olmsted County 
Minnesota who have access to sleep medicine services through the Mayo Clinic Center 
for Sleep Medicine, one of the largest such centers in the United States ("Mayo Clinic: 
Obstructive Sleep Apnea, Diagnosis," 2008), and the Olmsted Medical Center sleep 
program ("Olmsted Medical Center:  Services, Sleep Medicine/Lab," 2008).  Thus, these 
participants have substantial local access to sleep diagnostic and treatment services. 
The sample used for this study was the participants that continued in round two of 
the PAVD study. As described in chapter 2, this round two sample represents those 
participants that had completed round one of the study who then chose to continue their 
participation in round two. This study then analyzed this sample for participation bias 
comparing these round two participants with those from round one who did not 
participate in round two. A previous analysis for participation bias comparing those 
participating in round one, with those invited to participate in round one but choosing not 
to do so, had been carried out (Jacobsen et al., 2004).  The relationship of this analysis 
with the previous participation bias analysis (Jacobsen et al., 2004) after which it was 
modeled is graphically demonstrated in figure 2. Note that because previous PAVD 
analyses had been focused on echocardiographically defined endpoints, previously 
reported participation totals had been based on completion of the echocardiogram 
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(Redfield et al., 2003). This study focused on completion of the BQ, therefore the 
numbers of participants deviate slightly from those previous reports.
 
 




Figure 2. PAVD participation bias analyses 
Participants invited to participate 
in PAVD study 
N = 4,203
Round 1 Non-participants 
n = 2,156
Round 1 Participants 
n = 2,047 
Round 2 Non-participants 
n = 630
Round 2 Participants 
n = 1,417
Participation bias analysis by Jacobsen et al, 2004 




Power and Sample Size 
This study planned to detect a change in the prevalence of OSA clinical diagnosis 
among those at high risk for OSA compared to previous studies (Kapur et al., 2002; 
Young, Evans et al., 1997). These earlier studies had demonstrated prevalence of clinical 
recognition among those with OSA as shown in Table 9. 
Table 9 
 
Prevalence of Clinical OSA recognition among those with OSA 
Study Gender 
Prevalence of Clinical 
OSA Recognition 





Young, Evans et al., 1997 Male 0.18 77 
Young, Evans et al., 1997 Female 0.07 27 
Young, Evans et al., 1997 Combined 0.154 104 
Kapur et al., 2002 Combined 0.082 650 
 
With this study being part of a larger longitudinal study, the sample size has been 
fixed by the design and participation rates in rounds one and two of the overall PAVD 
study.  Thus this analysis of power and sample size considered the power of this study 
using this sample to detect a difference in the prevalence of OSA clinical recognition 
from these previous studies. 
The design considered the proportion of those with clinically recognized OSA in 
round two of the PAVD study compared to the two previous studies (Kapur et al., 2002; 
Young, Evans et al., 1997). Thus, this represents a comparison of two binomial 
proportions resulting from independent samples. A method for calculating the power in 
such circumstances has been described (Rosner, 2006) that involves the following 
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parameters as applied to this study:  the proportion with clinically recognized OSA in the 
two samples (p1 and p2), the difference in the proportions in the two samples (Δ), the 
complimentary proportion with clinically unrecognized OSA in each sample (q1 and q2), 
the average of the proportions and the complimentary proportions in the two samples 
( p and q ),  the number of participants, in this case with OSA, in the two samples (n1 and 
n2), and the level of statistical significance (α) where phi (Φ) is the cumulative 
distribution function of a standard normal distribution. From Rosner (2006) that 

















































Power α  
A preliminary analysis of the BQ results from PAVD round two classified a total 
of 527 participants as being at high risk for OSA including 328 men and 199 women with 
these participants representing the sample size (n2) in the study for the comparisons with 
previous reports. Use of the high risk classification on the BQ as an OSA proxy then 
provided the denominator for calculation of the prevalence. With increased physician 
awareness of OSA and increased availability of sleep laboratories as described in chapter 
2, it was highly unlikely that the clinical recognition of OSA would have decreased 
compared to that noted in the 1990s.  Thus, a one-sided power analysis with a z term of 
z1-α is used here rather than z1-α/2 as described above by Rosner (2006). 
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For this study this method of power calculation (Rosner, 2006) was used to 
determine the largest prevalence difference that can be detected with a power of at least 
80% relative to the four previously reported prevalence rates.  As illustrated in Table 10 
below, an increase in the prevalence of 0.171 compared to the previously reported 
prevalence would be detected with a power of 0.80 for females. For males and the two 
previously reported prevalence values for combined gender populations, there is a 0.80 
power to detect even smaller increases in prevalence as demonstrated in Table 10. Thus, 
this study had a power of 80% to detect an increase of prevalence of clinically recognized 
OSA to 31% in males, 24% in females, and 26% in a combined gender population with 
the probability of type I error less than 5%.
 
 





Power Analysis: Minimum Prevalence Increase Detected with a Power of  ≥0.80 Based on a One-sided Analysis 
Gender 
Number with 












detected with a 
power of 0.8  
(Δ) 
Prevalence 
detected with  a 
power of  0.8 
 (p2) 
Male 
(Young, Evans et 
al., 1997) 
77 328 0.180 0.133 0.313 
Female 
(Young, Evans et 
al., 1997) 
27 199 0.070 0.171 0.241 
Combined 
(Young, Evans et 
al., 1997) 
104 527 0.154 0.105 0.259 
Combined 





Instrumentation and Materials 
Berlin Questionnaire 
As part of the PAVD round two evaluation participants completed a 21-page 
survey developed by the PAVD investigators in cooperation with the Mayo Survey 
Research Center titled “Olmsted County Heart Survey.”  That instrument included a wide 
variety of questions related to cardiovascular symptoms, and previous cardiovascular 
care, and was largely similar to the 17-page survey previously used in round one.  The 
items from the BQ, with the exception of items eight and nine related to nodding off 
while driving (see Table 3 above), were included in the round two questionnaire. As 
described previously, after review by legal counsel these items were omitted from this 
questionnaire due to concerns about vicarious liability associated with recording 
participants’ propensity for nodding off while driving without ability to intervene in the 
research setting (A.S. Gami, personal communication, July 17, 2007).  
The BQ is, as originally described (Netzer et al., 1999; "Reprinting of the Berlin 
Questionnaire," 2000), an 11 item survey instrument that considers three categories of 
symptoms and conditions associated with OSA. Those three categories are (a) snoring, 
(b) daytime fatigue and sleepiness, and (c) the presence of hypertension and obesity. For 
these categories there are five, four, and two items, respectively, in the instrument’s 
original presentation each with either binary scoring, or scoring based on a five-point 
ordinal scale of severity (Netzer et al., 1999; "Reprinting of the Berlin Questionnaire," 
2000). 
    
  
90
As described in chapter 2 the BQ has been used as a research instrument in 53 
previous publications including fourteen that published a validation study for the 
instrument with a PSG-based diagnostic method for OSA as the gold standard. Though 
the overall structure of the instrument has been consistent in these studies, there have 
been a number of variations in the questions scored, and the exact scoring methods used 
in these studies. The details of these variations are described in chapter 2. 
In pooled analysis of these validation studies (see Tables 6 and 7) the BQ appears 
to perform best in predicting OSA defined by an AHI or RDI>5 with or without daytime 
symptoms.  Thus, the BQ, used in this manner, is an appropriate instrument to use in 
predicting OSA in the proposed study population. 
Using the REP for identification of PAVD participants with clinical OSA diagnosis 
The REP, as described in chapter 2, is a comprehensive medical record data 
linkage system that allows population-based study of a wide variety of health phenomena 
in Olmsted County, Minnesota (Melton, 1996).  Using a method typical for studies using 
the REP, the PAVD study had originally been initiated using REP resources to randomly 
select a population-based sample of those ages 45 and older on January 1, 1997 from the 
overall county population (Ammar et al., 2006; Redfield et al., 2003).  With the REP’s 
comprehensive data linkage system, it was possible to use REP resources to 
electronically return to the PAVD sample and identify participants likely to have 
undergone PSG or carry a clinical diagnosis of OSA.   
This was accomplished through the identification of the medical procedure billing 
and diagnostic codes potentially associated with PSG, OSA and other sleep-related 
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breathing disorders, and with the first-line therapy for OSA, CPAP. Then the medical 
records identified through the REP were reviewed to identify details of the diagnostic 
evaluation, the actual clinical sleep diagnosis, and the nature of any associated treatment. 
This study identified all participants from round one (which includes all round two 
participants) that had undergone PSG or carried a diagnosis of OSA. The inclusion of the 
round one participants that did not participate in round two allowed a comparative 
analysis of those participants with round two participants for possible participation bias. 
In Olmsted County there are two sources of sleep laboratory evaluation, one at the 
Mayo Clinic, and the second at Olmsted Medical Center. A comprehensive electronic 
database of the PSGs performed at Mayo Clinic is available. Thus, as iterations of the 
REP search criteria for PSG, OSA, and sleep-related diagnoses were developed, the 
resulting patient population was compared to the Mayo Sleep Laboratory Database 
(MSLD) as a means of assessing the performance of the search criteria in identifying all 
PAVD participants known to have had PSG performed in the Mayo Clinic Sleep 
Laboratory. This comparison of the participants identified using the REP search with 
roster of those already known to have undergone a Mayo PSG provided an indirect 
method of evaluating the validity and efficiency of the REP search criteria as they were 
developed. 
In the developing a search strategy for this study the first iteration of REP criteria 
was as follows:  Either a PSG or CPAP procedure code AND one of a broad, inclusive 
list of sleep breathing-related diagnostic codes. The list of the codes selected is displayed 
in Table 11. This iteration of the search identified 169 participants from the 2,042 
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participants that completed round one of the PAVD study.  These 169 participants 
included 151 of the 235 PAVD participants known to have had a PSG based on the 
MSLD, and 18 additional participants.  These 18 participants included 16 that were found 
to have had a PSG at the Olmsted Medical Center, one found to have had a PSG at Mayo 
Clinic that was not recorded in the MSLD, and an additional participant whose clinical 
records note an OSA diagnosis, but make no reference to when or where a PSG might 
have been performed.  With 152 of these 169 participants having had PSGs performed at 
Mayo Clinic, whereas 16 were performed at Olmsted Medical Center, an approximate 
9.5:1 ratio of studies performed in the two institutions was demonstrated. 





Sleep Breathing-related Diagnostic Codes 
Code Description 
7735110 Insomnia, NOS 
7735111 Disorder, Sleep, NOS 
7735112a Deprivation, Sleep 
7735113 Disturbance, Sleep 
7735115 Insufficiency, Sleep (Syndrome) 
7735120 Sleepiness, NOS 
7735130 Sleepiness, Cause Specified 
7735132 Disorder, Excessive Somnolence 
7781510 Hypoventilation, NOS 
7781511 Syndrome, Hypoventilation, NOS 
7781520 Syndrome, Hypoventilation, Cause Specified 
7781521 Hypoventilation, Cause Specified 
7782210 Respiration, Cheyne-Stokes, NOS 
7782211 Cheyne-Stokes See Also Respiration 
7782220 Respiration, Cheyne-Stokes, Cause Specified 
7782410 Apnea, NOS 
7782411 Apnea, Sleep 
7782412 Sleep, Disordered Breathing 
34199754 Clinic, Sleep Disorder Center 
327.1 Organic Hypersomnia, Unspecified 
327.11 Idiopathic Hypersomnia With Long Sleep Time 
327.12 Idiopathic Hypersomnia Without Long Sleep Time 
327.13 Recurrent Hypersomnia 
327.14 Hypersomnia Due To Medical Condition 
327.15 Hypersomnia Due To Mental Disorder 
327.19 Other Organic Hypersomnia 
327.2 Organic Sleep Apnea, Unspecified 
327.21 Primary Central Sleep Apnea 
327.22 High Altitude Periodic Breathing 
327.23 Obstructive Sleep Apnea (Adult)(Pediatric) 
327.24 Idiopathic Sleep Related Nonobstructive Alveolar Hypoventilation 
327.25 Congenital Central Alveiolar Hypoventilation Syndrome 
327.26 Sleep Related Hypoventilation/Hypoxemia In Conditions Classifiable Elsewhere 
327.27 Central Sleep Apnea In Conditions Classified Elsewhere 
327.29 Other Organic Sleep Apnea 
780.5 Sleep Disturbances 
780.5 Unspecified Sleep Disturbance 
780.51 Insomnia With Sleep Apnea, Unspecified 
780.52 a Insomnia, Unspecified 
780.53 Hypersomnia With Sleep Apnea, Unspecified 
780.54 Hypersomnia, Unspecified 
780.55 Disruption Of 24-Hour Sleep-Wake Cycle, Unspecified 
780.56 Dysfunctions Associated With Sleep Stages Or Arousal From Sleep 
780.57 Unspecified Sleep Apnea 
780.58 Sleep Related Movement Disorder 
780.59 Other Sleep Disturbances 
786.09 a Other Dyspnea And Respiratory Abnormality 
a Diagnostic code eliminated in the third iteration of the REP search criteria. 
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Because these criteria had failed to identify 35.7% of the PAVD participants 
known to have undergone PSG based on the MSLD, the criteria were modified to be 
more inclusive.  This second iteration of the REP Search Criteria was then submitted as 
follows: Either a PSG or CPAP procedure code OR one of the same broad, inclusive list a 
sleep breathing related diagnostic codes from Table 11. That search then identified 690 
participants including 229 of the 235 PAVD participants identified in the MSLD, and 443 
additional participants that were not in that database or among the 18 participants 
identified by the first iteration as having had sleep studies or OSA apart from that 
database. The six participants in the database not identified in the second iteration of the 
search criteria all had PSGs performed more than 12 years ago and thus may have had 
their studies coded in a different manner. 
An analysis of the specific diagnostic codes leading to the identification of these 
690 second iteration participants showed that the number of participants identified in the 
MSLD by each code compared to the other participants identified by that code varied 
widely as illustrated in Table 12.  Some codes exclusively identified participants known 
to have had PSGs, whereas other codes identified only participants not found in the 
MSLD, and other codes identified a mix of MSLD participants and the others.   
The ratio of participants with known PSGs to those without known PSGs is one 
indicator of the relative efficiency of each code in identifying participants that have 
undergone PSG.  A ratio of 1 participant with a known PSG for every 10 participants 
without a known PSG was arbitrarily selected as a threshold ratio for inclusion of the 
code in the search criteria.  This analysis demonstrates that elimination of four codes 
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would be predicted to reduce the number of participants identified but not found in the 
MSLD by 95, while leaving seven participants with PSGs unidentified. Recognize that 
the seven participants with known PSGs but not identified by the REP criteria did still 
ultimately contribute to the PSG analysis as they had been identified in the MSLD. Given 
the 9.5:1 ratio of Mayo to non-Mayo PSGs, the elimination of these codes was predicted 
to have missed less than one participant with a non-Mayo PSG. 






Participants Identified by REP Search Criteria, Iteration 2 
 Participants with 
a known PSG 
Participants without 
a known PSG 
Ratio of participants with known PSGs 
to those without a known PSG 
Code n n  
93.9 a 0 1 0.00 
327.23 3 0 b 
780.5 2 9 0.22 
780.51 1 0 b 
780.52 a 2 31 0.06 
780.53 1 0 b 
780.57 10 3 3.33 
786.09 a 5 58 0.09 
7735110 17 153 0.11 
7735111 9 52 0.17 
7735112 a 0 5 0.00 
7735113 5 38 0.13 
7735115 1 2 0.50 
7735120 1 9 0.11 
7735132 1 2 0.50 
7781510 1 0 b 
7781521 1 0 b 
7782410 1 5 0.20 
7782411 177 62 2.85 
7782412 6 8 0.75 
34199754 3 5 0.60 
Total 247 443  
a diagnostic codes eliminated for iteration 3 
b ratio cannot be calculated as it involves division by zero 
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Thus, a third iteration of the REP search criteria is as follows: Either a PSG or 
CPAP procedure code OR one of a shorter, but still inclusive list a sleep breathing related 
diagnostic codes. This iteration of the search criteria identified a total of 608 participants 
from the 2,042 that had participated in PAVD round one including the same 229 
identified in the second iteration from the MSLD, and the 18 participants previously 
recognized as having had PSG at the Olmstead Medical Center in the first iteration of the 
search criteria. This reduction of the number of participants identified in iteration three 
effectively reduced the number of participants outside of the MSLD by 81 to 362.  Based 
on the analysis above it appears unlikely that a further modification of these search 
criteria will substantively affect the efficiency of participant identification.   
The roster generated by iteration three then represents the PAVD participants 
identified by the REP search as likely having had PSG and carrying an OSA diagnosis.  
In the proposed study these participants’ linked records were reviewed to verify the 
performance of PSG, identify the facility at which it was performed and extract the 
date(s) of testing, quantitative and narrative diagnostic results from the PSG, and 
available information regarding the OSA therapies recommended. When available any 
references to patients’ current adherence to the recommended therapy was also abstracted 
from the records. 
To validate this REP search method and these final criteria, a random sample of 
50 participants not identified as having had PSG or an OSA diagnosis were also manually 
reviewed. As described in chapter 4, that sample indicated that less than 6% of 
participants (n<3) not identified by the REP search method actually had PSGs or carried a 
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sleep-related diagnosis, thus these search criteria were accepted, having identified 95% or 
more of PAVD participants undergoing PSG or having a sleep breathing related 
diagnosis.  
Data Collection and Analysis 
Existing PAVD data including the demographic parameters and many of the 
clinical parameters to be used in this proposed study are maintained by the PAVD data 
management staff in an electronic format based on standard research procedures for the 
Mayo Clinic. The author of this study completed and maintained the necessary ethics 
training for Mayo Clinic and REP research, and had obtained IRB approval for the 
research at both the Mayo Clinic and the Olmsted Medical Center.  Thus, the author had 
the necessary institutional approvals to access this data and carryout the proposed 
research. In addition, the author had obtained the approval of the Walden University IRB 
to carry out the analysis of this data once collected.  
The REP search criteria were developed in cooperation with a REP data 
analyst/programmer who then wrote the script that implements the search using the REP 
electronic resources.  The REP data analyst/programmer then provided an electronic 
spreadsheet roster of the participants identified by the search with additional associated 
data fields appropriate to chart review and analysis (Erickson et al., 2007).   
Chart review and data collection 
Using this electronic roster of participants meeting the REP search criteria a 
systematic review of participant records was done. The first step was to use the electronic 
REP browser to identify the types and location of records available for each patient. This 
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browser allows electronic access to listings of the medical procedure billing and 
diagnostic codes searched and scanned records that are archived by the REP. Manual 
review of these codes allowed the identification of the dates, type of records, and 
locations likely to provide the details of the PSGs performed and the final sleep-related 
breathing clinical diagnosis and treatment (Erickson et al., 2007). 
Once the dates and location of these records were identified the next step was 
accessing and reviewing those records.  For those records maintained in an electronic 
medical record, the necessary information was abstracted directly from these records. If 
the necessary records were maintained in a paper only format, the investigator provided a 
roster of these records to the REP research study assistant who then organized the 
collection of these paper charts at the appropriate institutional site and scheduled a time 
for the investigator to visit that record department for the abstracting review (Erickson et 
al., 2007). 
The record review focused on the PSG report, clinical notes that led to the 
ordering of the PSG, clinical notes subsequent to the PSG in which a sleep-related 
treatment had been ordered, and more recent notes that provided indications of current 
adherence to the currently prescribed sleep-related treatment.  In addition, where a PSG 
report or other definitive descriptions of sleep-related evaluations and treatments were 
not available, a general review of the record was carried out to determine the basis for the 
record’s identification by the REP search criteria.   
For this study the following data were then abstracted into an electronic 
abstraction record: (a) date and location of all PSGs performed; (b) PSG reported 
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parameters including the AHI or RDI, oxygen saturation nadir, portion of sleep time with 
oxygen saturation less than 90%, oxygen desaturation index, the central and obstructive 
AHIs, and total sleep time, (c) the clinical diagnosis from the narrative PSG report; (d) 
the sleep-related prescription recommended to the patient following the PSG; (e) 
narrative indications of the patient’s subsequent and current adherence to that therapy; 
and (f) a description of the dates and locations of the records reviewed. This abstraction 
record was maintained on a laptop computer to allow use at the multiple locations at 
which charts must be reviewed.  The electronic abstraction record was a password 
protected file that is electronically regularly backed up.   
At the conclusion of the abstraction the abstraction file was reviewed for 
consistency of data with corrections made as indicated noting that the original patient 
records remained available if needed to clarify inconsistencies.  
Analysis 
The analysis of the data obtained was approved by the Walden University IRB 
and was carried out in several stages.  The first stage was designed to provide assurance 
of the validity of the REP search criteria for the identification of at least 95% those with 
PSGs and clinically diagnosed OSA.  As described above, this involved the review of 50 
randomly selected patient records not identified by the REP criteria for participants that 
had completed round one of PAVD.  If there were three or more participants (≥6%) from 
this sample of 50, the search criteria would have been reevaluated based on the 
characteristics of those additional participants with PSG or OSA-related diagnoses.  Since 
there were two or fewer participants in this sample with a PSG or OSA-related diagnosis 
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the criteria were accepted as having effectively identified 95% or more of those in the 
PAVD study that have had PSG or an OSA-related diagnosis.   
The second stage of the analysis was to determine if there was evidence of 
participation bias by comparing those participating in round two with those from round 
one that did not participate.  Similar to the earlier evaluation for participation bias in 
round one (Jacobsen et al., 2004), this analysis included age, gender, marital status, 
educational attainment, BMI, history of cardiovascular diseases including coronary artery 
disease, congestive heart failure, hypertension, history of atrial fibrillation, other 
cardiovascular disease, diabetes, chronic obstructive pulmonary disease, and history of 
clinical PSG or diagnosis OSA.  Descriptive statistics were tabulated for these participant 
characteristics in round two participants and nonparticipants stratified by age and gender.  
For categorical variables statistical comparison was by chi-square test whereas 
continuous and ordinal variables were compared using the Student t-test.  The 
participation bias found was acknowledged in interpretation of the study’s results. 
Stage three of the analysis addressed the subtle difference in the scoring algorithm 
used in a BQ validation study previously done in our institution (Gami et al., 2004) 
compared to the original validation study (Netzer et al., 1999; "Reprinting of the Berlin 
Questionnaire," 2000).  Table 3 illustrates that the scoring of item one in the 
questionnaire varied from the original scoring algorithm. Thus, analysis of the resulting 
difference, if any, in the population prevalence of OSA by the BQ proxy was performed 
to determine the impact of this difference. 
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Once the first three stages of analysis were completed, the fourth stage involved a 
descriptive analysis of the participants with and without clinically diagnosed OSA among 
those with the OSA proxy based the modified BQ.  This descriptive analysis included 
demographic factors such as gender, age, educational attainment, and marital status.  In 
addition clinical factors previously recorded for the PAVD study were assessed, 
including BMI, change in BMI from round one to round two, a history of coronary artery 
disease, congestive heart failure, hypertension, atrial fibrillation, cerebral vascular 
accident (CVA), diabetes, chronic lung disease, and a cardiovascular disease composite, 
systolic and diastolic myocardial function, and lipid profile. For continuous variables 
mean, median, and standard deviation will be reported, and where appropriate continuous 
variables were analyzed in categorical groups.  For example, BMI was considered 
categorically in normal, overweight, and obese groups in addition to a comparison of 
means.  Since many of these variables were collected in both round one and round two, 
the more recent round two data was generally used, and an analysis based on the changes 
of relevant parameters from round one to round two was also performed.  
Based on these bivariate analyses factors statistically associated with clinical 
recognition of OSA were entered in a multiple logistic regression analysis to identify 
factors that independently predicted the clinical diagnosis of OSA among those with the 
BQ OSA proxy after adjustment for other variables.  The dependent variable was the 
presence or absence of clinically diagnosed OSA among those with OSA based on the 
BQ.  The regression analysis proceeded with a stepwise, backward strategy.  Those 
factors from the bivariate analysis with a statistically significant difference (p ≤ 0.05) 
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between those clinically recognized and unrecognized were all included in the regression 
model initially. Independent variables that then had insignificant coefficients (p>0.05) 
were the removed from the model one at a time starting with the variable with the highest 
p-value. This process was continued until all of the variables remaining in the model 
were significant. The final model then had identified the factors that are statistically 
independent predictors of clinical recognition of OSA among those with OSA based on 
the BQ proxy. 
The results of this analysis were then used to formulate strategies to better 
recognize those most likely to have undiagnosed OSA.  The prevalence of clinically 
recognized OSA among those with the BQ OSA proxy were also determined and 
compared to that previously reported in population-based studies using 1990s data 
(Kapur et al., 2002; Young, Evans et al., 1997).   
Protection of Participants Rights 
Prior to participation participants in the PAVD study completed a consent form 
approved by the Institutional Review Boards of both the Mayo Clinic and Olmstead 
Medical Center. That document includes a detailed description of the nature of the study, 
risks, and benefits of participation, the opportunity to withdraw from the study, and 
provides participants the opportunity to authorize investigators to review personal health 
records for relevant study information. In addition, patients obtaining healthcare from the 
Mayo Clinic and the Olmsted Medical Center have the opportunity to provide general 
permission for review of their records for research purposes when they seek routine care 
at these institutions.  Patients who choose not to grant that permission have their clinical 
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identification numbers censored in the REP browser, and thus their records are 
inaccessible to review (Erickson et al., 2007).  Thus, both the informed consent process 
within the PAVD study, and the routine consent process in obtaining care in Olmsted 
County provided mechanisms to protect participant rights for this study. 
All of the round two PAVD data, along with data previously obtained in round 
one of the PAVD study are maintained by the PAVD data management staff in a secure 
electronic format with appropriate electronic and paper data backup by standard research 
procedures for the Mayo Clinic. Those with appropriate research ethics training and 
Mayo Institutional Review Board (IRB) approval for specific PAVD research projects 
may have access to this data within the limits of their IRB approved research role. This 
allows for investigators to obtain a working data extract, typically in a standard 
spreadsheet or statistical analysis software format, from the primary, secure database for 
the approved project (Erickson et al., 2007). In addition, projects utilizing REP resources 
must have IRB approval from the Olmsted Medical Center, the other primary REP 
institutional partner, in order to access those REP resources.  The author of this study had 
completed and maintains the necessary ethics training for Mayo Clinic and REP research. 
In addition, the author had submitted and obtained IRB approval for the research at both 
the Mayo Clinic and the Olmsted Medical Center.  Finally the author had obtained 
approval of the Walden University IRB for the plan to analyze this data.  Thus, the author 
had the necessary institutional approvals to access this data and carryout the research.  
Since the data collected by this study is the property of the larger PAVD study, at the 
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study’s conclusion it will be submitted to the PAVD data management staff to be 
permanently archived with the rest of the PAVD data.  
Summary 
This study built on the longitudinal, population-based PAVD study of adults who 
were age 45 and older on January 1, 1997 to assess the prevalence of clinically 
recognized OSA in the population.  In the second round of that study participants 
completed the modified BQ which classified participants’ risk of OSA as high or low, 
and was used as a proxy for OSA.  Using the resources of the REP, PAVD participants 
from both rounds one and two with clinically recognized OSA were identified using 
billing codes for PSG and CPAP along with a group of diagnostic codes for sleep-related 
breathing diagnoses.  The charts of identified participants were reviewed to abstract 
parameters measured in the clinical PSG, the clinical diagnosis of OSA, and, where 
possible, any OSA treatment recommended and the participants’ adherence to that 
treatment was also abstracted.  
A preliminary analysis of the BQ responses demonstrated that a total of 527 of the 
original 1,402 participants in round two were at high risk for OSA including 199 women 
and 328 men. Thus, the study was powered at 80% to detect increases in clinical 
recognition of 13.3% among men, 17.1% among women, and 4.5 – 10.5% in a mixed 
gender populations compared to the two previous population based assessments of OSA 
clinical recognition (Kapur et al., 2002; Young, Evans et al., 1997). 
The study’s analysis included a validation analysis to assess the effectiveness of 
the REP search criteria used to identify participants with the clinical diagnosis of OSA by 
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reviewing 50 randomly selected charts not selected by these criteria.  The possibility of 
participation bias was considered by an analysis comparing the baseline characteristics 
and the clinical diagnoses of OSA for participants that participated in the round two with 
those that chose not to participate. A descriptive analysis determined the prevalence of 
clinically recognized OSA among those with a high risk of OSA based on the BQ. Finally 
both bivariate and multivariate analyses of factors predictive of OSA clinical recognition 
were performed. 
The study protected participants’ rights through a careful informed consent 
process that was a part of the PAVD study and when participants were provided 
opportunity to consent the to use of their clinical records in the course of obtaining 







CHAPTER 4:  RESULTS  
Introduction 
This study utilized the community-based sample established in 1997 for the 
ongoing Prevalence of Asymptomatic Ventricular Dysfunction (PAVD) Study to evaluate 
the prevalence of clinically recognized obstructive sleep apnea (OSA) among those at 
high risk for OSA (Redfield et al., 2003). The survey completed by PAVD participants in 
round two included a modified BQ which was used to predict which participants were at 
high risk for OSA (Netzer et al., 1999; "Reprinting of the Berlin Questionnaire," 2000). 
To identify participants with clinically recognized OSA the resources of the REP 
(Melton, 1996) were used to ascertain those participants’ medical records containing one 
of the sleep-related diagnosis and procedure codes in Table 12. The records of these 
participants were then reviewed to obtain information about any clinical PSG the 
participant had undergone and the clinical diagnosis of OSA. 
  The responses to the BQ items and a host of demographic and clinical parameters 
had been collected by the PAVD study in Round 1 and/or Round 2.  These data points 
had been electronically archived by study staff that then provided a data extract of the 
relevant data for this study.  The REP search for sleep-related procedure and diagnosis 
codes was carried out in October 2008 and identified 609 participants. The medical 
records of these participants were systematically reviewed recording PSG and OSA-
related parameters. To validate the REP code search process an additional 50 participants 
not selected by that process were randomly selected and manually reviewed for evidence 
of a clinical PSG testing or OSA diagnosis. Data from the REP identified charts that were 
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reviewed, the 50 participant validation study, the BQ responses, and other relevant fields 
from the archived PAVD study were then merged to form a single data set used for this 
study. Coded responses from the BQ were placed in an electronic algorithm to rate 
participants’ OSA risk based on the method of the original BQ validation study as 
modified for application in this setting(Netzer et al., 1999; "Reprinting of the Berlin 
Questionnaire," 2000). 
The research questions this study sought to answer were the following: 
1. What proportion of those at high risk for OSA based on the Berlin Questionnaire 
(BQ) have been clinically evaluated for OSA? 
2. What is the prevalence of clinically diagnosed OSA among those at high risk for 
OSA based on responses to the Berlin Questionnaire? 
3. Has the prevalence of clinically diagnosed OSA increased in the past decade? 
4. What factors are predictive of the clinical diagnosis of OSA among those at high 
risk of OSA? 
  The data analysis for this study was carried out in the following four stages: 
1. Validation of the diagnostic and procedure codes in Table 12 for the identification 
of clinically recognized OSA by the manual review of 50 randomly selected 
records not selected by these codes. 
2. Participation bias analysis comparing those participating in round two of the 
PAVD study with those from round one who did not participate, and a descriptive 
analysis of the resulting sample. 
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3. Analysis of OSA risk based on the Berlin Questionnaire and the impact of the 
Berlin Questionnaire scoring modifications used in this study. 
4. A descriptive, bivariate, and multivariate analysis of those with clinically 
recognized OSA in order to identify factors predictive of clinical recognition. 
  The purpose of stages one through three is to validate the method used to identify 
those with clinically recognized OSA, and to assess for bias in the data sets used.  Thus, 
these analyses are presented first.  Subsequently, the research questions are addressed 
following the presentation of results for the fourth analytic stage. 
Validation of the REP Codes Used for Identification of OSA Clinical Recognition 
  As described in chapter 3 sleep-related clinical diagnostic and procedure codes 
were compiled to electronically identify all participants with clinically recognized OSA.  
Through an iterative process using a database of known sleep studies the diagnostic and 
procedure codes were refined to efficiently identify all those with PSGs and OSA without 
selecting  those with other sleep-related diagnoses. The collection of codes used was from 
iteration three (Table 12).  Note that three codes in this table labeled with an asterisk (*) 
were eliminated for iteration three and thus, from this study. 
  The search for PAVD round one participants with sleep-related diagnoses was 
carried out in October 2008 using iteration three codes as noted in Table 12. The medical 
records of the 608 identified participants were reviewed beginning after final approval of 
the dissertation proposal in April 2009 with these reviews completed in early March 
2010. To validate this set of search codes to assure that at least 95% of participants with 
PSGs and/or OSA were identified by this process a random sample of 50 participants not 
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selected by iteration three codes was drawn in February 2010 and manually reviewed for 
evidence of PSG treatment or an OSA-related diagnosis. This review, completed in 
March 2010, identified a total of four of these 50 randomly selected participants with a 
sleep-related diagnosis as illustrated in Table 13. 
Table 13  
 
Sleep-Related Diagnoses Found in the 50 Participant Validation Sample 
Sleep-related diagnosis Diagnostic Date AHI by PSGa Treatment 
Periodic leg movements of sleep January 9, 2008 2 Iron supplementation 
Mild OSA November 8, 2008 9 CPAP 
Insomnia January 27, 2009 No PSG Sleep medication 
Insomnia January 4, 2010 No PSG Sleep medication 
a AHI by PSG: apnea-hypopnea index (AHI) by polysomnography (PSG) 
 
Only one participant with clinically recognized OSA was identified, and that 
clinical diagnosis was not made until after the REP search was carried out.  There were 
also two participants with other, nonOSA sleep-related diagnoses that were made after 
the REP search was performed. In addition, there was one participant that had a sleep-
related diagnosis not related to OSA that was made on January 9, 2008, prior to the REP 
search.  A review by REP staff indicates that this diagnosis was not identified by the 
search because it is likely that the January diagnosis and procedure codes had not yet 
been processed into the REP database when the search was carried out in October of 
2008 (S. Schrage, personal communication, May 3, 2010).  
Thus, in this validation sample there were no participants with clinically 
recognized OSA prior to the date of the search that were not identified by the iteration 
three collection of diagnostic and procedure codes. With one participant identified in this 
50 participant sample with a nonOSA sleep-related diagnosis there is an estimated 2% 
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chance that these criteria would not detect a participant with a sleep-related diagnosis 
which, in the entire study sample, could include some participants with OSA.  Since 
those with OSA represent a subset of those with any sleep-related diagnosis, the chance 
of this REP search method having failed to identify a participant with OSA is estimated 
to be less than 2%. Therefore, this validation analysis confirms that these criteria 
identified at least 95% of those with clinically recognized OSA in the PAVD sample. 
 
Round Two Participation Bias and Descriptive Analysis of the Sample 
This study was carried out using the population-based community sample 
established for the PAVD study as previously described in chapter 2 (Ammar et al., 2006; 
Redfield et al., 2003). The primary study using this database had been based on 
echocardiographic endpoints.  Thus, previous analyses used only participants that had 
completed an echocardiogram, which in Round 1 and 2 included 2,042 and 1,402 
participants, respectively. Further review of the archived PAVD data revealed that there 
were an additional five participants that were invited to participate in Round 2 despite not 
having completed the Round 1 echocardiogram.  In addition, in Round 2 there were an 
additional 15 participants that had completed the Berlin Questionnaire but did not 
complete the Round 2 echocardiogram. Because these additional participants had 
completed the essential elements for the present study, they have been included in the 
analyses which follow giving 2,047 participants in Round 1 and 1,417 participants in 
Round 2. The age and gender characteristics of these samples are described in Table 14.  
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Overall there was a nearly 70% participation rate from Round 1 to Round 2.  
Similar to a previously reported participation analysis for Round 1 (Jacobsen et al., 
2004), there was a somewhat lower Round 2 participation rate for the youngest age 
group, and a substantially lower participation rate for the oldest group in both genders. In 
addition, similar to that early analysis, there was a somewhat higher participation rate for 
men compared to women.  Thus, the subsequent bivariate analyses of participation are 
age- and gender-adjusted to the population participating in Round 1. 
Table 14 
 
Round 2 Participation Rate by Age and Gender 
Gender &  
















 Women 1061 714 67.3 64.5-70.1 
  45-54 302 220 72.9 67.9-77.9 
  55-64 312 243 77.9 73.3-82.5 
  65-74 264 278 67.4 61.7-73.1 
  75+ 183 73 39.9 32.8-47.0 
 
 Men 986 703 71.3 68.5-74.1 
  45-54 299 224 74.9 70.0-79.8 
  55-64 315 245 77.8 73.2-82.4 
  65-74 257 185 72.0 66.5-77.5 
  75+ 115 49 42.6 33.6-51.6 
 
Participation bias analysis for the initial Round 1 sample (Jacobsen et al., 2004) 
had considered a number of demographic and disease history factors as potentially 
associated with Round 1 participation. A similar analysis for Round 2 participation is 
presented in Table 15. In this bivariate analysis there was a statistically significant 
underrepresentation of those with noncoronary artery disease cardiovascular disease 
(nonCAD CV disease), congestive heart failure (CHF), any cardiovascular disease, 
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chronic obstructive pulmonary disease (COPD), those with no more than a high school 
education, and a higher Charlson Comorbidity Index weighted for age and severity 
(Charlson, Pompei, Ales, & MacKenzie, 1987). Relevant to the present study there was 
no statistically significant difference in Round 2 participation after age and gender 
adjustment related to BMI, having undergone a clinical PSG, or the clinical diagnosis of 
OSA.  
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Participation Rate by Disease History and Demographic Characteristics with Age and Gender Adjustment 
 Condition 






tion rate  
(%) 
Age & gender  
adjusted participa-
tion rate (%)a 
p b 
Coronary artery disease      
Present 248 143 57.7 65.5 
Absent 1799 1274 70.8 70.1 0.093 
NonCAD CV disease      
Present 515 290 56.3 63.2 
Absent 1532 1127 73.6 72.2 <0.0001
 c 
Atrial fibrillation/flutter      
Present 100 48 48.0 61.5 
Absent 1947 1369 70.3 69.9 0.202 
CHF      
Present 45 16 35.6 55.6 
Absent 2002 1401 70.0 69.7 0.0006
 c 
Hypertension      
Present 561 352 62.7 66.5 
Absent 1486 1065 71.7 70.8 0.074 
Any cardiovascular disease      
Present 550 316 57.5 64.1 
Absent 1497 1101 73.5 72.1 0.0002
 c 
COPD      
Present 94 39 41.5 45.8 
Absent 1953 1378 70.6 70.3 0.001
 c 
Diabetes mellitus      
Present 153 92 60.1 63.5 
Absent 1894 1325 70.0 69.8 0.072 
Marital Status      
Currently married 1588 1138 71.7 70.0 
Not currently married 447 273 67.0 67.0 0.227 
Education      
At least some college 1154 868 75.2 74.5 
No more than high school 759 466 61.4 63.1 <0.0001
 c 
Race/Ethnicity      
Caucasian, non-Hispanic 1996 1385 69.4 69.4 
Non-Caucasian or Hispanic 51 32 62.7 64.8 0.487 
Charlson Index, Weighted      
0 259 204 78.8 82.5 
1-2 912 689 75.5 69.6 
















Age & gender  
adjusted participa-
tion rate (%)a 
p b 
BMI      
<20 49 34 69.4 67.6 
20 – 24 466 318 68.2 68.3 
25 – 29 869 617 71.0 70.9 
30+ 662 448 67.7 66.5 
0.320 
Clinical PSG      
Performed 280 204 72.9 70.4 
Not performed 1767 1213 68.6 69.0 0.636 
Clinical OSA      
Diagnosed 270 197 73.0 70.9 
No diagnosis 1777 1220 68.7 68.9 0.505 
a Age and gender adjustments are to the standard of the Round 1 participating population.  b p values are for 
the Chi square Likelihood Ratio.  c Parameter considered statistically significant and retained in the initial 
multivariate logistic regression. 
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A multivariate logistic regression analysis comparing those from Round 1 that 
participated in Round 2 with those who did not participate was performed initially using 
only the conditions identified as statistically significant in the bivariate analysis in Table 
15.  Age and gender were also included since participation rates had been adjusted for 
these factors in Table 15.  In this model the continuous variable age was represented by 
an ordinal variable, categorized as shown in Table 14. In a stepwise manner, factors with 
coefficient p values greater than 0.05 were removed from the model. All of the age group 
variables were retained in the model despite the fact that the 65 – 74 year old age group 
was not statistically different from the reference group (45 – 54 years old) because of the 
lower participation rates in younger and older age groups. When considering the 
cardiovascular disease related variables with the other variables in the model only 
nonCAD CV disease ultimately remained statistically significant. The Charlson 
Comorbidity Index, which summarizes in a single variable comorbidity from spectrum of 
chronic disease, appears to be a better predictor of participation in this regression analysis 
than many of the individual chronic diseases included in this index (Charlson et al., 
1987). The unadjusted and adjusted odds ratios with 95% confidence intervals are 
presented for the variables retained in the final model in Table 16. 
 




Odds Ratios for Logistic Regression Analysis of Factors Predicting Round 2 Participation 
 Unadjusted OR b Adjusted OR c Adj. OR 95% CI 
Age Group, years     
 45-54 a 1 1  
 55-64 1.24 1.57 1.170 – 2.102 
 65-74 0.81 1.31 0.941 – 1.832 
 75+ 0.25 0.45 0.306 – 0.666 
Gender     
 Female a 1 1  
 Male 1.21 1.24 1.002 – 1.525 
Education     
 At least some college a 1 1  
 No more than high school 0.52 0.59 0.475 – 0.727 
COPD    
 Absent a 1 1  
 Present 0.30 0.40 0.250 – 0.645 
NonCAD CV disease    
 Absent a 1 1  
 Present 0.46 0.67 0.528 – 0.862 
Charlson Index      
 <3 a 1 1  
 3+ 0.47 0.73 0.559 – 0.965 
Note. Only variables retained in the final logistic regression model are presented. 
a Reference category. b Unadjusted OR based on bivariate analysis prior to age and gender 
adjustment. c Adjusted OR from the final logistic regression model including only the 
listed factors. 
 
This analysis indicates that those with COPD, nonCAD CV disease, and those 
with greater comorbidities as measured by the Charlson Index, were under-represented as 
participants in Round 2. Since participation in Round 2 involved completion of a survey 
and coming to the research clinic for physical examination and an echocardiogram, it is 
not unreasonable that those with a greater disease burden might have found it more 
difficult to participate in Round 2.  The younger, 45 – 54 year old age group was under-
represented compared to the 55 – 64 year old age group, likely because this group 
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probably had a greater proportion that were employed on a full time basis making the 
scheduling of Round 2 participation more challenging. Again the groups older than the 55 
– 64 year old group were comparatively under-represented likely due to difficulties in 
being able to participate in the study. Those better educated had a higher participation 
rate possibly on the basis of their having a greater interest in research participation. Men 
were also somewhat over represented, though note that the confidence interval nearly 
includes one.   
In an earlier analysis of participation bias in Round 1 of the PAVD study 
(Jacobsen et al., 2004) a similar group of factors had been analyzed, but there only age, 
COPD, and education demonstrated a statistically significant differential in participation. 
The direction of these earlier participation differentials was the same as that in the present 
analysis. Thus, it is important to recognize that in Round 2 these factors will be even 
more divergent from the original population-based sample from which Round 1 had been 
drawn. These differences from the population at large have been acknowledged in the 
interpretation of the study results. However, relevant to endpoints of the present study, as 
presented in Table 15 there was no statistically significant difference in participation 
related to BMI, having undergone clinical PSG, or having a clinical OSA diagnosis. 
This study then considers the resulting PAVD round 2 sample of 1,417 
participants. Tables 17 and 18 provide a descriptive analysis of this sample related to 
continuous and categorical variables, respectively. An analysis of gender differences in 
the sample is also presented.  




Descriptive Analysis of PAVD Round 2 Participants (n=1,417 including 49.6% males) 
 with Gender Comparison for Continuous Variables 






Age, round 2 (years) 1417 65.2 64.0 9.6 64.9 65.4 0.33 
Education, round 2 (years) 1373 14.3 14 2.6 14.6 14.0 <0.0001 
BMI, round 1 1417 28.3 27.6 5.1 28.9 27.7 <0.0001 
BMI, round 2 1417 28.5 27.9 5.1 29.1 28.0 <0.0001 
BMI difference, round 2 – round 1 1417 0.24 0.29 1.9 0.24 0.25 0.94 
Echocardiographic characteristics, 
round 2        
 Ejection fraction (%) 1073 65.7 66.3 7.7 63.8 67.3 <0.0001 
 Left atrial volume index (ml/m2) 1364 24.7 23.4 8.5 25.7 23.7 <0.0001 
Lipid Profile, round 1        
 Total cholesterol (mg/dl) 1411 203.1 201.0 34.2 196.4 209.7 <0.0001 
 Triglycerides (mg/dl)  1413 145.1 126.0 80.1 147.7 142.5 0.22 
 High density lipoprotein (HDL) 
(mg/dl) 1411 46.1 44.0 14.2 39.5 52.6 <0.0001 
 Low density lipoprotein (LDL) 
(mg/dl) 1411 128.0 127.0 31.4 127.3 128.6 0.45 
Charlson Index, round 2 1402 3.27 3.0 2.53 3.51 3.05 0.0006 
Biometric measurements, round 2        
 Hip circumference (cm) 1416 104.1 103.0 9.8 104.4 103.9 0.39 
 Neck circumference (cm) 1415 37.3 37.0 4.3 40.4 34.3 <0.0001 
 Waist circumference (cm) 1416 92.2 92.0 14.9 100.2 84.4 <0.0001 
 Waist-Hip Ratio 1416 0.884 0.889 0.102 0.959 0.810 <0.0001 
a  Number of participants with data for variable.  b Student t-test for difference of gender means.     
 





Descriptive Analysis of PAVD Round 2 Participants (n=1417 including 49.6% males)  
with Gender Comparison for Categorical Variables 
Variable na %b male %c female %c pd 
Marital status (married vs not-married) 1416 79.1 87.3 71.0 0.04 
Education  (at least some college vs ≤high school) 1380 65.1 66.7 63.6 0.22 
Race/ethnicity (Caucasian, non-Hispanic vs other) 1417 97.7 97.4 98.0 0.44 
Atrial fibrillation or Atrial flutter 1417 5.9 7.4 4.3 0.01 
Coronary artery disease (CAD) 1417 15.0 23.6 6.6 <0.0001 
NonCAD cardiovascular disease 1264 38.3 39.8 36.7 0.26 
Any cardiovascular disease 1266 40.8 43.9 37.5 0.02 
Congestive heart failure 1417 2.2 2.8 1.5 0.09 
COPD 1223 7.1 8.8 5.4 0.02 
Cerebral vascular accident 1220 3.4 3.4 3.3 0.90 
Hypertension 1417 42.6 42.5 42.7 0.94 
Diabetes mellitus, Type 2 1234 11.8 15.7 7.9 <0.0001 
REP search identified 1417 29.4 32.1 26.8 0.03 
Clinically diagnosed OSAe 1417 13.5 19.8 7.4 <0.0001 
Clinical testing by PSG e 1417 14.4 20.5 8.4 <0.0001 
a Number of participants with data for variable.  b Percentage with the first of the two dichotomous choices 
listed with the variable; for medical disorders and testing, percentage having the disorder or test.  c The 
proportion of male and female round 2 participants with the first of the two dichotomous choices, the disorder 
or test.   d p-value for Chi Square Likelihood Ratio comparing genders.  e Based on the validation analysis 
presented in Table 13 (and following) the OSA and PSG status for all participants is presumed to have been 
ascertained. 
 
The mean age of the round 2 sample was 65.2 ± 9.6 years and a median of 64 
years as illustrated in Table 17.  This is 2.4 years older than the original round 1 mean 
age; however, the mean age difference from round 1 to round 2 for round 2 participants 
was 4.03 years, consistent with the original study’s designed four year follow up 
(Redfield et al., 2003). Round 2 females were slightly but not significantly older than 
males.  As a socioeconomic marker, education was evaluated using both the continuous 
variable, total years of education (Table 17), and as dichotomous variable (Table 18) 
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comparing those with no more than a high school education with those having at least 
some college. Education levels when compared by gender using the dichotomous variable 
were not significantly different; however, using the continuous variable the mean 0.6 year 
difference was highly significant statistically. A large majority, 79.1%, of the sample was 
currently married with men statistically more likely to be married (87.3%) than women 
(71.0%). The race/ethnicity dichotomous variable considered participants as either, 
Caucasian, non-Hispanic, or other, and demonstrated this sample to be quite 
homogeneous with 97.7% of the sample identified as Caucasian, non-Hispanic.  As table 
15 illustrates there was no statistical difference with regard to race and ethnicity from 
round 1 to round 2.  However, the original round 1 sample and the round 2 sample do 
over represent this racial and ethnic category since U.S. Census Bureau data (US Census 
Bureau, 2010) indicate that Olmsted County was 95.3% and 89.0% Caucasian, non-
Hispanic in 1990 and 2000, respectively. Thus, this study’s result should not be 
extrapolated to non-Caucasian and Hispanic populations. 
Analysis of obesity in the sample demonstrates that the BMI for the round 2 
participants had significantly (p<0.0001) increased from round 1 to round 2 (mean BMI 
28.5 vs. 28.3), and that men were statistically more obese than women (mean BMI 29.1 
vs. 28.0).  However, the increases from round 1 to round 2 for men and women were not 
statistically different (p=0.94).  Two echocardiographic characteristics were considered, 
ejection fraction which is a measure of systolic function, and left atrial volume index, a 
measure of left atrial size that has been correlated with OSA and atrial fibrillation (Orban 
et al., 2008; Rodrigues et al., 2009; Toh et al.). In comparing the genders, both of these 
variables were statistically different. Other biometric measures of body habitus show that 
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men and women did not differ significantly in hip circumference, whereas there was, as 
expected, a statistically significant difference in neck and waist circumference as well as 
waist-hip ratio. 
Analysis of clinical variables in Table 18 demonstrates that, in this sample, men 
were more likely than women to have atrial fibrillation/flutter, CAD, COPD, type 2 
diabetes mellitus, and a composite of any cardiovascular disease. This increased 
morbidity is also illustrated by a statistically higher Charlson Index for men than women 
(3.51 vs. 3.05).  However, there was no statistical difference in the prevalence of 
cerebrovascular accidents and hypertension between men and women in this sample. 
Round 2 participants’ lipid profile data collected at round 1 demonstrated a higher total 
cholesterol and HDL cholesterol for women than men with there being no statistical 
difference between the genders for triglyceride and LDL cholesterol levels. 
As described in more detail in Table 22, chart review found 204 (14.4%) of round 
2 participants had undergone a clinical PSG and that 197 (13.5%) had clinically 
diagnosed OSA. Men were 2.68 times more likely to have clinically diagnosed OSA than 
women, and 2.44 times more likely have undergone PSG with both of these differences 
statistically significant (p<0.0001). 
In summary, the round 2 sample was relatively gender balanced, with a mean age 
of 65.2 years.  Multivariate participation bias analysis from round 1 to round 2 
demonstrates underrepresentation of the youngest and oldest, women, those less 
educated, and those with co-morbidities generally based on the Charlson Index, and 
specifically related to COPD and nonCAD cardiovascular disease.  There were a number 
of gender differences with men being more obese, having greater morbidity related to 
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atrial fibrillation/flutter, CAD, COPD, type 2 diabetes mellitus, and a composite any 
cardiovascular disease measure. Men were also far more likely to have undergone PSG 
and to be diagnosed with OSA. 
OSA Risk by BQ, Analysis of Scoring Modification, and Diagnostic Performance 
The round two survey for the PAVD study had included questions for the 
modified BQ with participants’ responses having been coded in the PAVD database.  For 
this study the BQ responses were among the fields extracted from that database and 
ultimately merged with the clinical chart review data for analysis in this study.  The BQ 
responses were scored based on the originally validated algorithm (Netzer et al., 1999; 
"Reprinting of the Berlin Questionnaire," 2000) and OSA risk classifications were 
assigned. In round two 705 (49.8%) participants were at high risk for OSA as 
demonstrated in Table 19 which also includes age and gender specific prevalence rate for 
this population. 





BQ OSA Risk & Prevalence by Age and Gender  
OSA risk by BQ, Netzer scoring algorithm 
("Reprinting of the Berlin Questionnaire," 2000) Gender, round 2  
Age (yrs) Low High Total Prevalence  %  (95% CI) 
Overall 712 705 1417 49.8 (47.2 - 52.4) 
 Women 416 298 714 41.7 (38.1 – 45.3) 
  45-54 66 42 108 38.9 (29.7 – 48.1) 
  55-64 158 112 270 41.5 (35.6 – 47.4) 
  65-74 117 91 208 43.8 (37.1 – 50.5) 
  75+ 75 53 128 41.4 (32.9 – 49.9) 
 Men 296 407 703 57.9 (54.3 – 61.5) 
  45-54 60 71 131 54.2 (45.7 – 62.7) 
  55-64 97 144 241 59.8 (53.6 – 66.0) 
  65-74 88 130 218 59.6 (53.1 – 66.1) 
  75+ 51 62 113 54.9 (45.7 – 64.1) 
 
 
These prevalence rates are substantially higher than those reported in the literature 
as summarized in Table 1.  A previous application of the BQ to assess prevalence had 
indicated gender specific rates of 37.9% and 27.8% for men and women, respectively, 
from a nonpopulation-based sample in Cleveland, Ohio (Netzer et al., 2003).  The 
previous study (Redline et al., 2003) that most closely approximates the prevalence noted 
here was done in a much younger population with a mean age of 32 compared to 65.2 in 
the present study. The gender differential and increasing prevalence prior to age 65 
demonstrated here is also consistent with previous studies as described in Table 1 and 
elsewhere (Young, Peppard et al., 2002). Thus, based on the application of the BQ in this 
study it appears that the prevalence of OSA is greater than most prior studies, but follows 
a pattern otherwise similar to previous studies. 
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  As noted in this study’s literature review the wording, use of questions, and the 
scoring algorithm for the BQ have varied somewhat in applications reported in the 
literature. In the application of the BQ in this study there were two questions regarding 
nodding off or falling asleep while driving (Table 3, questions 8 and 9) that were not used 
due to concerns regarding vicarious liability (A.S. Gami, personal communication, July 
17, 2007). Excluding these questions from this application of the BQ while using the 
same scoring algorithm that was used in the original validation study (Netzer et al., 1999; 
"Reprinting of the Berlin Questionnaire," 2000) would lead to lower scores in category 
two (Table 3) and a lower rate of high OSA risk classification for this study compared to 
the instrument’s original application. 
Though it is not possible to accurately predict what responses to these questions 
might have been in this study, 19.0% of the participants responding to this question in the 
original validation study (Netzer et al., 1999) had reported nodding off or falling asleep 
while driving (Table 2, p. 488) including 4.4% who reported doing so at least three times 
weekly. In that study a total of 231 (31.0%) participants had met the scoring threshold for 
a positive category two.  
In the present study there were only 177 (12.7%) participants that were positive in 
category two. However, among the 1222 participants with a negative category two, 532 
(43.5%) were still classified as high risk based on their responses to questions in 
categories one and three. Had there been a similar portion (31%) with a positive category 
two, there would have potentially been an additional 18.3% of the sample with a positive 
category two, though some portion of these would likely have already met the threshold 
for high risk based on category one and three responses. Thus, it is likely that the 
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exclusion of questions 8 and 9 from Table 3 in this application of the BQ has 
underestimated the prevalence of high risk for OSA by no more than about 15%.  
An analysis of a difference in the BQ scoring algorithm used previously in our 
institution also is an example of the impact on overall BQ performance with a difference 
in the algorithm used for a threshold-based classification system. The first published use 
of the BQ to assess OSA risk in our institution (Gami et al., 2004) had not scored 
question one as part of a positive determination for category one in Table 3. That study 
had validated the BQ based on a subset of 44 patients who had clinical PSGs performed 
during the course of their care.  In this validation set a sensitivity of 86%, specificity of 
89%, and a positive predictive value of 97% had been demonstrated.  However, the 
original validation study for the BQ (Netzer et al., 1999; "Reprinting of the Berlin 
Questionnaire," 2000) had scored question 1 as one of the items included in a positive 
determination for category one. To evaluate the impact of this variation in scoring 
algorithm the BQ responses for this study were scored using both algorithms for 
comparison. 
In round two of this study 1417 participants completed the BQ with 1355 
responding to question one which had included a “don’t know” response.  Of these 
respondents, 1322 reported knowing their snoring status including 989 indicating that 
they snored and 333 that reported not snoring.  An additional 33 reported not knowing 
their snoring status.  Based on these responses the original scoring algorithm (Netzer et 
al., 1999; "Reprinting of the Berlin Questionnaire," 2000) would have numerically scored 
989 (69.8%) participants differently than the previous application and validation of the 
instrument in our institution (Gami et al., 2004). However, because the BQ algorithm 
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places participants in a high risk category based on a threshold in each of three 
categories, it is possible that these 989 participants met the category one threshold 
without having question one scored, or met criteria for the high risk classification in 
categories two and three alone. Thus, additional analysis was carried out to determine the 
actual impact of this algorithm difference on the BQ OSA risk classification. 
This analysis is presented in Table 20.  Based on this OSA risk classification 
comparison for these two algorithms 168 (11.9%) participants were classified as low risk 
for OSA by the Gami algorithm whereas the Netzer algorithm classified them as high 
risk. For the 989 (69.8% of the sample) participants that reported snoring that could have 
led to BQ risk misclassification comparing the Gami and Netzer algorithms, only 168 
were ultimately misclassified. Thus, with a threshold-based scoring system a variation in 
the scoring algorithm does not misclassify all those responding to the items associated 
with the algorithm variation.  Note that, as illustrated in Table 3, this study used the 
originally validated scoring algorithm for responses to question 1 rather than the Gami 
algorithm. 




Comparison of BQ risk classification for Netzer and Gami Scoring Algorithms 
 BQ score & OSA risk, Netzer algorithm  
 Low risk High risk 
BQ score & OSA risk, 
Gami algorithm 0 1 2 3 
Total 
Low Risk      
0 166 144 0 0 
1 0 402 168 0 
880 
High Risk      
2 0 0 442 19 












This study’s REP directed chart review identified 204 participants that had 
completed the BQ and had undergone clinical PSG testing.  Therefore it is possible to 
construct a PSG-based validation analysis for BQ diagnostic performance in assessing 
OSA risk. Because the diagnoses made by a clinician evaluating the patient consider a 
variety of factors in addition to the PSG-based AHI, there was variation between the 
clinical diagnosis and the AHI-based diagnosis for 27 participants.  Table 21 presents 
two-by-two table analyses of BQ validation and performance for both AHI-based and 
clinical OSA diagnoses.  
 




Validation of the BQ with Diagnostic Performance by Clinical and AHI-Based OSA Diagnoses 
Clinical diagnosis  AHI-based diagnosis  
Risk by BQ OSA No OSA  OSA No OSA Total 
High 148 17  136 29 165 
Low 32 7  28 11 39 
Total 180 24  164 40 204 
 
 BQ diagnostic performance (95% CI) 
Sensitivity %)8877(%2.82180
148












Positive Predictive Value %)9485(%7.89
165
148





Negative Predictive Value %)306(%9.1739
7






In previous studies of test validation based in clinical practice test verification 
bias has been recognized as impacting diagnostic performance in this setting (Roger et 
al., 1997). In clinical practice, though it is unlikely that the BQ is formally used broadly, 
clinicians now are likely recognize elements of the BQ as OSA risk factors and pursue 
PSG for participants likely to have OSA. So it might be expected that those undergoing 
PSG are more likely to ultimately be found to have OSA. Indeed in round two only a 
minority, 11.8% - 19.6%, of those undergoing clinical PSG ultimately were found not to 
have OSA depending on whether a clinical or AHI-based diagnostic criterion was used. 
Thus, this BQ validation analysis will be less robust with regard to specificity and 
negative predictive value (NPV), and more robust for sensitivity and positive predictive 
value (PPV) as is illustrated by the confidence intervals in Table 21.  
When comparing the BQ performance in this analysis with the published 
literature as displayed in Table 3, values for sensitivity and PPV are similar and 
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sometimes higher, whereas those for specificity and NPV are generally lower. Thus, 
based on the analysis in this sample with over 80% prevalence of OSA, the BQ appears 
to be a substantially better instrument to screen for OSA, than it is to rule out OSA. 
Indeed among those that were at high risk for OSA based on the BQ and were studied by 
PSG, only 10.3% - 17.6% were ultimately found not to have OSA by clinical and AHI-
based diagnostic criteria, respectively. By contrast, for those identified as being at low 
risk by the BQ a majority, 71.8% - 82.1%, were ultimately found have OSA and 
represent false negatives by the BQ. 
Clinical Recognition of Those with OSA by BQ 
As previously described this study used the REP resources to identify participants 
with diagnostic and procedure codes indicating that a sleep-related diagnosis had been 
made or PSG had been performed.  That process had identified 608 participants from 
round one of the PAVD study.  In addition there were five participants not previously 
included in round one as an echocardiogram was not completed but that were invited to 
round two, and 15 additional participants that had completed the round two survey 
including the BQ but had not completed the round two echocardiogram.  In addition, as 
previously described, 50 round one participants were randomly selected for manual 
review to validate the REP search criteria. The clinical records for all of these 
participants were manually reviewed; however, because several these participants were 
identified for review by more than one of these methods, ultimately there were 666 round 
one participants’ records that underwent review, including 460 round two participants. 
Among the 666 round one participants a total of 280 participants were identified 
with at least one clinical PSG including 204 round two participants. The clinicians caring 
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for these 204 participants reported a clinical diagnosis of OSA in 180 of these 
participants, whereas AHI-based criteria for OSA were met in only 164 of these 
participants.  In addition, there were 12 of the 256 round two participants without a PSG 
for which there was a clinician reported OSA diagnosis based on clinical symptoms, or 
possibly other diagnostic testing such as overnight oximetry. Combining the clinician 
reported and AHI-based OSA diagnoses then classified a total of 197 of the 460 
participants whose charts were reviewed having clinically recognized OSA. Table 22 




Clinician Reported and AHI-Based OSA Diagnoses 
Type of OSA diagnosis PSG No PSG Total 
Present 180 12 192 Clinician reported 
Absent 24 244 268 
     
Present 164 0 164 AHI-based 
Absent 40 256 256 
     
Present 185 12 197 Clinician reported or 
AHI-based Absent 19 244 263 
 Total 204 256 460 
 
 
Consideration of the data in Table 22 demonstrates that there were five 
participants for whom AHI-based diagnostic criteria for OSA had been met which were 
not confirmed by the clinician, 21 clinician reported diagnoses that were not supported by 
the PSG performed, and 12 diagnoses made without the benefit of PSG.  This analysis 
illustrates that, though the PSG is an important element in the clinical diagnosis of OSA it 
appears not to represent a sine qua non for OSA. For the purpose of the analyses of the 
clinical recognition of OSA which follow, these 197 participants recognized by either 
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clinician reported OSA diagnosis or AHI-based OSA diagnostic criteria will be 
considered to have been recognized clinically with OSA. 
Table 23 
 











OSA clinically recognized 160 37 197 
Predicted number with OSA 







Clinical recognition rate based on predicted 







a Table 6, AHI>5 without regard to symptoms: PPV 72%, NPV 59%; 95% CI based on the CI for PPV 
& NPV from Table 6.  b 95% CI based on portion recognized from the number predicted to have OSA.
 
Table 23 demonstrates that 160 of the 705 participants with BQ identified high 
risk for OSA have been clinically recognized in this sample. This represents 22.7% (95% 
CI: 20 – 26%) of those at high risk. However, the BQ is known to have a PPV and NPV 
of less than 100%. Using the PPV and NPV values reported from a pooled analysis based 
on the 1038 participants in nine published studies in Table 6, a PPV of 72% and a NPV 
59% are used to predict the actual number of participants with OSA in the sample in this 
study. Based on these estimated numbers of participants with OSA in this sample, an 
estimated 24.6% of those with OSA have been clinically recognized.  
Consideration of these confidence intervals demonstrates that the rate of clinical 
recognition is not significantly different whether assuming a PPV and NPV of 100%, or 
an actual PPV and NPV from Table 6. In addition, use of the actual PPV and NPV only 
allows prediction of a number of participants likely to actually have OSA based on the 
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BQ.  It does not allow prediction of the specific participants in high or low BQ risk 
groups that will actually have OSA.  There are also no reliable data regarding the 
variation of the BQ PPV and NPV by age, gender or other variables germane to the 
analyses which follow.  Therefore, the following analyses will be based on BQ OSA risk 
without accounting for the PPV and NPV of the instrument. 
Bivariate analysis of demographic characteristics potentially associated with 
clinical recognition is displayed in Table 24. Gender difference is highly predictive (p 
<0.0001) of clinical recognition with the rate of recognition for males more than twice 
that for females. Age, considered as a continuous variable, reaches statistical significance 
(p = 0.043) as a predictor of clinical recognition with those recognized being, on average, 
1.7 years younger than those with unrecognized OSA. However, when age is considered 
as a categorical variable in 10-year increments it is no longer statistically significant in 
predicting clinical recognition. 















pa   
Gender     
 Male 407  29.5 
 Female 298  13.4 < 0.0001
c 
Age 705 63.8, 65.5 yrs  0.043 c 
  45-54 113  20.0 
  55-64 256  36.9 
  65-74 221  31.3 
  75+ 115  11.9 
0.20 
Age by Gender     
 Male Age 407 63.9, 65.3 yrs  0.19 
   45-54 71  33.8 
   55-64 144  29.9 
   65-74 130  29.2 
   75+ 62  24.2 
0.68 
 Female Age 298 63.4, 65.8 yrs  0.14 
   45-54 42  19.1 
   55-64 112  14.3 
   65-74 91  13.2 
   75+ 53  7.6 
0.40 
Educationb 686 14.7, 14.1 yrs  0.015 c 
  At least some college 435  23.7 
  No more than high school 254  22.4 0.71 
Education by Gender     
  Male Educationb 395 14.8, 14.2 yrs  0.056 c 
   At least some college 255  31.4 
   No more than high school 143  28.0 0.48 
  Female Educationb 291 13.9, 14.1 yrs  0.58 
   At least some college 180  12.7 
   No more than high school 111  15.3 0.54 
Marital Status     
  Currently married 568  23.4 
  Not currently married 136  19.9 0.37 
Marital Status by Gender     
  Male     
   Currently married 360  30.3 
   Not currently married 46  23.9 0.36 
  Female     
   Currently married 208  11.5 
   Not currently married 90  17.8 0.16 
(table continues) 
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Note.  Totals for analyses are not always equal to sample and gender totals due to missing 
data for individual variables. 
a  p-values represent chi square likelihood ratios for categorical variables and comparison 
of means and Student t-test for continuous variables.  b The continuous education variable 
is total years of educational attainment. c Parameter considered statistically significant and 
retained in the initial multivariate logistic regression. 
 
Because gender was so highly significant in predicting clinical recognition, age, 
education, and marital status were analyzed both in the total sample and segregated by 
gender. Years of educational attainment as a continuous variable was predictive of 
clinical recognition with those recognized having, on average, 0.6 years more education 
than those with unrecognized OSA. Segregated by gender, years of educational 
attainment only approached statistical significance for males. When education was 
dichotomized to at least some college versus no more than a high school education, it was 
not a significant predictor of clinical recognition.  Marital status was not a predictor of 
clinical OSA recognition in the total sample or when segregated by gender. Among these 
demographic factors, gender, age, and education appear to be significant predictors of 
clinical recognition, the latter two variables only when considered as continuous 
variables. 
As previously noted in chapter 2, BMI is a significant OSA risk factor with a one 
standard deviation difference in BMI increasing the odds of OSA by 55% (Young, 
Shahar et al., 2002), and a longitudinal weight increase of 10% associated with a 32% 
increase in OSA severity (Peppard et al., 2000). The standard epidemiology classification 
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of BMI includes <20 under weight, 20 – 25 normal weight, 25 – 29 overweight, and >30 
obese. This classification was used to assign BMI groups in this study for round 1 and 
round 2. 
As a longitudinal study PAVD data allows assessment of clinical recognition 
based on the BMI at the time of BQ completion (round 2), an average of four years 
previously (round 1), and based on the change in BMI during this four year interval. The 
bivariate analysis for these BMI characteristics is presented in Table 25 for the entire 
sample at high risk of OSA based on the BQ. Note that BMI at either round 1 or round 2 
considered as either a continuous or ordinal variable was associated with a statistically 
significant difference in clinical recognition with those with a higher BMI most likely to 
be clinically recognized.  However, the BMI difference from round 1 to round 2 was only 
associated with a significant difference in clinical recognition when considered based on 
the change in BMI group. It appears that those most likely to be clinically recognized 
were those with the least change in BMI. 




Bivariate Analysis of BMI Characteristics Comparing Those with Clinically Recognized and 











pa   
Round 2 705 33.5, 30.0  <0.0001b 
 <20 10  0 
 ≥20 - <25  89  12.4 
 ≥25 - <30 212  15.6 







33.0, 29.7  
 
<0.0001 b 
 <20 11  0 
 ≥20 - <25  82  14.6 
 ≥25 - <30 253  15.0 
 ≥30 359  30.6 
<0.0001 
 




0.49, 0.35  
 
0.47 
Group difference, round 2 – round 1     
 2 group decline 2  0 
 1 group decline 48  10.4 
 No change in group 573  25.0 
 1 group increase 82  14.6 
0.012 b 
a  p-values represent chi square likelihood ratios for categorical variables and comparison of 
means by Student’s t-test for continuous variables.  b Parameter considered statistically 
significant and retained in the initial multivariate logistic regression model. Where continuous 
and ordinal variables are both significant only the continuous variable was retained. 
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As noted above in Table 24 there was a substantial difference in OSA clinical 
recognition by gender. Thus, gender specific bivariate analyses of BMI characteristics 
were performed.  The p-values for these gender specific analyses are summarized in 
Table 26. Note that the BMI at either round 1 or 2 was, similar to the overall sample, 
statistically associated with a difference in clinical recognition for either gender whether 
considered as an ordinal or continuous variable.  Again, BMI difference was not 
statistically significant for either gender when considered as a continuous variable.  In 
this gender segregated analysis, however, the BMI group difference between round 1 and 
2 was only significant for males with those with no change in BMI group most likely to 
be clinically recognized (32.0%) compared to those with increasing (18.2%) or 
decreasing (16.0%) BMI group. 
Table 26 
 
Bivariate Analysis of BMI Characteristics Comparing Those with Clinically Recognized 
and Unrecognized OSA Among Those at High BQ risk by Gender 
p-values a  BMI Variable 
All Male Female 
Round 2b <0.0001 c <0.0001 c <0.0001 c 
Round 2 group <0.0001 0.0037 0.0030 
Round 1b <0.0001 c <0.0001 c <0.0001 c 
Round 1 group <0.0001 0.0005 0.0056 
Difference, round 2 – round 1b 0.47 0.23 0.92 
Group difference, round 2 – round 1 0.012 c 0.041 c 0.33 
a  p-values represent chi square likelihood ratios for categorical variables and comparison of 
means by Student’s t-test for continuous variables.  b Continuous variable.   c Parameter 
considered statistically significant and retained in the initial multivariate logistic regression 
model. Where continuous and ordinal variables are both significant only the continuous 
variable was retained. 
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OSA is associated with a number of chronic medical problems including 
cardiovascular disease (Caples et al., 2007), cerebrovascular disease (Yaggi et al., 2005), 
metabolic syndrome (Coughlin et al., 2004), and hypertension (Duran et al., 2001). It is 
conceivable that participants with these other medical problems would be more likely to 
have been clinically recognized with OSA with the care provided for these problems than 
those without such problems. PAVD study participants have been well characterized with 
regard to cardiovascular disease, myocardial function, and a variety of other medical co-
morbidities. Thus, bivariate analyses of selected measures of cardiovascular disease and 








Bivariate Analysis of Clinical Characteristics Comparing Those with Clinically Recognized and Unrecognized OSA Among Those at High BQ Risk 









nized  With Without  All Male Female 
Atrial fibrillation or flutter 49   28.6 22.2 0.32 0.52 0.92 
Coronary artery disease (CAD) 140   23.6 22.5 0.78 0.29 0.83 
NonCAD CV disease 279   22.9 23.9 0.77 0.48 0.96 
Any CV disease 299   22.4 24.3 0.57 0.19 0.90 
Congestive heart failure 23   34.8 22.3 0.18 0.22 0.95 
COPD 50   28.0 22.8 0.40 0.57 0.99 
Cerebrovascular accident 30   20.0 23.3 0.68 0.98 0.51 
Diabetes mellitus (Type 2) 103   34.0 21.2 0.007 d 0.03 d 0.38 
Hypertension 459   23.3 21.5 0.59 0.96 0.15 
Echocardiogram parameters, round 2         
 Diastolic myocardial dysfunction 308   23.7 20.4 0.32 0.18 0.92 
 Systolic myocardial function (EF%) 503 64.7 65.7   0.23 0.55 0.35 
 Left atrial volume index (ml/m2) 680 27.4  25.7   0.039 d 0.20 0.45 
Lipid profile analysis, round 1         
 Total cholesterol (mg/dl) 701 196.9 203.2   0.047 d 0.59 0.46 
 Triglyceride (mg/dl) 702 167.4 154.1   0.088 0.03 d 0.90 
 HDL (mg/dl) 701 38.2 43.7   <0.0001 d 0.01 d 0.09 
 Calculated LDL (mg/dl) 701 125.3 128.7   0.24 0.32 0.85 
Biometric parameters, round 2         
 Hip size (cm) 705 112.2 106.4   <0.0001 d <0.0001 d <0.0001 d 
 Neck size (cm)  704 41.3 38.2   <0.0001 d <0.0001 d <0.0001 d 
 Waist (cm) 705 107.0 96.4   <0.0001 d <0.0001 d <0.0001 d 
 Waist-Hip Ratio 705 0.955 0.905   <0.0001 d 0.0003 d 0.59 
a  The means for the characteristic for those with clinically recognized and unrecognized OSA for both genders.  b The rate of clinical recognition with 
and without the identified clinical characteristics for both genders. c p-values represent chi square likelihood ratios for categorical variables and 
comparison of means and Student t-test for continuous variables.  d Parameter considered statistically significant and retained in the initial multivariate 
logistic regression model. 
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Based on the analyses in Tables 25 – 27 the following variables are included in an 
initial multivariate logistic regression analyses for OSA clinical recognition: gender, age, 
years of education, BMI at rounds 1 and 2, BMI group difference from round 1 to 2, type 
2 diabetes mellitus, left atrial volume index, total cholesterol, HDL, hip circumference, 
waist circumference, neck size, and waist to hip ratio. Table 28 depicts the subsets of 
variables entered into the initial modeling of gender-stratified logistic regression 
analyses.  In a stepwise manner factors with p values greater than 0.05 were removed 
from the model until all remaining variables were statistically significant. The odds ratios 
from the resulting final model are depicted in Table 29. 
Table 28 
 
Factors Identified from Bivariate Analyses for Inclusion in the Initial Multivariate 
Logistic Regression Models for the Prediction of OSA Clinical Recognition 
All Male Female 
Gender   
Age (years)   
Education (years) Education (years)  
BMI, round 1 BMI, round 1 BMI, round 1 
BMI, round 2 BMI, round 2 BMI, round 2 
BMI group difference BMI group difference  
Diabetes mellitus, type 2 Diabetes mellitus, type 2  
LA volume index   
Total cholesterol   
 Triglycerides  
HDL cholesterol HDL Cholesterol  
Hip circumference Hip circumference Hip circumference 
Neck circumference Neck Circumference Neck Circumference 
Waist circumference Waist circumference Waist circumference 







Adjusted ORs for Clinical Recognition of OSA Among Those at High 
Risk by BQ with Gender Stratified Analysis 
 OR 95% CI p 
All (n=686) 
Education, total  (1 year) 1.10 1.03 – 1.19 0.005 
BMI, round 1 (5 kg/m2) 1.48 1.21 – 1.81 0.0001 
Neck circumference (2.5 cm) 1.44 1.27 – 1.64 <0.0001 
 R2=0.1217 
Male (n=395) 
Education, total (1 year) 1.10 1.02 – 1.20 0.01 
Waist  (5 cm) 1.31 1.19 – 1.44 <0.0001 
 R2=0.0784 
Female (n=298) 




This modeling demonstrates that most of the variables in the mixed gender 
analysis apply to only one of the two gender-specific analyses.  An additional mixed 
gender model was therefore constructed with interaction terms for each of these variables 
with gender; however, none of these interaction terms remained significant following 
stepwise regression.  Given the significant differences between the genders a mixed 
gender analysis was performed with gender being retained throughout the stepwise 
regression even when not statistically significant.  The model resulting from this analysis 






ORs for a Final Logistic Regression Model with Gender Included 
 OR 95% CI p 
All (n=686) 
Gender (male as reference) 0.76 0.55 – 1.03 0.08 
Education, total  (1 year) 1.10 1.02 – 1.18 0.009 
BMI, round 1 (5 kg/m2) 1.66 1.31 – 2.11 0.0001 
Neck circumference (2.5 cm) 1.27 1.05 – 1.54 <0.0001 
 R2=0.1259 
 
This model suggests that education, BMI, and neck circumference are the primary 
predictors of clinical recognition with a 1 year educational increase increasing the 
likelihood of recognition by about 10%, a BMI increase of 5 kg/m2 increases the 
likelihood of recognition by about 66%, and an 2.5 cm increase in neck circumference 
increases the likelihood of recognition by 27%.  Though gender only approaches 
statistical significance, this model suggests that, holding education, BMI, and neck 
circumference constant, women are 24% less likely to be recognized than men. 
Research Question One 
  What proportion of those at high risk for OSA based on the Berlin Questionnaire 
have been clinically evaluated for OSA? 
This study sought to determine the proportion of those at high risk for OSA based 
on the BQ that had been clinically-evaluated for OSA. The gold standard for the clinical 
diagnosis of OSA is PSG. The analysis that follows is based both on that gold standard, 
and a review of narrative descriptions in the clinical record describing participants’ 
clinical evaluation.  
The REP search process had been designed using a broad group of sleep-related 
diagnosis and procedure codes in an effort to identify those for whom the diagnosis had 
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been considered and evaluation pursued. The REP search had identified 417 participants 
in  round 2 that had a sleep-related diagnosis or procedure. In addition, there were 37 of 
the 50 participants selected at random to valid the REP search criteria and six additional 
participants from round 2 that were manually reviewed giving a total of 460 clinical 
records that were reviewed.  
As demonstrated in Table 31 these reviews identified a total of 192 clinician 
reported diagnoses of OSA at the mild level or greater.  In addition, there were five 
participants that had PSG and met AHI criteria for OSA but did not receive a clinician 
verified OSA diagnosis. These five participants had diagnoses reported as mild upper 
airway resistance syndrome, REM-related apnea, periodic leg movement disorder (2), 
and for one the PSG had been performed only as part of a study protocol. Because these 
participants PSGs met criteria for mild OSA with AHI’s ranging from five to 17, these 
participants were considered to have clinically recognized OSA for the purpose of this 
analysis. 
 Of the remaining 263 records that were reviewed there were an additional 18 that had 
OSA-related diagnoses but were not formally diagnosed as having OSA including six that 
had undergone PSG.  These diagnoses included upper airway resistance syndrome 
(UARS), snoring, and possible sleep disordered breathing (SDB) as well as possible 
OSA.  Of the 12 of these participants that did not have PSG performed, the clinical record 
suggested that eight participants had declined further evaluation including PSG. The 
remaining 232 records included nonOSA related sleep diagnoses, most commonly 
insomnia or restless leg syndrome (RLS), which had prompted identification by the REP 
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search process. Therefore of the 460 records reviewed, there was evidence that at least 
228 had been clinically evaluated more specifically for OSA including 204 for whom 
PSG had been performed. The validation of the REP search codes described above 
demonstrated that at least 95% of PAVD participants with OSA had been identified.  
Table 31 
 
Clinical Diagnosis and PSGs Performed for Round 2 Records Reviewed 
Clinical diagnosis n PSGs 
OSA, mild or greater 192 180 
AHI-based criteria for OSA 5 5 
OSA-related diagnosis 6 12a 
6 
0 
NonOSA related diagnoses 13 232 
13 
0 
Total 460 204 




 Of the 228 clinically evaluated 184 were classified as high risk by BQ, whereas 165 
of the 204 undergoing PSG were at high risk.  Thus, of the 705 participants at high risk 
for OSA based on the BQ, 26.1% (95% CI 22.9 – 29.3%) had undergone clinical 
evaluation for OSA including 23.4% (95% CI 20.3 – 26.5%) that had undergone PSG.  
Thus, the first null hypothesis for this study, “There is no difference between the 
population at high risk for OSA and those that have been clinically evaluated,” is rejected 
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and the associated alternate hypothesis, “There is a portion of those at high risk for OSA 
that has not been clinically evaluated,” is accepted.  
Research Question Two 
  What is the prevalence of clinically diagnosed OSA among those at high risk for 
OSA based on responses to the Berlin Questionnaire? 
The prevalence of clinically diagnosed OSA among those classified as high risk 
for OSA by the BQ, as described above in Table 23 and following is 22.7% (95% CI 20 – 
26%). Recognizing that the BQ does not have a PPV or NPV of 100% the analysis in 
Table 23 demonstrated that the recognized prevalence could be as high as 23.6% (95% CI 
21 – 26%).  A demographic bivariate analysis (Table 24) demonstrated that this 
prevalence was substantially higher in males than females, 29.5% (95% CI 25 – 34%) vs 
13.4% (95% CI 10 – 17%).  In this analysis age also significantly predicts recognition 
with those recognized being, on average, 1.4 years younger (p=0.043) than those 
unrecognized. 
Therefore the second null hypothesis for this study, “There is no difference 
between the population at high risk for OSA and those that have been clinically 
diagnosed,” is rejected and the associated alternative hypothesis, “There is a portion of 
those at high risk for OSA that has not been clinically diagnosed,” is accepted. 
Research Question Three 
  Has the prevalence of clinically diagnosed OSA increased in the past decade? 
Previous population-based studies of OSA clinical recognition, as shown in Table 
32, reported clinical recognition rates in mixed gender populations from 8.3% and 15.4% 
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for moderate to severe OSA, and 6.5% for mild to severe OSA.  The present study used 
the BQ for OSA identification.  The best diagnostic performance of this instrument is for 
mild to severe OSA as shown in Table 6. Thus, the more comparable clinical recognition 
rates to those found in this study are those reported Young and colleagues (1997) based 




Previously Reported Prevalence of OSA Clinical Recognition for Those with OSA  
Stratified by Gender and Severity 
Prevalence of clinical  
recognition among those  
with OSA (95% CI) 
Number with OSA (n) 
Study Gender 
moderate to 





Young, Evans et al., 1997 Male 18.2% (9.6 – 26.8%) 
9.0% 
(4.5 – 13.5%) 77 93 
Young, Evans et al., 1997 Female 7.4% (0 – 17.3%) 
2.2% 
(0 – 5.1%) 27 155 
Young, Evans et al., 1997 All 15.4% (8.5 – 22.3%) 
6.5% 
(3.4 – 9.5%) 104 248 
Kapur et al., 2002 All 8.3% (6.2 – 10.4%) - 650 - 
 
In Table 33 a comparison of these prevalence rates for both genders combined 
and gender specific samples, along with the applicable confidence intervals, with those 
found in this study demonstrates that the prevalence of clinical recognized OSA has 
significantly increased compared to rates reported in 1997. The clinically recognized 
prevalence in this study generally appears to be in the range of three to six times as high 
as that reported in the most comparable of the previous analyses (Young, Evans et al., 
1997).  However, there remains a large majority of OSA, 70.5 – 86.6%, depending on 





Comparison of the Current Prevalence of OSA Clinical Recognition with Historically Reported Levels 
 Prevalence of OSA clinical recognition (95% CI) 
 All Male Female 
Young et al 1997 6.5% (3.4 – 9.5%) 9.0% (4.5 – 13.5%) 2.2% (0 – 5.1%) 
Present study 22.7% (19.6 – 25.8%) 29.5% (25.1 - 33.9%) 13.4% (9.5 – 17.3%) 
Prevalence Ratio 3.5 (2.1 – 5.8) a 3.3 (1.9 – 5.7) a 6.2 (1.5  - 25.8) a 
a  Confidence interval for rate ratio (Rosner, 2006, p. 757). 
 
 
 Therefore the third null hypothesis for this study, “There has been no change in the 
proportion of prevalent OSA that is diagnosed clinically compared to the mid-1990s,” is 
rejected and the associated alternative hypothesis, “There has been an increase in the 
proportion of prevalent OSA that is diagnosed clinically compared to the mid-1990s,” is 
accepted. 
Research Question Four 
  What factors are predictive of the clinical diagnosis of OSA among those at high 
risk of OSA? 
Bivariate analyses of OSA clinical recognition identified a number of factors 
associated with OSA clinical recognition in mixed gender and gender specific strata of 
this population as summarized in Table 28.  Those factors include the demographic 
factors gender, age, and education, the biometric factors BMI, neck, hip, and waist 
circumference, and clinical factors related to diabetes and lipid profile. As noted above in 
Table 33 there was a statistically significant difference in the prevalence of OSA clinical 
recognition between the genders. In gender specific bivariate analysis, the factors 
associated with clinical recognition also differed between the genders. 
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Multivariate logistic regression analyses using these factors as described above in 
Table 29 identifies total years of education, BMI, and waist circumference as statistically 
significant predictors of OSA clinical recognition. Gender-specific logistic regression 
analysis demonstrates that years of education and waist size predict clinical recognition 
for men, whereas BMI is the lone predictor for women.  
The unadjusted gender-specific prevalence rates for OSA clinical recognition in 
this population demonstrate that men are 2.20 times more likely to be recognized than 
women (29.5% vs 13.4%).  However, analysis holding gender as a variable in a logistic 
regression model regardless of statistical significance suggests that there is only a 24% 
(p=0.08) lower clinical recognition rate when years of education, BMI, and neck 
circumference are held constant. 
The null hypothesis related to this research question was “Among those at high 
risk for OSA there is no difference regarding the following characteristics among those 
with a clinical diagnosis of OSA than among those undiagnosed:  age, gender, BMI, and 
socioeconomic status.”  In the null hypothesis four factors where hypothesized to be 
without difference between those diagnosed and undiagnosed: age, gender, BMI, and 
socioeconomic status. Among these factors age was identified as being different in 
bivariate, mixed gender analysis (Tables 24 and 28), but was not different in gender 
stratified bivariate analyses and not associated with clinical recognition when other 
factors were held constant in all of the multivariate analyses (Tables 29 and 30).  Thus, 
for age, the null hypothesis is accepted.  
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Gender was also identified as being different in bivariate analysis (Tables 24 and 
28).  However, in multivariate analyses (Tables 29 and 30) gender nearly reached 
statistical significance with a confidence interval that just included unity (95% CI 0.55 – 
1.03) and had a p-value of 0.08. However, because of the divergence of factors associated 
with clinical OSA recognition in gender stratified analyses (Tables 24, and 27 – 30) 
combined with this near statistical significance, the null hypothesis was de facto rejected 
for gender. 
With respect to BMI, there was an association with a difference between those 
recognized and unrecognized with OSA in mixed gender and gender stratified bivariate 
analyses (Tables 25, 26, and 28).  In multivariate analyses BMI was found to be 
statistically different in mixed gender analyses (Tables 29 and 30), but only for women in 
gender stratified multivariate analyses (Table 29).  However, for men in gender stratified 
multivariate analysis another marker of obesity, waist circumference, was found to be 
associated with a clinical OSA recognition difference. Therefore, de facto for BMI 
recognized as a measure of obesity, the null hypothesis was also rejected. 
Finally, with regard to socioeconomic status, this study represented 
socioeconomic status using education variables.  Those variables included years of 
education, a continuous variable, and the dichotomous variable, “no more than high 
school” versus “at least some college.”  Only the continuous variable was found to be 
associated with a difference between those with recognized and unrecognized OSA in 
mixed gender analyses.  In gender stratified bivariate analyses this variable was only 
associated with a difference for men.  Similarly, in multivariate analyses, the variable was 
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only associated with a difference in mixed gender and male specific gender stratified 
analyses. Thus, for socioeconomic status, as represented by the variable years of 
education, the null hypothesis was rejected. 
To summarize, the null hypothesis was accepted for age as follows, “Among 
those at high risk for OSA there is no difference regarding the following characteristics 
among those with a clinical diagnosis of OSA than among those undiagnosed:  age.”  By 
contrast the null hypotheses were rejected, in some cases de facto, for gender, BMI, and 
socioeconomic status, and the following alternative hypothesis was accepted, “Among 
those at high risk for OSA the following characteristics will be more common among 
those with a clinical diagnosis of OSA than among those undiagnosed:  male gender, 
higher BMI, and higher socioeconomic status [as represented by years of education].” 
Summary 
This study used data previously collected as part of the PAVD study (Redfield et 
al., 2003) which included responses to a modified BQ. Using the resources of the REP, 
those participants likely to have clinically recognized OSA were electronically identified 
and their clinical records systematically reviewed manually to obtain data regarding 
clinical PSGs performed and OSA diagnoses. To validate the REP identification process 
50 randomly selected participants’ records not identified by the REP process were also 
manually reviewed.  Clinical records for an additional 20 participants not initially 
included in PAVD analyses but later identified as having completed the essential 
elements for the present study were also manually reviewed. Data from the PAVD 
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archive was then merged with data from the record review process to produce the single 
database for this study’s analyses. 
Analysis of this data first included validation of the REP electronic clinical OSA 
identification process. This validation demonstrated that the process was able to identify 
more than 95% of participants with clinical OSA with an estimated 98% of sleep-related 
diagnoses present at the time of the REP search detected by the process. The PAVD study 
was initiated with a population-based sample in 1997 (Ammar et al., 2006; Redfield et 
al., 2003). Participation bias had previously been assessed for those participating in round 
one of the PAVD study compared to the population-based sample (Jacobsen et al., 2004). 
A similar analysis of participation from round one to round two demonstrated 
underrepresentation of the youngest and oldest participants, women, those less educated, 
and those with co-morbidities generally based on the Charlson Index, and specifically 
related to COPD and nonCAD cardiovascular disease. 
Descriptive analysis of OSA risk based on responses to the modified BQ 
demonstrated that nearly half (49.8%) of round two participants were at high risk of 
OSA.  Based on comparison with the original BQ validation study (Netzer et al., 1999) it 
was estimated that the BQ modifications in this study could have underestimated OSA 
prevalence by no more than 15%.  The REP guided chart review process identified a total 
of 197 round two participants with either a clinician reported or an AHI-based diagnosis 
of OSA.  Of these 160 were among the 705 participants classified as high risk by the BQ 
giving a prevalence of OSA clinical recognition of 22.7% (95%CI 20 – 26%).  
Recognizing that this assumes the BQ to have 100% positive and negative predictive 
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values, the prevalence of OSA clinical recognition was recalculated using PPV and NPV 
values of 79% and 61%, respectively, for mild to severe OSA from the pooled analysis of 
BQ performance representing 586 participants in Table 6.  The resulting prevalence of 
OSA clinical recognition, 23.6% (95% CI 21 – 26%), did not differ significantly from 
that based on the 100% PPV and NPV assumption.  Thus, the remainder of the analysis 
used BQ high risk as an OSA proxy. 
There was a substantial difference in unadjusted gender-specific prevalence rates 
for OSA clinical recognition in this population with men 2.20 times more likely to be 
recognized than women (29.5% vs 13.4%). Further bivariate analysis of OSA clinical 
recognition demonstrated that other demographic factors including age and education, 
biometric factors BMI, neck, hip, and waist circumference, and clinical factors related to 
diabetes and lipid profile all predicted OSA clinical recognition. However, multivariate 
logistic regression analyses identified total years of education, BMI, and waist 
circumference as the only statistically significant predictors of OSA clinical recognition 
in a mixed gender analysis. Gender-specific logistic regression analysis demonstrated that 
years of education and waist size predict clinical recognition for men, whereas BMI is the 
lone predictor for women. In mixed gender analysis, holding years of education, BMI, 
and neck circumference constant, there was only a 24% (p=0.08) lower clinical 
recognition rate for women compared to men. 
Finally, though this analysis demonstrates that clinical recognition of OSA is 
three to six times greater compared to a previous population based analysis from the 
1990s, OSA continues to be substantially (70.5 – 86.6%) under recognized clinically.  
 
 
CHAPTER 5:  SUMMARY, CONCLUSION, AND RECOMMENDATIONS 
Overview 
OSA is a disorder in which the airway collapses producing airway obstruction 
during sleep (Parish & Somers, 2004).  It is associated with increased cardiovascular 
(Caples et al., 2007) and cerebrovascular (Yaggi et al., 2005) morbidity and mortality, 
and increased risk of metabolic syndrome (Coughlin et al., 2004), depression (Peppard et 
al., 2006), hypertension (Duran et al., 2001), and automobile accidents (Young, Blustein 
et al., 1997).  Treatment of OSA, typically with CPAP, attenuates or reverses many of 
these associated risks (Doherty et al., 2005; Milleron et al., 2004; Peker et al., 2006).  
However, previous studies (Kapur et al., 2002; Young, Evans et al., 1997) based on 
1990s data suggest that most OSA is clinically unrecognized. 
This study sought to determine the proportion of those with OSA in the 
population who have been clinically evaluated and diagnosed. As a longitudinal 
benchmark, it also sought to determine if there had been a change compared to earlier 
published recognition rates (Kapur et al., 2002; Young, Evans et al., 1997). Finally, the 
study sought to identify factors predictive of clinical recognition.  Once identified, these 
identified factors can then be used to propose strategies for enhanced clinical recognition 
that would represent a positive social change. 
This study used data previously collected by the PAVD study to identify those at 
high risk for OSA based on a modified BQ. The resources of the REP were then used to 
identify participants with clinically recognized OSA. Based on a BQ-based OSA proxy, 
this study demonstrated that 22.7% (95% CI 20 – 26%) of those with OSA had been 
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clinically recognized including 29.5% (95% CI 25 – 34%) of men, but only 13.4% (95% 
CI 10 – 17%) of women. Though these rates of clinical recognition represent a three to 
six fold increase from those published more than a decade ago (Young, Evans et al., 
1997), it is important to recognize that a majority of OSA remains clinically 
unrecognized despite this increased recognition. Multivariate logistic regression analysis 
identified education and measures of obesity including waist size for men, and BMI for 
women and mixed genders, and neck circumference in mixed gender populations, as 
predictors of clinical recognition.  
Interpretation of Findings 
The first three of the four stages in this study’s analysis were designed to evaluate 
(a) the methods used to identify participants with clinically recognized OSA, (b) the 
potential for participation bias from round 1 to round 2 of the PAVD study, and (c) the 
performance of the high risk classification on the modified BQ as a proxy for OSA in the 
sample. Subsequently, in the fourth stage of the analysis, the research questions related to 
the prevalence of the clinical recognition of OSA are addressed.   
Validation of REP Search Method to Ascertain OSA Clinical Recognition 
A collection of sleep-related diagnostic and procedural codes had been used in 
search using the resources of the REP to electronically identify those likely to have 
clinical recognized OSA.  The identified participants’ clinical records were then 
systematically reviewed manually to obtain OSA-related data.  A validation sample of 50 
participants not selected in the electronic search was then manually reviewed to 
determine the validity of this electronic process in the identification of clinical recognized 
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OSA. The results of this 50 participant review are displayed in Table 13 and demonstrate 
that the electronic search had identified more than 95% of participants with clinical 
recognized OSA.   
This validates the REP search process was being able to comprehensively identify 
essentially all participants in the sample with clinically recognized OSA.  This method of 
ascertaining participants’ status with regard to OSA clinical recognition is in contrast to 
those used in previously published studies (Kapur et al., 2002; Young, Evans et al., 1997) 
where participant self-report in a survey had been used to ascertain clinical OSA 
recognition.  The earlier of these two studies had followed up with the 49 participants 
who had indicated that they had been told by a physician that they had sleep apnea 
(Young, Evans et al., 1997).  In follow up, however, 33 of these participants admitted that 
they only suspected they had OSA and had not been clinically evaluated or diagnosed. 
No attempt was made in either of these studies to validate the responses of participants 
indicating that they did not have OSA.  Thus, the method used here to ascertain OSA 
clinical recognition represents a substantial enhancement compared to previous methods. 
Participation Bias from Round one to Round two of the PAVD Study 
An earlier PAVD participation bias analysis (Jacobsen et al., 2004) had shown 
that, compared to the population-based sample invited, round one participants were more 
likely to have more than a high school education and less likely to have COPD.  In 
addition, those from age 55 – 74 were more likely to have participated than those older or 
younger. Because the OSA clinical recognition outcomes in this study are based on the 
sample remaining in round two of PAVD, a similar participation bias analysis was carried 
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out comparing those participating in round two with those from round one who did not 
participate. That multivariate analysis, presented in Table 16, demonstrated that men 
were more likely to participate than women, whereas those with less education, COPD, 
cardiovascular disease other than coronary artery disease, and greater co-morbidities as 
measured by the Charlson Index (Charlson et al., 1987) were less likely to participate. 
With education limited to high school and the presence of COPD associated with lower 
levels of participation in both analyses, the round two under representation compared to 
the population-based sample for these variables is likely to be greater than that suggested 
by the Table 16 multivariate logistic regression.  
With males over represented by about 24% (95% CI 2 – 53%) in round two, the 
overall prevalence of OSA in this sample is likely to be overestimated since men have 
been two to three times more likely to have OSA in the general population (Young, 
Peppard et al., 2002). Concurrently those with only a high school education are under 
represented by about 41% (95% CI 27 – 53%) which, based a previous study (Young, 
Evans et al., 1997), was associated with clinical under recognition of OSA. In a large 
epidemiologic study, OSA was found not to be associated with COPD (Sanders et al., 
2003). Thus, the overall prevalence of OSA in the round two sample is likely unaffected 
substantially by the under representation of those with COPD. Both the Charlson Index 
and cardiovascular disease other than coronary artery disease (nonCAD CV disease) 
represent mixes of a variety of comorbidities making it difficult to meaningfully predict 
the impact of this under representation on the overall prevalence of OSA or its clinical 
recognition in the round two sample.  
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The participation bias analysis, based only on a consideration of factors for which 
prior associations with OSA prevalence or recognition exist, suggests that the round two 
sample appears more likely to overestimate the prevalence of OSA and its clinical 
recognition than to under estimate these parameters. The magnitude of these deviations 
from the original population-based sample invited to round one of the PAVD study, 
however, is not possible to predict. Using gender stratified analyses would limit the 
impact of the gender differential in round two participation. 
Additional variables of particular relevance to this study’s endpoints are those 
related to the performance of clinical PSG and the clinical diagnosis of OSA presented in 
Table 15. There was no statistical difference after adjustment for age and gender in the 
participation rates based on having undergone PSG, or having a clinical diagnosis of 
OSA. There also was no statistical difference in the rate of clinical evaluation by PSG (p 
= 0.15) or OSA diagnosis (p = 0.15) comparing those in round two with those not 
participating in round two prior to age and gender adjustment. Thus, though there may 
have been some over representation of those more likely to have OSA among round 2 
participants, this appears not to have been significant enough to have led to increased 
clinical evaluation or clinical OSA recognition among round 2 participants. Because the 
potential over representation appears related to gender, the impact of this potential 




Performance of the BQ High Risk Classification as the OSA Proxy 
The BQ is an instrument designed to identify those likely to have sleep apnea 
(Netzer et al., 1999).  As noted in Table 4 it has been used in some 30 previously 
published studies sometimes as a proxy for OSA.  Table 5 identifies the 10 studies that 
have published PSG-based validation data for the instrument whereas Table 6 provides an 
analysis of its diagnostic performance at differing levels of OSA severity using data 
pooled from these validation studies. 
The overall prevalence of OSA in this study based on the BQ OSA proxy was 
49.8% (95% CI 47.2 – 52.4%) with gender specific prevalence of 57.9% (95% CI 54.3 – 
61.5%) and 41.7% (95% CI 38.1 – 45.3%) for men and women, respectively, as 
illustrated in Table 19. This is substantially higher than all but one study (Redline et al., 
2003) of the multiple studies reporting OSA prevalence summarized in Table 1.  It is 
important to note, however, that the PAVD round two population is substantially older 
with a mean age of 65.2 (median 64.0) years and a range from 49.9 to 93.4 years 
compared to most studies in Table 1. Knowing that the prevalence of OSA increases with 
age (Young, Shahar et al., 2002), this higher prevalence may not be unreasonable for this 
older PAVD round 2 population.  
The BQ was administered as part of the round 2 follow up evaluations in the 
PAVD study conducted from September of 2001 through March of 2005, after many of 
the studies in Table 1.  With the increasing prevalence of obesity over time the 
prevalence of OSA in the population is also increasing (Young, Peppard, & Taheri, 
2005). At round two 717 participants (50.6%) had gained weight since round one 
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whereas 166 (11.7%) had weights that were unchanged and 534 (37.7%) had lost weight. 
Thus the secular trend toward increased obesity prevalence generally, and as 
demonstrated for round two participants, would also predict a higher OSA prevalence 
compared to earlier studies. 
This study’s literature review described the variations in the questions included in 
the BQ from published applications of the instrument.  The application in this study had 
excluded two questions from the original instrument due to concerns regarding vicarious 
liability (A.S. Gami, personal communication, July 17, 2007).  As described in the 
analysis of the BQ results following Table 19, this variation would be expected to 
produce an underestimation of OSA prevalence by no more than about 15%. Thus, 
despite the BQ yielding an overall prevalence rate higher than most previous studies, the 
method used is likely still to have underestimated OSA prevalence. 
The analysis of BQ diagnostic performance in this study presented in Table 21 
demonstrates that, for those round two participants that underwent a clinical PSG, the 
sensitivity and positive predictive value of the BQ was over 80%. Consistent with the 
previously described test verification bias when a diagnostic instrument is applied in the 
clinical setting (Roger et al., 1997), the specificity and negative predictive value were 
much lower, in the range of 17 – 30%. Thus, the BQ in this study, similar to previous 
studies as illustrated in Table 5 and 6, was a substantially better instrument for predicting 
the presence of OSA than for predicting the absence of OSA.  
Table 23 shows that the prevalence of clinical OSA recognition does not differ 
significantly when the PPV and NPV of the BQ are considered, compared to a prevalence 
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calculation that assumes a 100% PPV and NPV. This confirms that because this study 
considers the prevalence of clinical OSA recognition of those with OSA, the limited 
ability of the BQ to identify those without OSA has only a modest impact on the study. 
In summary, the BQ as applied in this study appears to have been an effective tool 
in identifying OSA in the study population with the limitations of the instrument not 
significantly impacting the prevalence of OSA recognition. The higher prevalence rate 
for OSA compared to most previously reported studies may be related to the relatively 
older population studied, and a secular trend toward increasing obesity and OSA in the 
general population. 
The Clinical Recognition of OSA 
The central focus of this study is the four research questions regarding the clinical 
recognition of OSA. The results with regard to research questions one and two, as 
described in chapter 4 indicate that, of the 705 round two participants with BQ-based 
OSA, 26.1% (95% CI 22.9 – 29.3%) had undergone some type of clinical evaluation for 
OSA including 23.4% (95% CI 20.3 – 26.5%) that were evaluated with PSG. Of those 
with BQ-based OSA 22.7% (95% CI 20 – 26%) had clinically recognized OSA. Thus, 
only about one quarter of those with BQ-based OSA have been evaluated, and of those 
evaluated a large majority, 87.0%, were found clinically to have OSA. Of note, there 
were an additional 44 participants that did not have BQ-based OSA that had been 
clinically evaluated including 37 (84.1%) that were found to clinically have OSA. 
These results suggest that nearly 75% of those with BQ-based OSA have not been 
clinically evaluated.  Among those evaluated clinically, most are ultimately found to have 
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OSA regardless of whether they have BQ-based OSA. Thus, it appears that if the clinical 
care system pursues an OSA clinical evaluation regardless of their BQ-based risk, most 
(84.1 – 87.0%) were ultimately be shown to have OSA. However, a majority of those 
with OSA are never clinically evaluated or recognized. Therefore it appears that 
healthcare system continues to substantially under recognize OSA. 
With regard to research question three, as presented in Table 33, a comparison of 
these prevalence rates for OSA clinical recognition with those previously published 
(Young, Evans et al., 1997) suggests that there has been a substantial improvement over 
time. The level of improvement was the most substantial among women with a 
prevalence ratio for clinical recognition of 6.2 (95% CI 1.5 – 25.8). Clinical recognition 
has increased by 3.3 (95% CI 1.9 – 5.7) times for men since the report of Young and 
colleagues in 1997. For a total, mixed gender population, recognition has increased 3.5 
(95% CI 2.1 – 5.8) times. Thus, though the prevalence of OSA clinical recognition has 
improved substantially compared to rates published more than a decade ago (Young, 
Evans et al., 1997), the clinical care system still fails to recognize a substantial majority, 
about 75%, of OSA in the community. 
Research reports have suggested that there had been increased health practitioner 
education regarding OSA during the decade of the 1990s (Haponik, 1992; Papp et al., 
2002). Though there have been no more recent reports quantitatively documenting further 
curricular enhancement since 2002, a description of one institution’s use of hand held 
digital devices to provide a podcast sleep curriculum to neurology residents has been 
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described (Gamaldo & Salas, 2008) suggesting that at a minimum some institutions have 
developed creative solutions to enhancing physician sleep training.  
The increased rate of clinical recognition during a time when there was evidence 
of increasing sleep instruction for clinicians would be consistent with the theoretical basis 
for this research.  That basis was the theory of hypothesis generation which requires the 
diagnostician have some prior knowledge of a disorder in order for that disorder to be 
included among the diagnostic hypotheses generated in evaluating a patient (Bockenholt 
& Weber, 1993; Round, 2001). Thus, these results would support an increased physician 
awareness of OSA leading to increased clinical recognition. 
In addressing research question four regarding factors predictive of OSA clinical 
recognition, Tables 29 demonstrated that factors predicting recognition in the mixed 
gender model tend to segregate to only one gender in the gender stratified analyses. In 
these gender stratified models, increased education and waist size are predictive of 
recognition for men, whereas only BMI is predictive for women. In addition, when 
gender is retained regardless of statistical significance in a stepwise regression (Table 
30), it remains nearly significant (p = 0.08) in the final model with men more likely to be 
recognized, whereas greater education, BMI, and neck circumference are statistically 
significant predictors of clinical recognition. 
Based on this review of this study’s results and the analysis of  the null and 
alternative hypotheses the following conclusions were drawn: 




2. There is a portion of those at high risk for OSA that has not been clinically 
diagnosed. 
3. There has been an increase in the proportion of prevalent OSA that is diagnosed 
clinically compared to the mid-1990s. 
4. Among those at high risk for OSA there is no difference regarding the following 
characteristics among those with a clinical diagnosis of OSA than among those 
undiagnosed:  age. 
5. Among those at high risk for OSA the following characteristics will be more 
common among those with a clinical diagnosis of OSA than among those 
undiagnosed:  male gender, higher BMI, and higher socioeconomic status [as 
represented by years of education]. 
In summary, it would appear that OSA clinical recognition is generally best 
predicted by the classic OSA description of the Pickwickian Syndrome (Conti et al., 
2006), that is, primarily those with obesity or male gender. The predictive marker for 
obesity varies by gender (Table 29) with waist circumference being the better 
multivariate predictor in male populations whereas BMI is more predictive for females.  
In the mixed gender model (Table 30) both neck circumference and BMI are statistically 
significant predictors.  Finally, in predictive models for men and in mixed gender 
populations education is a statistically significant predictor of clinical OSA recognition. 
Implications for Social Change 
This study’s results have implications for public health and for the clinical 
practice of medicine. The unadjusted odds ratio for gender as a predictor of OSA clinical 
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recognition is 0.37 (95% CI 0.25 – 0.55) suggesting substantially lower clinical 
recognition among women.  In multivariate analysis, holding education, BMI, and neck 
circumference constant, the adjusted odds ratio is only 0.76 (95% CI 0.55 – 1.03) 
suggesting a much smaller differential by gender in OSA clinical recognition. It would 
seem that strategies targeted toward enhancing clinical recognition in women could be 
helpful in addressing this disparity. 
The statistically significant disparities associated with the measures of obesity 
including BMI, and biometric parameters including hip, waist, and neck size, along with 
waist-hip ratio in mixed gender and gender stratified bivariate analyses. In multivariate 
analyses both for mixed gender and gender stratified populations a differing measure of 
obesity always remained significant in the adjusted models presented in Tables 29 and 
30.  
A review of the bivariate analysis of OSA clinical recognition stratified by BMI 
(Table 25) shows that none of the underweight participants with BQ-based OSA had been 
clinical recognized, whereas those in the normal and overweight classifications (BMI 20 
– 29) had clinical recognition rates no more than about half of those with obesity (BMI 
≥30). 
A gender stratification of this bivariate analysis, as shown in Table 34, 
demonstrates that prevalence of OSA clinical recognition for the nonobese is less than for 
the obese in both genders, and that women are less likely recognized with OSA.  The 
gender stratified relative risks of recognition for the nonobese compared to the obese are 
0.56 (95% CI 0.40 – 0.77) and 0.31 (95% CI 0.15 – 0.64) for males and females, 
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respectively. These confidence intervals indicate that, in this sample, the differential in 
OSA recognition rates between nonobese and the obese is not statistically different 
between males and females. Thus, it seems quite clear that those with OSA who are not 
obese are significantly less likely to be clinically diagnosed, and women are much less 




OSA Clinical Recognition Rates by Obesity (BMI ≥30) and Gender 
High risk by BQ, n  OSA clinically recognized, n (%)  
All Male Female  All Male Female pa 
BMI <30 311 177 134  44 (14.2%) 36 (20.3%) 8 (6.0%) 0.0002 
BMI ≥30 394 230 164  116 (29.4%) 84 (36.5%) 32 19.5%) 0.0002 
Total 705 407 298  160 (22.7%) 120 (29.5%) 40 (13.4%) <0.0001 
a  p-value for the Chi square likelihood ratio for the male - female comparison. 
 
 
This reduced clinical recognition of OSA among the nonobese appears to confirm 
a hypothesis generated from a study of OSA in patient samples drawn from military and 
civilian populations where obesity was less prevalent in the military sample (Lettieri et 
al., 2005). That study noted that obesity was common among those with OSA, but 
recommended that BMI not be used as a criterion for identifying which patients should 
undergo evaluation for OSA.  
Thus, developing strategies to educate clinicians regarding the overall low clinical 
recognition of sleep apnea, with substantially lower recognition rates for those with a 
BMI less than 30, and among women would be expected to lead to improved clinical 
recognition of OSA with associated increased likelihood of OSA treatment and 
prevention of the OSA associated morbidity and mortality.  In addition, public education 
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efforts to raise the awareness of sleep apnea in general, and the fact that OSA affects both 
men and women, and though more common among the obese, is more commonly 
unrecognized among the nonobese would also encourage more people to seek evaluation 
for OSA. Together these strategies would lead to a positive social change with respect to 
the impact of sleep apnea on society. 
Strengths of the Study 
This study was conducted within a large, population-based longitudinal cohort 
study originally focused on ventricular dysfunction (Redfield et al., 2003). Since the 
components focusing on OSA were initiated in round two of that study, the study 
population was well characterized with regard to many cardiovascular and biometric 
variables both at the time of the BQ was administered, and four years previously.  Thus, 
potential associations between these variables both at the time of BQ administration and 
four years previously with OSA clinical recognition were able to be explored. 
The two previous studies of OSA clinical recognition (Kapur et al., 2002; Young, 
Evans et al., 1997) had used participant self-report to identify those with clinically 
recognized OSA.  In verifying these reports from a survey by contacting the participants 
by telephone Young and colleagues (1997) found that only 33% had actually been 
clinically diagnosed whereas the remainder only personally suspected OSA. In addition, 
in this study there had been no effort to validate responses indicating the lack of a clinical 
OSA diagnosis.  Kapur and colleagues (2002) did not attempt to validate self-reported 
clinical recognition in their study.  Thus, this study is the first population-based study in 
which OSA clinical recognition has been validated by review of the clinical records. 
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In addition, this study used the resources of the REP to identify records 
documenting clinical recognition of OSA. The REP has been shown to retrieve records 
for 96% of the Olmstead County population (Melton, 1996).  The codes used by the REP 
search in this study were validated and demonstrated that more than 95% of those with 
OSA in the study population were identified.  Thus, the methods used in this study 
provide an essentially complete enumeration of all of the participants in this study 
population with clinically recognized OSA. 
In summary, the primary strength of this study was the use of the resources of the 
REP to identify those with clinically recognized OSA and to validate the diagnosis using 
the original clinical records. As such, this is the first population based study of OSA 
clinical recognition to utilize such a rigorous method to validate clinical recognition. In 
addition, the study was carried out in a well characterized population both at the time of 
the BQ OSA determination, and longitudinally from four years previously. 
Limitations of the Study 
The assessment of OSA clinical recognition was conducted as part of the round 
two analyses in a larger longitudinal cohort study (Redfield et al., 2003). Thus, the 
sample studied represented those returning an average of four years following the initial 
round one assessment of the respondents to original population-based invitations to 
participate in the study.  Those completing the BQ were only those that chose to 
participate in the study on two separate occasions four years apart. This method then has 
potential for participation bias. 
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Round one multivariate participation bias analysis (Jacobsen et al., 2004) had 
identified overrepresentation of those with more than a high school education, those 
between the ages of 55 – 74 years old, and those without COPD.  As presented in Table 
16, multivariate participation bias from round one to round two demonstrated the same 
age, education, and COPD biases that were identified in round one.  In addition, female 
gender and the presence of nonCAD CV disease, along with a score of three or greater on 
the more general Charlson Index (Charlson et al., 1987) of comorbidities predicted under 
representation in round two. However, the clinical diagnosis of OSA and clinical testing 
by PSG was not associated with a differential in round two participation. With gender 
being among the factors associated with participation, the performance of gender specific 
analyses was one means of dealing with gender-based participation bias in this study. 
The round two sample was 97.7% Caucasian, non-Hispanic which is an under-
representation of other races and ethnicities.  The US Census had shown that the 
Olmstead County population as a whole was only 95.3% and 89.0% Caucasian, non-
Hispanic in 1990 and 2000, respectively (US Census Bureau, 2010). Thus, the results of 
this study cannot be extrapolated to non-Caucasian and Hispanic populations. 
With a mean age of 65.2 years and the youngest participant being age 49.9 years 
old at the time the BQ was administered, this study’s sample was older than both of the 
previous studies of OSA clinical recognition.  The mean age in the study by Kapur and 
colleagues (2002) though younger was similar at 63.1 years.  However, the study by 
Young and colleagues (1997) had an age range from 30 – 60 years and the mean ages of 
those with screen detected and clinically recognized OSA were all in the 40s, younger 
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than the youngest participant in the current study.  Thus, comparison of the results in the 
present study with those of Young and colleagues (1997) must be done with caution.  In 
addition, the ability to extrapolate these results to a younger adult population less than 
age 50 is also limited. 
This study used the high risk classification on the BQ as an OSA proxy whereas 
the gold standard for OSA diagnosis is laboratory based PSG. Based on previously 
published validation analyses of the BQ and analysis of the clinical PSGs performed in 
the study population, the instrument has stronger diagnostic performance for OSA 
identification than for identifying those without OSA. In Table 23 a comparative analysis 
of OSA clinical recognition when the PPV and NPV of the BQ are considered, compared 
to a prevalence calculation that assumes a 100% PPV and NPV demonstrated no 
statistically significant difference. However, there may be some segments of the 
population in which there is an unrecognized differential in the diagnostic performance of 
the BQ. Thus, this study is limited by the lack of a gold standard OSA ascertainment 
method. 
This study was carried out in Olmsted County, Minnesota where there are two 
sleep laboratories, one at Mayo Clinic with 24 beds and performing 4,440 PSGs annually 
(Mayo Foundation for Medical Education and Research, 2010), and a second smaller 
sleep lab at Olmsted Medical Center (Olmsted Medical Center, 2008).  Therefore the 
participants in this study have comparatively easy access to sleep medicine services 
compared to many communities. Thus, the prevalence of clinical OSA recognition may 
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be higher in this community than other settings with comparatively limited access to 
sleep medicine services. 
In summary, the limitations of this study include differential participation 
subsequent to the population-based sampling conducted in 1997 that appears to be related 
to age, gender, education, COPD,  nonCAD CV disease, and general comorbidities as 
measured by the Charlson Index (Charlson et al., 1987). The impact of these biases 
appears to be limited as the evaluation rate with clinical PSG and the rate of OSA 
diagnosis did not differ between round two participants and nonparticipants. The impact 
of the gender-based biases on this study’s results has been attenuated by use of gender 
stratified analyses. Because of the sample’s demographics results should not be 
extrapolated to non-Caucasian and Hispanic population, or to populations younger than 
50 years old. In addition, because the study used the BQ as a proxy for OSA rather than a 
laboratory-based PSG method, the diagnostic limitations of the BQ must be considered in 
interpreting the results. Finally, the study was conducted in a community with relatively 
easy access to sleep medicine services, thus the prevalence of OSA clinical recognition 
for this population may be higher compared to other communities with more limited 
access to these services. 
Recommendations for Action 
In 2006 the Institute of Medicine (IOM) concluded that “although clinical 
activities and scientific opportunities in the field [of sleep medicine] are expanding, 
awareness among the general public and health care professionals is low given the 
magnitude of the burden” (Colten & Altevogt, 2006, p. 1). The IOM recommended that 
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there be “increase[d] awareness of the burden of sleep loss and sleep disorders among the 
general public” (p. 3) and “expand[ed] awareness among health care professionals 
through education and training” (Colten & Altevogt, 2006, p. 3).  
The present study suggests that, there may have been some improvement in OSA 
clinical recognition since the analysis by Young, Evans, and colleagues (1997).  
However, the majority, about 75%, of OSA in this older adult population remains 
unrecognized, with women, the nonobese, and those less well educated even more likely 
to be unrecognized.  Thus, this study would support further expansion of both health 
professional and public education regarding OSA. 
Given the population segments most under-recognized (i.e. women and the 
nonobese) these educational efforts should be carefully structured so as not to portray 
OSA as a disorder of obese men while still acknowledging that male gender and obesity 
are risk factors for OSA.  In addition, noting that years of education was a predictor of 
OSA clinical recognition (Table 30) such public educational efforts should be structured 
in a manner making them meaningful regardless of educational level. 
Where there are large clinical care systems that share a common electronic 
medical record system, it may also be possible to develop a set of electronic markers that 
predict OSA.  For example, either using data from already existing tools by which 
patients report their symptoms, or by modifying such tools to include OSA-related 
symptoms, and adding other electronically recorded data such as BMI and the diagnosis 
of hypertension, it may be possible to construct an automated electronic BQ or similar 
algorithm predictive of OSA.  This electronic BQ could then function in the background 
 173
  
and provide clinicians an electronic message that the patient is at high risk for OSA and 
suggest further testing. 
Recommendations for Further Study 
Because generalization of these results is limited by the lack of racial and ethnic 
diversity, and the relatively older population studied, repeating or expanding the study 
population to include younger adults and greater racial and ethnic diversity would be of 
value. The additional participants could then be selected using a population-based 
sampling method that could further attenuate the participation bias that resulted from this 
study’s placement at round two of an ongoing study. With the existing round two cohort 
there would also be value in pursuing follow up to assess the impact of the BQ-based 
OSA classification on longitudinal outcomes. 
  With OSA ascertainment in this study having been based on the BQ whereas PSG 
represents the gold-standard for OSA diagnosis using PSG-based ascertainment in further 
study would be advantageous.  Because of the cost of in laboratory PSG, use of in home 
unattended PSG may be an acceptable, cost-efficient alternative recognizing that at least 
one large population-based study had already used such a method (Quan et al., 1997).  An 
additional alternative would be to study by PSG a randomly selected sample of the study 
population for validation of the BQ. 
In parallel with the potential development of an automated electronic BQ for a 
larger clinical care system, research analysis of the impact of implementing such a system 
would be of significant value.  Such research could then be used to validate the electronic 
algorithm, and ultimately document the impact of such a system on clinical outcomes 
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that, in the long-term could include cardiovascular disease, cerebrovascular accidents, 
hypertension, and diabetes. 
Thus, this study’s results provide a spring board to pursue OSA-related research 
addressing a variety of issues of both scientific and public health value. 
Concluding Statement 
Obstructive sleep apnea (OSA), a disorder in which the airway collapses causing 
an airway obstruction during sleep, is associated with multiple morbidities and increased 
mortality.  Treatment of OSA, typically with continuous positive airway pressure 
(CPAP), attenuates or reverses many of these associated risks. Historically most OSA 
was clinically unrecognized and thus, untreated. Improved physician awareness of OSA 
and increased availability of sleep medicine services should predict increased recognition 
of OSA since it was last evaluated using data from the 1990s. 
This study demonstrated an increase in clinical recognition from 6.5% (95% CI 
3.4 – 9.5%) to 22.7% (95% CI 19.6 – 25.8%) overall in a mixed gender population. 
However, this still indicates that a majority of OSA, about 75%, remains unrecognized 
and thus, still untreated. Bivariate and multivariate analyses of OSA clinical recognition 
in this study demonstrated that, OSA recognition is most likely for obese men, that is, 
those that more closely resemble the classic Pickwickian Syndrome description. 
Conversely, women and the nonobese are among those less likely to be recognized with 
OSA. 
Consistent with the IOM’s 2006 statement titled, Sleep Disorders and Sleep 
Deprivation: An Unmet Public Health Problem the results of this study point to the need 
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for increased clinician and public education about OSA, its diagnosis and treatment.  
Such educational efforts should highlight both the risk factors for OSA and risk factors 
that are currently associated with clinical under-recognition of the disorder. Concurrent 
development of systems-based tools built into electronic medical record systems that 
automatically alert clinicians to their patients’ OSA risk would also have the potential to 
enhance OSA recognition and treatment, and lead to a reduction in OSA-related 
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Programs,” coauthor with Hadley, RD, paper presentation, Association of PA Programs Educational 
Forum, Phoenix, AZ, October 24, 2003. 
“What constitutes a Master’s Project?” co-presenter with Robert Hadley, PhD, PA-C, roundtable 
presentation, Association of Physician Assistant Programs, Semiannual Meeting, New Orleans, LA, 
May 23, 2003. 
“PA Adjunct Faculty Development and Utilization: Models of Inclusion,” co-presenter with Mare Wheeler, 
MS, PA-C, roundtable presentation, Association of PA Programs Educational Forum, Miami, FL, 
November 7, 2002. 
“Update on the Male Genitourinary Exam,” invited presentation, Minnesota Academy of PAs, Fall 
Conference, Rochester, MN, 28 September 2001. 
“Don’t Judge a Book by its Cover: An Overview of Medical Literature Interpretation,” invited presentation, 
Wisconsin Academy of PAs, Fall Conference, Eau Claire, WI, October 21, 2000. 
“Using the Medical Literature in Clinical Practice”, invited presentation, American Academy of PAs 
Annual Conference, Chicago, IL, May 2000. 
 “A Review Process for Applying Research Literature to Clinical Practice”, invited presentation, American 
Academy of PAs, Annual Conference, Chicago, IL, May 2000. 
“Net Essentials for PAs”, invited presentation, American Academy of PAs, Annual Conference, Chicago, 
IL, May 2000. 
"Using the Medical Literature in Clinical Practice", Minnesota Academy of PAs, Fall CME Conference, 
September 1997, presenter. 
"The Physician Assistant in Primary Care," in "Perspectives in Primary Care, A Symposium in Celebration 
of National Primary Care Day", sponsored by the SW Wisconsin AHEC, La Crosse, WI, September 28, 
1995, panelist. 
"Physician Assistant Education in La Crosse," Gundersen Medical Foundation Noon Conference, La  
Crosse, WI,  September 25, 1995, presenter. 
"Effective Use of NPs, PAs and CNMs" at the 1995 National Health Service Corps’ "Recruitment in the 
1990's: Challenges & Opportunities," May 25, 1995, St. Paul, MN, Co-presenter. 
"An Update on PA Education In Minnesota," MAPA Spring CME, St. Louis Park, MN, April 7, 1995. 
"Physician Assistants and PA Education in South Dakota," 9th Annual South Dakota Rural Health 
Conference, Pierre, SD, November 4, 1993, Presenter. 
"The Clintons' Healthcare Reform Proposal in the view of the American Academy of Physician Assistants," 
the Rural Health Policy Board of the National Rural Health Association, November 12, 1993, Chicago, 
IL, Presenter. 
"The Education of PAs for Underserved Areas", National Health Service Corps 20th Anniversary 
Celebration:  A Forum on Primary Care, Arlington, VA, June 24, 1992, Co-Presenter. 
"Panel Discussion: Physician Assistants in the Emergency Department", Advances in Emergency Medicine 
sponsored by the Minnesota Chapter of the American College of Emergency Physicians, Minneapolis, 
MN, May 1, 1992, Panelist. 
"Rural Health/Inner City Initiatives: Can We Fulfill Our Original Professional Mandate?", North Central 
Regional Meeting of the AAPA, Lansing, MI, February 2, 1992, Presenter. 
"Panel Discussion: PA Prescribing and Regulation in Minnesota", Minnesota Academy of PA Fall CME, 
Duluth, MN, October 27, 1991, Moderator. 
"Membership Development Workshop: 24 Great Membership Ideas", AAPA Constituent Chapter Officers 
Workshop, Alexandria, VA, September 13, 1991, Panelist. 
"Panel Discussion: What's New With Recertification, Information and Discussion", North Central Meeting 





"Panel Discussion: PA Regulation, Which Model is Best, A Comparison of Several States' PA Regulatory 
Systems", North Central Meeting of the AAPA, Minneapolis, MN, February 2, 1991, Moderator. 
"Practice Demographics and PA Salaries in Two North Central States: Implications for the Profession", 
North Central Meeting of the AAPA, Minneapolis, MN, February 2, 1991, Presenter. 
 
ACCREDITATION SITE VISITOR: 
Site visitor for the Accreditation Review Commission for Physician Assistant Education (ARC-PA) 
Daemen College, Buffalo, NY, April 2006, team chair 
Samuel Merritt College, Oakland, CA, June 2005 
Grand Valley State University, Grand Rapids, MI, May 2004, team chair 
Medical College of Ohio, Toledo, OH, January 2004, team chair 
 College of Health Sciences, Roanoke, VA, January 2003, team chair 
 University of Texas Health Science Center, San Antonio, Texas, July 2002, team chair 
Central Michigan University, Mount Pleasant, MI, January 2002, team chair 
Arcadia University, Philadelphia, PA, July 2001 
Medical College of Ohio, Toledo, OH, January 2001 
St. Francis University, Fort Wayne, IN, January 2000, team chair 
St. Francis College, Loretto, PA, January 1999 
New York Institute of Technology, Long Island, NY, July 1998 
SUNY Downstate, Brooklyn, NY, January 1998, team chair 
Grand Valley State University, Grand Rapids, MI, July 1997 
Brooklyn Hospital/Long Island University, Brooklyn, NY, January 1997 
 
OTHER MEDICAL EDUCATION: 
2008-present   Advanced Trauma Life Support (ATLS), completion of provider course, St. Cloud, MN. 
2007-present   Pediatric Advanced Life Support (PALS), Minnesota Affiliate, American Heart 
Association. 
1983-present  Advanced Cardiac Life Support (ACLS), Provider 1983-present; Instructor 1983-2007. 
 Iowa, Minnesota, Dakota and Wisconsin Affiliates of the American Heart Association 
1983    Advanced Trauma Management 
                  Emergency Medical Services Learning Resource Center 
                  University of Iowa Hospital and Clinic, Iowa City, IA 
1981   Instructor/Coordinator EMT Course, Mount Vernon Extension Class 
    Kirkwood Community College, Cedar Rapids, IA 
1981   Research Assistant for John Weiler, MD, Department of Allergy Immunology, University 
of Iowa. Performed Complement tissue culture research. 
1980    EMT-Paramedic 
 Emergency Medical Services Learning Resource Center 
 University of Iowa Hospital and Clinic, Iowa City, IA 
1979-80   EMT, Training Officer and Charter Member, Dumont Ambulance Service, Dumont, IA 






OTHER MEDICAL EXPERIENCE: 
June 1982- May 1983  Physician Assistant Program Clinical Rotations, University of Iowa PA Program, 
Iowa City, IA 
Emergency Medicine  Schoitz Hospital, Waterloo, IA 
  Family Practice           Broadlawns Hospital, Des Moines, IA 
Muscatine Health Center, Muscatine, IA 
Franklin Medical Center, Hampton, IA 
General Surgery    VA Medical Center, Iowa City, IA 
Internal Medicine   Park Clinic, Mason City, IA 
Obstetrics & Gynecology University of Iowa Hospitals, Iowa City 
Orthopedic Surgery  Muscatine General Hosp., Muscatine, IA 
Pediatrics                Marshfield Clinic, Marshfield, WI 
Psychiatry                 VA Medical Center, Des Moines, IA 
Sept. 1980 - March 1983 EMT-Paramedic, Mercy Hospital/Area Ambulance, Cedar Rapids, IA: 
A hospital emergency room based ambulance service providing assessment, 
advanced cardiac life support and transportation to the sick and injured with 
ground and helicopter air ambulances. 
 
OTHER WORK EXPERIENCE: 
School Years 1978-1980 Senior High Science Instructor, Dumont Community School, Dumont, IA.       
Taught Chemistry, Biology, and Physical Science. Coached Football, Basketball 
and Track.  
Summer 1978   House Parent, Frontier Farm Group Home for Boys, Effie, MN 
Parented boys ages 12-18 in the development of positive relations with peers, 
family and authority figures on a homestead farm. 
School year 1977-78  High School Science Instructor, Villard Public School, Villard, MN:  Taught 
Chemistry, Physics, Biology, and Life Science. 
School year 1976-77  Science teaching intern, Bloomington Lincoln High School, Bloomington, MN. 
Summer 1976   Nursing Assistant, Augustana Home for the Aged, Minneapolis, MN. 
Summer 1975   Guide/counselor, Wilderness Canoe Base, Grand Marais, MN. 
Summer 1974   Youth Service Corps Counselor, Woodward Hosp./School for the Retarded, 
Woodward, IA   
Summers 1971-73  Camp Counselor, EWALU Bible Camp, Strawberry Point, IA.           
 
GOVERNMENTAL APPOINTMENT: 
Member, Rural Health Advisory Committee, Minnesota Department of Health, Office of Rural Health, 
1992-1993. 
 
PROFESSIONAL ORGANIZATION MEMBERSHIPS AND OFFICES: 
American Academy of Sleep Medicine (AASM), Student member, 2005 to the present. 
American Public Health Association (APHA), Student member, 2005 to 2009. 
American Academy of Physician Assistants (AAPA), Fellow Member; Member since 1983;  Official 
Liaison for the AAPA to the National Rural Health Association 1992-98;  Chapter and Member 
Relations Committee, North Central Region Representative, 1992 - 1994;  Member, Advisory 
Committee of PA Employment 1991-92;  House of Delegates, Reference Committee Member 1993 & 
Observer 1992, Delegate 1989, 1992-93, Alternate Delegate 1990 & 1991; Coordinator for the North 
Central Regional meeting, February 1991;  Reviewer, Taskforce on PA Specialty Practice report, 1993;  
Reviewer National Health Program Position Paper, 1990 & 1996;  Reviewer of Rural Health Policy 
Paper, 1989. 




PROFESSIONAL ORGANIZATION MEMBERSHIPS AND OFFICES (continued): 
Rural Health Caucus of the AAPA, Member, 1991-1996; Newsletter Editor/Board Member At Large, 
1992-1996; Charter member and Secretary-Treasurer, 1991-92. 
South Dakota Academy of Physician Assistants (SDAPA), Fellow Member 1993-95, Legislative 
Committee, 1993-95. 
Minnesota Academy of Physician Assistants (MAPA), Fellow Member since 1988; President 1991; 
Member Board of Directors 1988-1992; Board Liaison for development of a Minnesota PA Training 
Program, 1989-1993; Past Chair Legislative Committee, 1989-91; Past chair, Membership Committee, 
1989-90; Member, ad hoc judicial affairs committee, 1992. 
Association of Physician Assistant Programs (APAP), Director of member program, 1995-2005; Member, 
CASPA Steering Committee, 2004-present; Associate Member, 1990-1995; Member Leadership 
Training Institute Advisory Committee, 1994-1997; Reviewer, J. Peter Nyquist Writing Contest, 2003. 
National Rural Health Association, Member, 1992-2004; Member Rural Health Policy Board, 1996-1998, 
Clinical Services Constituency Group. 
American Geriatrics Society, Member, 1991-1995. 
University of Iowa Student PA Society, Past Member and Past President, 1981-83. 
 
AWARDS/HONORS:   
Who’s Who in Medicine and Healthcare, 1996, 2000, 2002 
Who’s Who in America, 1997 
Minnesota Academy of Physician Assistants, Presidential Award, 1990 & 1993. 
Who's Who Among American and College & University Students, 1975-76 
Academic Achievement Award, Science Award, North High School, 1972                      
National Honor Society, North High School, 1971-72 
 
COMMUNITY SERVICE ACTIVITIES: 
Our Savior’s Lutheran Church:  Call Committee Chair, 2005, Church Council President, 2002, Board of 
Worship and Music, Chair, 1999-2001, Member 1999-present; Church council member, 1999-2003; 
Senior Choir Member, 1995-present; Sunday School Teacher, 1997-98, Our Savior’s Lutheran Church, 
La Crosse, WI 
Lutheran Campus Ministry, Chair, 1998-2003; Directing Committee Member, 1996-2003, Building 
Committee member, 2002-2004; La Crosse, WI 
Soccer Coach, 1994, Vermillion Youth Soccer League, Vermillion, SD 
Sunday School Teacher, 1993-94, Trinity Lutheran Church, Vermillion, SD 
EMT Guest Instructor, 1993-94, Vermillion-Clay County Ambulance Service, Vermillion, SD 
Sunday School Teacher, 1992-93 & 1989-91, Senior Choir Member, 1987-1993, United Lutheran Church, 
Red Wing, MN 
Host Parent, American Field Service (AFS), foreign exchange program, 1989-90, Red Wing, MN 
Member, Dawnbreaker Kiwanis Club, 1987-1992, Red Wing, MN 
Member Red Wing American Field Service Chapter, 1989-1992, Red Wing, MN 
Past President, Butler County Chapter, American Heart Association, Allison, IA 
Member and President, Allison Lions Club, Allison, IA, 1984-87 
Member, Medi-Search, Ltd., 1979-80, a community physician recruitment committee, Hampton, IA 
Host Parent, 1979-80, Youth For Understanding, Dumont, IA 
 
 
